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       Abstract 
Devil Facial Tumour Disease (DFTD) is an infectious cancer cell line transmitted as 
an allograft between Tasmanian devils. On transmission it does not evoke an 
immune response, is 100% fatal and is driving the Tasmanian devil towards 
extinction in the wild. Due to their endangered status, access to Tasmanian devils to 
study DFTD is limited. As a consequence this study of DFTD was undertaken in 
mice to complement studies being done in Tasmanian devils.  
Inoculation of immunocompetent mice with DFTD cells did not result in DFTD tumour 
establishment. This rejection was a specific immune response because DFTD 
specific antibodies were produced. This provided evidence that DFTD cells are 
immunogenic and susceptible to killing by the immune system making them suitable 
targets for immunotherapy and vaccines. Immunocompetent mice also provided a 
model to study immunogenicity of various DFTD cell preparations and injection 
protocols applicable to vaccine development. For example, 14 day prime-boost 
intraperitoneal injections of DFTD cells resulted in enhanced antibody and cytokine 
responses in mice compared to subcutaneous injections. Inactivation of DFTD cells 
by freeze-thawing or sonication reduced the immunogenicity of DFTD cells while 
irradiation of DFTD cells maintained immunogenicity.   
NOD/SCID mice have severe immune system defects that prevented protective 
immune responses against DFTD cells allowing tumours to establish. Consequently, 
these mice provided a xenograft model to study aspects of DFTD that could not be 
replicated in an in vitro setting. This included DFTD establishment and growth as 
well as efficacy of adoptive cell transfer trials. Adoptive cell transfer from 
immunocompetent mice conferred protection against DFTD as did adoptive transfer 
of Tasmanian devil lymphokine activated killer (LAK) cells. In this context, LAK cells 
refer to lymphocytes which have been stimulated in vitro with mitogens or cytokines 
to induce non-specific activated killer cells capable of killing DFTD cells without 
harming normal cells.  
The xenograft model also facilitated the evaluation of the chemotherapeutic agents 
afatinib, withaferin A and imiquimod. The most promising results came from 
intratumoural injections of imiquimod which caused the upregulation of β2-
microglobulin on the surface of the DFTD cells. DFTD cells avoid immune 
xii 
 
recognition in Tasmanian devils because they do not express MHC on the cell 
surface. Upregulation of β2-microglobulin indicates that MHC was upregulated. This 
has important implications for the Tasmanian devil as the MHC would make the 
DFTD cells visible to the Tasmanian devil’s immune system and this should invoke 
protective immune responses.  
In conclusion, DFTD cells are immunogenic and can be targeted by antibodies and 
cytotoxic cells. This makes them suitable candidates for vaccines or immunotherapy 
in Tasmanian devils. They avoid the Tasmanian devils immune system by 
downregulating MHC. This ignorance can be overcome by non-specific activation of 
LAK cells capable of killing DFTD cells in a MHC independent manner. The tumour 
cells can be targeted by imiquimod to upregulate surface molecules including β2-
microglobulin and MHC to make them more immunogenic and potential targets for 
MHC dependent cytotoxic responses. 
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1 Literature review  
1.1 Devil Facial Tumour Disease  
Devil Facial Tumour Disease (DFTD) is a new and emerging disease having a 
devastating impact on the wild Tasmanian devil (Sarcophilus harrisii) population that 
is restricted to the island of Tasmania south of mainland Australia (Pyecroft et al 
2007). The disease only occurs in the Tasmanian devil and “Epidemiology theory” 
advocates that a pathogen restricted to a single host species is unlikely to drive its 
host to extinction (Lachish et al 2007). However, the 100% mortality rates associated 
with this disease fuels speculation that the Tasmanian devil will face extinction in the 
wild (Lachish et al 2007).   
To date there is no evidence of recovery or natural immunity to DFTD in any 
Tasmanian devil (Lachish et al 2007). Over 50% of the state of Tasmania, 
representing more than 85% of the original devil distributional range has been 
impacted by the disease. The population has declined by more than 85% with local 
population declines exceeding 95% (Brueniche-Olsen et al 2013, Cheng et al 2012, 
Lachish et al 2007). The disease front is yet to extend to the west coast and pockets 
in the mid-north coast of Tasmania (DPIPWE 2012, Pyecroft et al 2007).  
The timeframe for the emergence of the disease is contentious. Animals with chronic 
scarring, acute wounds, tumours and other lesions cannot be distinguished visually 
from early stage DFTD. It is generally accepted that the first signs of the disease 
were recorded as photographs in 1996 (Hawkins et al 2006, McCallum and Jones 
2006). In retrospect, the photographs revealed what appear to be facial tumours 
typical of the appearance of confirmed DFTD tumours (Hawkins et al 2006). The first 
field biopsy and necropsy from Tasmanian devils to confirm what would become 
known as DFTD was undertaken at Freycinet National Park in 2001 (Hawkins et al 
2006). Karyotype and genetic studies of DFTD tumour cells support a recent origin of 
DFTD from a single Tasmanian devil (Murchison et al 2012, Pearse and Swift 2006). 
DFTD pathology is consistent with an undifferentiated neoplasm resulting from 
atypical uncontrolled cell growth (Pyecroft et al 2007). Historically neoplasia has 
been a common problem observed in captive devil populations (Griner 1979). It has 
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been reported that 50% of Tasmanian devils necropsied (n=18) at San Diego Zoo 
had neoplasms or preneoplastic hyperplasia. In comparison, only 3% of other 
mammals and marsupials at the same zoo had neoplasms detected during necropsy 
(Griner 1979). This suggests that devils are predisposed to development of 
neoplasms. This may be as a result of increased susceptibility to carcinogens or 
oncogenic viruses (Griner 1979).  
Archived samples of the neoplasms from San Diego Zoo are not suggestive of DFTD 
and previous population crashes anecdotally recorded in the literature around 1863 
and 1908-1920 make no mention of a facial tumour (Loh et al 2006a). The pathology 
for DFTD neoplasm is inconsistent with previously described neoplasms in devils 
(Loh et al 2006a). DFTD cells can be described as pleomorphic and anaplastic 
because they bear little resemblance to normal cells and rapidly divide to form large 
tumourous growths that serve no physiological function (Pyecroft et al 2007). Unlike 
the spontaneously occurring neoplasms that the Tasmanian devils have been 
plagued with, DFTD is a clonal cell line that originated in a single devil as a Schwann 
cell tumour (Murchison et al 2010) and has been transmitted as an allograft between 
individuals (Pearse and Swift 2006).   
Aside from DFTD the only other known naturally occurring infectious cancerous cell 
line is CTVT (Murgia et al 2006, Rebbeck et al 2009). DFTD and Canine 
Transmissible Venereal Tumor (CTVT) diseases can both be described as parasitic 
cancers (Siddle and Kaufman 2013). Another transmissible cancer in golden Syrian 
hamsters has been observed in experimental settings only (Fabrizio 1965, McCallum 
2008).   
1.1.1 Impact of disease on Tasmanian devil population 
Once abundant throughout Australia the Tasmanian devil is now restricted to the 
island of Tasmania (165,000 km2) (Jones et al 2004). The oldest fossil records for 
Tasmanian devils on mainland Australia are dated between 3000 to 4000 years 
(Brown 2006). It has been suggested that the introduction of the dingo around 3500 
years ago, anthropogenic extinction by Aboriginals and susceptibility to the effects of 
climate variability could have all contributed to the extinction of mainland devil 
populations (Brown 2006).    
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The Tasmanian devil is regarded as a keystone species that has co-evolved with 
other endemic species and developed equilibrium predator-prey relationships (Jones 
et al 2007). This has resulted in unique biodiversity for Tasmanian wilderness areas 
that has significant positive impacts including the benefits for ecosystem health and 
financial benefits of tourism based on the natural appeal of  the Tasmanian 
ecosystem. It has been suggested that the Tasmanian devil has a counteractive 
affect on invasive species such as the feral cat and red fox minimising their impact 
and in the case of the red fox possibly preventing its establishment in Tasmania 
(Lachish et al 2007, Wright and DPIPWE 2010).  
If the Tasmanian devil becomes extinct in Tasmania its niche will be filled by feral 
species including the red fox and feral cats which have not coevolved with the native 
species. The predator prey relationship will not be a balanced one and some species 
will be preyed on to the point of extinction. The impact of foxes on mainland Australia 
has irrefutably resulted in the loss of many endemic species. The success of the fox 
invasion on mainland Australia may have been facilitated by the absence of 
Tasmanian devils. The fox and the cat are regarded as “super-predators” that our 
native animals are ill equipped to coexist with (Lachish et al 2007, Wright and 
DPIPWE 2010).    
1.1.2 Pathogenesis DFTD  
DFTD neoplasms have a 100% mortality rate and the actual mechanism of death is 
still speculative but implications include starvation, septicaemia from secondary 
infections, metastases and toxins release by necrosis (Deakin et al 2012).  
Starvation and cachexia may occur because the tumour growth may impair the 
senses associated with finding food by overgrowing the eye and obscuring vision, 
diminishing the tactile senses of the whisker beds, or compromising the senses of 
smell and taste. The lesions associated with the face and mouth may preclude the 
acts of seizing, holding and chewing on food (Pyecroft et al 2007). The devil’s 
appetite may be suppressed by the tumour producing appetite suppressing cytokines 
(Inui 2002). Other causes of cachexia include increased catabolism, diverting 
calories to tumour growth and the loss of protein through the tumour surface (Bruera 
1997, Pyecroft et al 2007). 
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There is a large amount of necrosis associated with DFTD. This has the potential to 
release toxins and promote secondary infections which could result in septicaemia 
(Pyecroft et al 2007). The disease has demonstrated a high rate of metastatic 
invasion of other organs and this may impact on the functioning of organs such as 
the respiratory organs (Loh et al 2006a). Even the factor of pain may contribute to 
the mortality of the disease (Loh et al 2006b, Pyecroft et al 2007). 
1.1.3  DFTD pathology 
DFTD is a malignant neoplasm producing large amounts of necrosis (73% n=91), 
rapid tumour growth and a high incidence of metastatic disease in infected devils 
(65% n=91) (Loh et al 2006a, Loh et al 2006b). DFTD presents with a singular 
morphology as an undifferentiated subepithelial sarcoma, presumed to arise at the 
site of transfer as a result of biting (Loh et al 2006b). The tumours develop into large 
masses that usually protrude from the face, mouth or neck region and tend to be 
ulcerated, exuding flat surfaces that crumble and deposit infectious cells on the 
canine teeth making possible further transmission of the disease (Loh et al 2006a). 
Post mortem examinations (n=91) detected metastases in lymph nodes (57%), lungs 
(47%); spleen (12%); heart, ovary and serosal surface of rib (6%); kidney, mammary, 
adrenal and pituitary glands (5%); and vascular invasion in 4% of cases (Loh et al 
2006a).  
DFTD cells are anaplastic and pleomorphic presenting as round (≈ 8 µm) or spindle 
shaped with no distinctive ultrastructural features. They have a single round nucleus 
(≈ 5.75 µm) with scattered condensed chromatin and the cytoplasm is a hazy blue 
colour with a high nuclear to cytoplasmic ratio of 1:1.2. Transmission electron 
microscopy revealed that concentration of organelles was low and included rough 
endoplasmic reticulum, free ribosomes, polyribosomes, cytoskeletal filaments, large 
vesicular mitochondria, ribosomelamella complexes, secretory granules, endocytotic 
vesicles, well developed Golgi apparatus, centrioles and myelin bodies. Primitive 
desmosome-like structures were detected at low numbers which explains their 
tendency to clump together in preparations (Loh et al 2006a).      
The principle of immunohistochemical tests when determining origin of cells in poorly 
differentiated neoplasms presumes that immunophenotypes are preserved. By 
studying the proteins expressed by the DFTD cells it was hoped that the origin of 
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DFTD could be determined. This work was hindered by the lack of previous studies 
of immunohistochemistry (IHC) applied to the Tasmanian devil. What was seen was 
that the DFTD neoplasm develops as a heavily vascularised well defined dense 
cellular structure that is resistant to infiltrates and is often enclosed in a 
pseudocapsule produced by the compression of the surrounding connective tissue. 
Cells can be arranged in a variety of patterns including bundles, cords, palisades 
and sheets (Loh et al 2006a). The DFTD cells test positive for vimentin (n=50/50), S-
100 (n=41/48), melan A (n=11/39), neuron specific enolase (n=35/35), chromogranin 
A (n=12/12) and synaptophysin (n=29/30) (Loh et al 2006b, Pyecroft et al 2007).  
It should also be noted that DFTD neoplasms tested negative for cytokeratin (n= 
0/48), epithelial membrane antigen (n= 0/42), von Willebrand factor (n= 0/11), 
smooth muscle actin (n= 0/26), desmin (n= 0/47), glial fibrillary acid protein (n= 0/13), 
CD16 (n= 0/13), CD57 (n= 0/43), CD3 (n= 0/18), LSP1 (n=0/16) and amyloid (n= 
0/30). They were weakly argyrophilic (n= 3/40) using Grimelius histochemical stain 
but failed to be stained with silver using the Singh silver method (n= 0/34) (Loh et al 
2006b). 
The IHC results are inconsistent with DFTD originating from Ewing’s sarcoma, 
CTVT, Merkel cell tumour, melanoma, neuroblastoma and lymphosarcoma. The 
negative results for desmin, smooth muscle actin and glial fibrillary acid protein 
suggest that it is unlikely that DFTD originated from muscle or neural cells. The lack 
of CD16, CD57 and LSP 1 demonstrates that DFTD is not associated with 
leukocytes including B cells, T cells, monocytes, dendritic cells (DCs) and 
macrophages. Lack of epithelial markers including cytokeratin, epithelial membrane 
antigen and von Willebrand factor combined with the positive results for S-100 and 
vimentin support DFTD being classified as a sarcoma (Loh et al 2006b).    
These staining characteristics are consistent with cells of neuroectodermal origin and 
electron microscopy failed to contribute towards the histiogenic origins of DFTD (Loh 
et al 2006b). The positive staining of DFTD tumour tissues with antibody specific to 
Schwann cell specific myelin protein, periaxin (PRX) further narrowed down the 
origin of DFTD to a Schwann cell tumour (Murchison et al 2010). Periaxin was 
identified as a most useful molecular marker to confirm DFTD neoplasm in 
suspected neoplasms and associated biopsies (Tovar 2012). 
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The premise that DFTD arose from a Schwann cell origin is consistent with the 
observation of S-100 (n= 41/48) which is regarded as a marker associated with 
neural-derived tumours (Stroup and Pinkus 1988). Further evidence of neural origin 
is the consistent detection of neuron specific enolase (n= 35/35), chromogranin A 
(n= 12/12) and synaptophysin (n= 29/30) which are IHC stains specifically 
associated with neuroendocrine cells (Loh et al 2006b). The morphology, 
ultrastructural characteristics and weak argyrophilic differentiation of DFTD cells are 
consistent with a Schwann cell origin (Loh et al 2006b).  
DFTD tumours are arranged in a manner comparable to neuroendocrine organs 
such as the thyroid, islets of Langerhans, pituitary and adrenal glands. 
Neuroendocrine cells are also dispersed throughout the body and are particularly 
concentrated in tissues associated with the sense of touch including the lips and 
whisker beds. These facial regions are the locations were DFTD transmission is 
usually observed and therefore the tissues would be conducive to the establishment 
of the disease after transmission by biting (Loh et al 2006b).      
1.1.4 Karyotype reveals clonal nature of DFTD 
The consistency of IHC and chromosome rearrangement of DFTD cells regardless of 
gender and geographic location of Tasmanian devils supports the contention that 
DFTD is a single tumour clone transmitted between individuals (Loh et al 2006b, 
Pyecroft et al 2007). The DFTD karyotype represents an extensive rearrangement of 
the Tasmanian devil’s chromosomes that is relatively stable and consistent between 
hosts (Pearse and Swift 2006). There are now nine strains identified which are 
closely related and easily explained by evolution of the original strain (DPIPWE 
2009)  
A normal devil has 14 chromosomes including the sex chromosomes. DFTD cells 
lack the sex chromosomes, chromosome 2 pair is missing, chromosome 6 is not a 
pair and the long arm of chromosome 1 is deleted. DFTD has an additional four 
marker chromosomes present (M1-M4) giving it a total of 13 chromosomes but only 
eight of these are in pairs (Figure 1-1) (Pearse and Swift 2006).   
 
1-7 
 
 
Figure 1-1 - Chromosomes of DFTD cells compared to male Tasmanian devil (Pearse and Swift 
2006) 
a) Typical karyotype for male Tasmanian devil 
b) Karyotype of DFTD consistent between hosts 
 
The lack of intermediate stages during disease development supports the theory that 
DFTD is an infectious allograft. Molecular studies reveal that DFTD cells have MHC 
class I and II genes that are distinct from the host’s genes and Amplified Fragment 
Length Polymorphism have revealed considerable genetic difference between DFTD 
cells and those of the host (Pyecroft et al 2007). Further supporting evidence that 
DFTD represents a clonal cell line came from the observation of a pericentric 
inversion of chromosome 5 in all the tissues of a particular devil. The chromosome 5 
in the DFTD cells did not have this inversion indicating the tumour had not developed 
from the devil’s own tissues (Pearse and Swift 2006).  
1.1.5 DFTD transmission 
Most primary tumours develop on the face. This is consistent with the theory that 
DFTD is an allograft transmitted through the biting behaviour of Tasmanian devils 
(Pyecroft et al 2007). These tumours ulcerate, become friable and deposit 
contagious cells on the canines of infected devils which in turn facilitate the 
transmission of the allograft to the next devil (Pearse and Swift 2006). Biting is 
frequent in Tasmanian devils when squabbling over sex or food and penetrating 
bites are more frequent in adults rather juveniles (Hamede et al 2008).   
Tasmanian devils have competent immune systems and on transmission should 
reject the DFTD cells (Kreiss et al 2008). Examination of haematoxylin and eosin 
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sections of DFTD tumours revealed only 7% demonstrated lymphocyte infiltration 
providing little evidence of cell-mediated immunological responses (Loh et al 2006b). 
Possible explanations for the lack of immune surveillance and rejection include 
alteration of MHC class I and class II antigen expression by the DFTD cells (O'Neill 
2010).  However, Siddle et al. (2007) stated that this form of immune escape was not 
occurring based on results from real-time PCR experiments. They proposed that lack 
of MHC diversity in the Tasmanian devils allowed DFTD cells to be seen as ‘self’ 
rather than ‘non-self’ thereby avoiding elimination by the immune system (Siddle et 
al 2007). 
Research on other species, such as the African cheetah (Acinonyx jubatus), indicate 
that MHC rejection between individuals can be compromised due to limited MHC 
diversity (O'Brien et al 1985). In skin graft trials all allografts between unrelated 
cheetahs were accepted and did not cause acute graft rejection (O'Brien et al 1985). 
A similar trial with Tasmanian devils revealed an acute rejection of all skin grafts 
providing evidence for sufficient MHC diversity amongst the devil population to cause 
allograft rejection (Kreiss et al 2011a). Therefore MHC expression on DFTD cells 
should be recognised by at least some Tasmanian devils as non-self.  
The Tasmanian devil skin graft results meant that a lack of allorecognition did not 
explain the transmissibility of DFTD cells (Kreiss et al 2011a). Despite this, in 2012 
the hypothesis of MHC bottleneck in Tasmanian devils being the prime mechanism 
facilitating DFTD transmission was still highly regarded and cited by experts in the 
field of DFTD (Belov 2012). In 2013, further research by Siddle et al. revealed MHC 
was epigenetically downregulated and lack of surface MHC molecules was the prime 
mechanism facilitating transmission of DFTD cells (Siddle et al 2013).     
1.1.6  DFTD management  
When the disease was first detected in animals inhabiting the Freycinet Peninsula in 
2001, it had been thought that younger animals were not susceptible to the disease 
or that there was a long latency period for the disease (Hawkins et al 2006). In due 
course diseased sub-adults were captured (Hamede et al 2008, McCallum et al 
2009). The natural progression of the disease in a population was older animals first, 
followed by younger adults and when the majority of the adults had died out then 
juveniles became infected (Lachish et al 2007).  
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Research into the contact networks of Tasmanian devils suggest that DFTD is 
capable of spreading to every individual within the population once a single individual 
becomes infected (Hamede et al 2009). To facilitate disease management there is 
an urgent need for a pre-clinical diagnostic test capable of rapid detection of infected 
animals before they become infectious.  Such a test would permit population 
surveillance and suppression of the disease by removal of infected animals before 
they have the opportunity to transmit the disease (Hamede et al 2009). The benefit 
of removing infected individuals from a population needs to be balanced against the 
reproductive input that the diseased individual contributes to the population (Lachish 
et al 2007, McDonald-Madden et al 2010). 
1.2 Canine Transmissible Venereal Tumor 
Besides DFTD, CTVT is the only other known transmissible tumour in real world 
populations. CTVT transmission occurs during coitus and results in a neoplastic 
disease that affects the external genitalia of both sexes (Harmelin et al 2001).  
Molecular studies of the CTVT tumour genes support the theory that all cases of 
CTVT, despite being geographically diverse, arose from a single cellular clone that is 
transmitted by engraftment (Harmelin et al 2001). Characteristic marker 
chromosomes make CTVT genetically distinct to the host (Murgia et al 2006). The 
dog leukocyte antigen haplotype of CTVT is different to each host but consistent 
between all CTVT tumours (Murgia et al 2006).  
The possibility of viral aetiology has been considered in the case of both CTVT and 
DFTD (Pyecroft et al 2007). CTVT can only be transmitted by viable tumour cells and 
not dead cells or cell free filtrates which argue against a viral aetiology and supports 
the suggestion of a transmittable clone (Murgia et al 2006). Additional evidence in 
the case of both CTVT and DFTD is that the host’s individual MHC is not expressed 
on the cell surface of the tumours suggesting that the tumours did not arise from a 
virally caused transformation of the host cells (Harmelin et al 2001, Pyecroft et al 
2007).   
CTVT has three distinct disease phases. The first phase is the “progressive phase” 
immediately following infection. MHC class I expression by the tumour is relatively 
low in this first phase (Das and Das 2000). This protects the cells from T cell 
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responses while the partial expression of MHC is protective from natural killer (NK) 
cell responses (Fassati and Mitchison 2010). The second phase of CTVT is the 
“stationary phase” were the tumour neither seems to progress or regress and this 
may be as a result of equilibrium between immunosurveillance killing CTVT cells and 
proliferation of CTVT cells (Fassati and Mitchison 2010). When this equilibrium is lost 
the disease moves into the third phase, “regression phase”, which ultimately results 
in elimination of experimentally induced CTVT after 3-9 months (Fassati and 
Mitchison 2010, Murgia et al 2006).  
In the regression phase of CTVT MHC class I is upregulated to normal levels and the 
immune system recognises the tumour and eliminates it (Fassati and Mitchison 
2010). The ability of CTVT to regulate MHC expression differentially suggests an 
epigenetic mechanism is at work and pathology suggests that tumour infiltrating 
lymphocytes (TILs) and macrophages may be altering the tumour’s 
microenvironment triggering regression (Fassati and Mitchison 2010). This can be 
explained by the TILs producing IL-6 and IFN-γ which counteracts the TGF-β activity 
and induces MHC class I antigen expression (Hsiao et al 2008).  
As well as suppression of MHC class I, additional elements of immune system 
invasion revealed by the CTVT model include suppression of MHC class II 
molecules, downregulation or loss of β2-microglobulin and expression of cytokines 
that suppress immune system responses against the tumour (Fassati and Mitchison 
2010). CTVT production of TGF-β suppresses MHC expression and inactivates 
IFN-γ activity (Hsiao et al 2008).         
The upregulation of MHC class II expression in the regression phase may also be 
significant as suggested by the presence of antibodies to MHC II in recovered dogs. 
MHC class II is fundamentally a receptor to facilitate communications between 
lymphocytes and is rarely expressed in other types of cancer and tumour cells 
(Fassati and Mitchison 2010).     
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1.3 Immune system responses to tumours  
1.3.1 Cancer immunosurveillance and immunoediting hypotheses 
The “cancer immunoediting hypothesis” proposes that the immune system is 
constantly surveying the health of cells, recognising and destroying cancerous or 
pre-cancerous cells before they have the opportunity to proliferate. This process on 
one hand eliminates most tumours before they become clinically relevant but on the 
other hand subjects tumours to selection pressures that are responsible for the 
immunogenic phenotype of tumours that overwhelm, evade or hijack the immune 
system becoming clinically relevant (Dunn et al 2002, Finn 2012).  
Mouse models have demonstrated that tumours which develop in 
immunocompromised mice are typically more immunogenic than those that develop 
within the constraints of healthy immune systems. It would be debatable if this is 
simply a case of “survival of the fittest” selecting the least immunogenic transformed 
cells for survival or if it is an active adaptation by tumours regulating expression of 
genes associated with immunogenic markers (Dunn et al 2002).    
It has been proposed that immunoediting consists of three stages or processes: 
elimination, equilibrium and escape. Immunosurveillance may detect and destroy 
individual transformed cells before they proliferate or when a critical mass of cells is 
reached. A deficient immune response may allow the tumour to enter the equilibrium 
or escape phase. In the equilibrium phase a bed of tumour cells survives. These are 
presumably genetically unstable and mutating into new variants facilitating “natural 
selection” for tumour variants capable of escaping immunosurveillance and 
ultimately leading to clinical disease (Dunn et al 2002). In the escape stage the 
tumours have thwarted the immune system responses. This may be as a result of 
becoming invisible to the immune surveillance or through genetic or epigenetic 
changes downregulating the immune system response or proliferating at a rate that 
overwhelms the immune system (Dunn et al 2002).     
1.3.2 Immunosurveillance by the innate and adaptive immune system  
Innate and adaptive tumour suppression pathways that depend on cytokines and 
lymphocytes are well defined (Dunn et al 2002). The innate immune system is the 
first line of protection if the host has an inflammatory response to tumour cells. The 
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response includes activation of the complement system to label cells for destruction 
and migration of neutrophils and NK cells to the site of inflammation (Mroz et al 
2011). The NK cells have the function of directly killing tumour cells as well as 
producing cytokines to attract and activate additional NK cells, macrophages and 
DCs to intensify the immune response (Hanna et al 2004, Kelsall and Rescigno 
2004, Orange and Ballas 2006, Trinchieri 1994).  
When foreign antigens are detected by macrophages the primary response is to 
phagocytose and destroy the antigens making them poor antigen presenting cells 
(APCs). Dendritic cells preserve antigenic peptides from the cells they phagocytose, 
migrate to the lymphoid organs and present antigens to the naïve T cells and B cells 
to initiate adaptive immune responses making them more effective APCs (Herr et al 
2000, Savina and Amigorena 2007). 
Upon presentation of tumour antigens in the lymphoid organs clonal expansion of 
tumour-specific CD4+ T helper cells, CD8+ cytotoxic T cells (CTLs) and antigen 
specific B cells occurs. Chemokines attract these cells to the tumour site and if the 
immune system response is strong enough and specific enough the tumour will be 
eliminated (Dunn et al 2002). 
The innate immune system is characterised by the lack of immunological memory 
and cannot be educated to initiate stronger responses on subsequent exposures 
(Mroz et al 2011). The components of the adaptive immune system, such as T and B 
cells, are capable of being educated into a memory response that enhances 
subsequent responses to a previously experienced antigen. The adaptive immune 
system can then recruit components of the innate immune system through 
antibodies and cytokines to work in synergy as part of a memory response to provide 
lifelong immunity to some tumours (Mroz et al 2011).   
1.3.3 Cells of the innate immune system involved in immunosurveillance   
Granulocytes 
Neutrophils, basophils and eosinophils are a group of innate immune cells that are 
classified as granulocytes. Their main function is releasing leukotrienes, 
prostaglandins and cytokines to promote inflammation. Tumour–infiltrating 
neutrophils are implicated in promoting anti-tumour CD8+ T cell responses in mouse 
models (Grivennikov et al 2010, Mroz et al 2011). Chronic inflammation can promote 
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tumourigenesis so granulocytes can also have a pro-tumour role (Grivennikov et al 
2010).  
NK cells 
Natural killer cells are thymus independent innate immune cells. On activation NK 
cells lyse tumour/virus infected cells, produce cytokines to upregulate the innate 
immune system and promote development of adaptive immune responses (Sivori et 
al 2014).  
Activation is controlled by a balance of inhibitory receptors and activating receptors. 
Natural killer cells have killer Ig-like receptors (KIRs) that bind to self MHC class I 
molecules which inhibits activation to protect healthy cells. These receptors have 
been identified in the Tasmanian devil (Kraan et al 2012). The KIRs can induce 
activation if binding is to aberrant or foreign MHC. Tumour cells and virally infected 
cells often have compromised MHC class I expression making them NK–susceptible.  
Some tumours, such as CTVT, maintain a degree of MHC expression to avoid NK 
killing (Das and Das 2000, Sivori et al 2014).  
NK cells have a number of activating receptors including natural cytotoxicity 
receptors (NCRs) and toll-like receptors (TLRs) with affinity for microbial antigens 
and the ability to detect transformed or foreign cells. In order to be NK-sensitive 
aberrant cells need to present ligands for these receptors. Inducing downregulation 
of NCR expression on NK cells is a mechanism used by some cancer cells to resist 
NK cells (Sivori et al 2014). Besides binding to viral ligands on infected cells natural 
cytotoxicity receptors (NCRs) can bind to tumour cells, which over-express self-
antigens on the cell surface (Sivori et al 2014). For example, membrane bound 
Hsp70 is immunogenic to NK cells but not to T cells (Moser et al 2002).  
Macrophages  
Macrophages are phagocytes derived from monocytes circulating in the blood. As 
well as the secondary lymphoid organs they are located in tissues in close proximity 
to the external environment such as the skin and mucosa (Kelsall and Rescigno 
2004, Mroz et al 2011). Macrophages express a multiplicity of receptors specific for 
many endogenous and exogenesis ligands as well as antibodies and complement. 
Microbes and other cells that have been targeted by opsonisation with antibodies or 
complement are more effectively phagocytosed by macrophages (Mroz et al 2011).  
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Macrophage phenotypes are controlled by gene expression rather than lineage or 
differentiation pathways (Grivennikov et al 2010). Macrophages can be either 
induced into M1 macrophages or M2 macrophages by the tumour microenvironment 
(Heusinkveld et al 2011, Qian and Pollard 2010). 
M1 macrophages arise from stimulation with IFN-γ and TNF-α and produce 
inflammatory cytokines including IL-12 and IFN-γ, which  polarises immune 
responses to TH1 cells (Grivennikov et al 2010, Hao et al 2012). M1 macrophages 
are associated with anti-tumour activity and killing (Qian and Pollard 2010).  
 M2 macrophages are induced by TH2 cytokines, such as IL-4, IL-10 and IL-13 and 
produce IL-10 and IL-4 cytokines, which polarise immune responses to TH2 cells 
(Grivennikov et al 2010, Hao et al 2012). M2 macrophages promote tolerance to 
tumours by suppressing TH1 cells (Heusinkveld et al 2011, Lindau et al 2013). These 
M2 macrophages also support pro-tumour functions including facilitating metastasis, 
angiogenesis, intravasation, immune suppression, tumour cell invasion and 
inflammation (Qian and Pollard 2010).  
Dendritic cells 
Dendritic cells derived from bone marrow are particularly efficient APCs and 
fundamental to promoting long-term tumour immunity (Fong and Engleman 2000, 
Mroz et al 2011). This is because, unlike macrophages, DCs preserve antigenic 
peptides from the cells they phagocytose. These mature DCs then migrate to the 
lymphoid organs where they present antigens to the naïve T cells and B cells to 
initiate adaptive immune responses (Herr et al 2000, Savina and Amigorena 2007). 
Dendritic cells exist in either an immature state or are activated by environmental 
signals into a mature state. Tumours often evade the immune system by 
suppressing the necessary signals within the tumour microenvironment to activate 
DCs (Mroz et al 2011). When immature DCs examine the tumour environment, 
capture antigens, migrate to the lymph nodes and present these antigens to T cells 
without costimulation this leads to tolerance by deleting reactive T cells and 
generation of regulatory T cells (Tregs) (Mroz et al 2011).  
Cytokines associated with inflammation induce maturation of DCs which then 
presents the phagocytosed antigens to CD4+ and CD8+ T cells in the lymph nodes 
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via surface expressed MHC molecules in conjunction with the necessary 
costimulatory molecules. This results in adaptive immune system responses from 
primed CD4+ T helper cells, CD8+ cytotoxic T cells and antigen specific B cells. 
Mature DCs express IL-12 which promotes TH1 immune responses which are 
required for anti-tumour immunity (Mroz et al 2011). 
Dendritic cells also express TLRs. When DCs are stimulated through TLR3 they 
produce cytokines including IL-12 which recruit and activate NK cells. These NK 
cells then target the viral infected cells and immature DCs. This ‘editing’ of DCs 
selects for mature DCs that will present to CTLs to promote a TH1 type response 
(Sivori et al 2014).       
1.3.4 Cells of the adaptive immune system involved in immunosurveillance   
B cells 
During immunosurveillance macrophages and DCs present tumour antigens to naïve 
B cells (Finn 2012). Naïve B cells then mature into either plasma B cells or memory 
B cells. Plasma cells are relatively short lived and act as antibody factories to assist 
the immune system’s acute response to a pathogen. The memory cells are long lived 
and serve a surveillance role that rapidly switches to clonal expansion of new plasma 
cells on subsequent exposure to the specific antigen (Abbas and Lichtman 2003).  
These antibodies can have direct cytostatic or cytotoxic effect on the tumour cells. 
Antibody binding to tumour cells can engage NK cells to directly kill the tumour cells 
as well as increasing the efficiency of phagocytosis by DCs and macrophages. 
These phagocytes can then cross-present more tumour antigens to T cells and B 
cells further enhancing the immune response by generating polyclonal responses 
against multiple tumour antigens. This would minimise antigen-negative tumour 
escape mechanisms (Finn 2012).   
B cells can also have a pro-tumour role subverting TH1 anti-tumour responses 
towards ineffective TH2 responses. This is because B cells can produce IL-10 which 
counterbalances IFN-γ activity. IL-10 promotes Tregs, inhibits CTL responses and 
prevents maturation of DCs. When immature DCs present tumour antigens to T cells 
this promotes tolerance rather than elimination (Lo-Man 2011).    
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T cells 
A suite of naïve T cells are located in the lymphoid organs and clonal expansion of 
the naïve T cells with the correct antigen specificity occurs on APC presentation. 
These differentiate into memory T cells and CD4+ effector cells or CD8+ effector T 
cells. Some cells remain in the lymphoid organ while others disperse into the 
bloodstream where they can be transported to the site of infection. Effector cells are 
relatively short lived and primarily serve the role of an acute response to eliminate 
the pathogen (Abbas and Lichtman 2003, Herr et al 2000, Savina and Amigorena 
2007).  
CD4 T helper cells can be TH1, TH2 or TH17 phenotype (Grivennikov et al 2010). 
CD4+ TH2 cells recognise class II MHC associated peptides presented on the cell 
surface of APCs and secrete cytokines and express membrane molecules to switch 
M1 macrophages to M2 phenotype and direct B cells to produce antigen–specific 
antibodies (Abbas and Lichtman 2003, Grivennikov et al 2010). These actions tend 
to be ineffective against tumours and often promote tumour tolerance, growth and 
metastasis (Grivennikov et al 2010).  
CD4+ TH1 cells also recognise MHC class II associated peptides presented on the 
cell surface of APCs but produce TH1 cytokines such as IFN-γ that help CTL 
responses against tumours. CD4+ TH1 cells can switch M2 macrophages to M1 
macrophages (Heusinkveld et al 2011). CD4+ TH17 cells promote the activation of 
CTL by producing appropriate cytokines (Grivennikov et al 2010).   
CD8+ T cells function as CTLs and kill atypical cells based on MHC I associated 
peptides presented on cells. The CTLs have the discerning power to ignore self and 
target foreign MHC I associated peptides. They directly lyse tumour cells and secrete 
cytotoxic TH1 cytokines such as IFN-γ and TNF-α (Grivennikov et al 2010). They 
initiate a long-term cellular response (Karbach et al 2012, Stevanovic 2002).  
Before exposure to a specific antigen about one in a million naïve T cells is specific 
to that antigen. Following presentation of the antigen by APCs clonal expansion of 
the antigen specific naïve T cells occurs. Then one in ten T cells may be specific for 
that antigen during the peak phase of immune response. Post infection the antigen-
specific T cells undergo apoptosis and stabilise at about one in ten thousand T cells.  
Compared to naïve T cells, effector and memory T cells require lower levels of 
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antigen to develop strong responses. This makes B cells and macrophages efficient 
APCs in the effector phase of T cell responses (Abbas and Lichtman 2003). 
However, it has been suggested that there is impaired interactions between the T 
cells and the macrophages in the Tasmanian devil (Michael and Sangster 2010).  
1.3.5 Immunosuppression in the tumour microenvironment 
While the immune system is capable of mounting effective anti-tumour responses it 
can also promote tumour survival, invasiveness and metastasis. Tumour cells can 
attract immunosuppressive cells (Finn 2012, Freire and Osinaga 2012). The most 
common suppressive cells include Tregs, regulatory B cells (Bregs), M2 
macrophages, type 2 NKT cells and myeloid derived suppressor cells (Bjordahl et al 
2012, Lindau et al 2013, Vasievich and Huang 2011). The purpose of these cells is 
to prevent harm such as autoimmune diseases from an unrestrained immune 
response but tumours subvert these cells to their advantage (Finn 2012, Freire and 
Osinaga 2012). 
1.3.6 Cytokines and cancer  
Cytokines play a critical role in promoting or suppressing tumours. There is a 
fundamental concept of a balance between TH1 and TH2 responses that can be 
characterised by cytokines and the type of immune cells that become activated 
(Shurin et al 1999). Interferon-gamma (IFN-γ) is the dominant TH1 cytokine that is 
counterbalanced by the TH2 cytokine IL-10 (Shurin et al 1999). TH2 cytokine 
responses are seen as pro-tumour and supportive of the growth and spread of 
cancer (Shurin et al 1999)   
TH1 cytokines: IL-2, IFN-γ and IL-12 
Good anti-tumour responses are initiated and maintained by CD4+ TH1 cells 
producing IL-2 and IFN-γ cytokines. Lack of IL-2 and IFN-γ responses promotes 
allograft acceptance (Shurin et al 1999).   
IL-2 promotes proliferation of CTLs and enhances the function of NK cells (Dranoff 
2004, Shurin et al 1999). Downregulation of IL-2 is associated with most cancers and 
Tregs suppress CTL responses by consuming IL-2 which is critical to CTL function 
(Schreiber et al 2011, Shurin et al 1999). 
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IFN-γ mediates activation of CTLs and other TH1 cells (Shurin et al 1999). It is 
produced by T cells, NK cells, NKT cells and to a smaller degree macrophages and 
DCs (Dranoff 2004). IFN-γ can increase the immunogenicity of tumour cells by 
upregulation of MHC class I expression (Dunn et al 2002). It increases tumour 
antigen presentation, promotes cytotoxicity and suppresses tumours of microbial 
aetiology (Dranoff 2004).  
IL-12 is the foremost cytokine in promoting a TH1 response that increases 
cytotoxicity and inhibits angiogenesis (Dranoff 2004, Shurin et al 1999). IL-12 along 
with IFN-α and IFN-γ are produced by mature DCs to overcome tolerance and switch 
the T cell responses from regulatory T cell responses to effective CTL responses 
(Yong et al 2012).  
The anti-tumour activity of TH1 inflammatory cytokines is counterbalanced by the 
tumourigenesis role of these cytokines during chronic infection and inflammation 
(Dranoff 2004). 
TH2 cytokines: IL-10 and IL-4 
IL-10 is widely recognised for its anti-inflammatory properties and immunoregulatory 
functions (Emmerich et al 2012). It is a cytokine of particular significance to the study 
of cancer as it has a dominant role in suppressing anti-tumour TH1 responses and 
promoting ineffective TH2 responses (Shurin et al 1999). Activation of CD4
+ T cells is 
inhibited by IL-10 signals, preventing them from expressing cytokines (Emmerich et 
al 2012).  
IL-10 promotes tumour survival by inhibiting tumour antigen presentation by APCs 
(Dranoff 2004). This is achieved by suppressing the expression of MHC class II and 
co-stimulatory molecules of APCs (Emmerich et al 2012). Expression of pro-
inflammatory cytokines such as IFN-γ by APCs is also downregulated by IL-10 acting 
as an immunoregulatory cytokine (Emmerich et al 2012).   
The immunoregulatory suppression role of IL-10 is most evident in the priming phase 
of the immune system response (Emmerich et al 2012). This results in suppressed 
activation of macrophages, DCs and T cells. However, previously activated CD8+ T 
cells, because of their increased expression of IL-10 receptors become reactivated 
rather than suppressed by IL-10 (Emmerich et al 2012).     
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IL-4 is an important TH2 cytokine that is often upregulated in the tumour 
microenvironment and contributes towards metastatic disease (Shurin et al 1999). 
IL-4 promotes T cell activation and eosinophil function but inhibits CTLs (Dranoff 
2004, Shurin et al 1999). IL-4 contributes towards tumour progression but does not 
play a critical role when tumours are in a state of equilibrium (Teng et al 2012). 
Upregulation of both IL-4 and IL-10 suppresses CTLs and promote allograft 
acceptance by inducing antigen specific tolerance (Shurin et al 1999). 
 Anti-tumour cytokines: IL-15, IL-18, M-CSF, GM-CSF, IFN-α, TNF-α and 
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IL-15 is produced mainly by APCs and promotes cytotoxic responses by stimulating 
the clonal expansion of CD8+ T cells, memory cells and to a lesser extent effector 
cells (Abbas and Lichtman 2003, Dranoff 2004).  
IL-18 promotes a TH1 response increasing cytotoxicity and inhibiting angiogenesis 
(Dranoff 2004, Shurin et al 1999). IL-18 can be generated by DCs in the tumour 
microenvironment and this maintains CTLs and TH1 cells (Shurin et al 1999). 
Macrophage colony-stimulating factor (M-CSF) is a cytokine produced by 
macrophages, endothelial cells, fibroblasts, bone-marrow stroma cells and promotes 
anti-tumour macrophage function (Dranoff 2004). 
Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a cytokine produced 
by T cells, NK cells, NKT cells, macrophages, endothelial cells, fibroblasts and 
respiratory epithelial cells. It promotes growth, differentiation and tumour antigen 
presentation of DCs (Dranoff 2004, Yong et al 2012). It also increases the activity of 
macrophages, granulocytes and NKT cells (Dranoff 2004). 
IFN-α increases tumour antigen presentation and promotes cytotoxicity. Clinical trials 
with IFN-α have shown that some patients have prolonged survival and generate 
CD8+ T cells that are specific to the tumour (Dranoff 2004). 
TNF-α induces apoptosis in tumour cells and activates endothelium and 
granulocytes as well as promoting DC maturation and antigen presenting abilities to 
elicit CTL anti-tumour responses (Dranoff 2004, Yong et al 2012). 
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TNF-related apoptosis-inducing ligand (TRAIL) is a cytokine produced by most 
normal tissues and by binding to death receptors on tumour cells it can induce 
apoptosis of tumour cells (Cormier 2013, Dranoff 2004). 
Pro-tumour cytokines: IL-6, IL-13 and TGF-β 
The role of IL-6 in cancer is difficult to define as it has both pro- and anti-tumour 
activities ( Dranoff 2004, Sato et al 1993). It is a regulator of Tregs and enhances T 
cell and B cell function (Kimura and Kishimoto 2010). Downregulation of IL-6 inhibits 
proliferation of lymphocytes (Dranoff 2004). IL-6 is often upregulated in the tumour 
microenvironment (Shurin et al 1999). IL-6 and IL-15 upregulation correlates to 
increased NK cell killing in CTVT (Fassati and Mitchison 2010).   
IL-13 stimulates humoral responses and inhibits cytotoxic responses (Dranoff 2004, 
Shurin et al 1999). 
Transforming growth factor beta (TGF-β) is a cytokine secreted by many cells and 
can be released by the tumour cells themselves as a mechanism to weaken immune 
responses (Dranoff 2004, Shurin et al 1999). It is one of the most potent 
immunosuppressive cytokines that directly inhibits DC, NK and CTL functions while 
promoting the activation and proliferation of Tregs which suppress effective anti-
tumour immune system responses (Dandawate et al). Upregulation of TGF-β is 
tumour protective and worthy of investigation in the DFTD microenvironment; 
however, CTVT cells secrete TGF-β but levels do not significantly vary between 
progressive and recessive disease stages (Hsiao et al 2008).  
 Cytokine therapies 
Intratumoural injections of cytokines such as IL-2, IL-4, IL-6, IL-7, IL-12, IFN-γ, 
lymphotactin and GM-CSF can promote anti-tumour immune responses. Systemic 
therapies involving cytokine injections are less promising causing what could be 
described as a cytokine storm (Dranoff 2004).  
High dose IL-2 therapy results in tumour regression in only a small number of 
patients. Lower doses of IL-2 upregulates NK cells, however, regulatory T cells 
which suppress anti-tumour responses are also upregulated (Dranoff 2004). IL-2 has 
been given FDA approval for treatment of melanoma and renal cancer. The IL-2 can 
be included in vaccines to maintain dendritic cell growth (Yong et al 2012).  
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While the pro-tumour effects of IL-10 are widely recognised the anti-tumour roles of 
IL-10 are rarely reported. Localised IL-10 in the tumour micro-environment promotes 
tumour resident CD8+ T cell activation, proliferation and anti-tumour cytotoxic 
responses (Emmerich et al 2012). The benefits of this IL-10 induced anti-tumour 
effect are dependent on the presence of CD8+ resident T cells that have previously 
been activated by tumour antigens (Emmerich et al 2012). 
Treatment with IL-10 has been shown to increase the IFN-γ expression by tumour 
infiltrating CD8+ T cells while lacking a similar effect on CD8+ lymphocytes resident in 
secondary lymphoid organs (Emmerich et al 2012). This observation is consistent 
with the fact that most lymph node resident CD8+ T cells are naïve while the tumour 
resident CD8+ T cells are more likely to be antigen activated cells which are known to 
have increased IL-10 receptor expression (Emmerich et al 2012).  
1.3.7 Apoptosis in cancer 
A characteristic of many cancers is the ability to resist apoptosis. This can lead to 
tumour development, growth and metastasis in addition to hindering anticancer 
therapies (Fulda 2009, Leblanc et al 1999, Lowe and Lin 2000).  
It has been suggested that most tumour cells retain the machinery required for 
apoptosis but have pathway mutations (Lowe and Lin 2000). The apoptosis 
signalling pathway is a multifaceted complementary combination of pro- and anti-
apoptosis signals produced within the cell and in the external tumour environment 
(Lowe and Lin 2000).  
The intrinsic apoptotic pathway is controlled by the cell’s mitochondria to facilitate 
programmed cell death by upregulation of pro-apoptotic molecules (Igney and 
Krammer 2002b). The extrinsic apoptotic pathway involves signalling via death 
receptors and Fas receptors by cytotoxic cells during immunosurveillance.  
The Bcl-2 pathway, Fas/CD95 receptor pathway and PI-3 kinase pathway all have 
significant roles in apoptosis (Lowe and Lin 2000). The downregulation and mutation 
of pro-apoptotic molecules or the expression of anti-apoptotic molecules can inhibit 
apoptosis at the death receptor as well as interfering with perforin/granzyme pathway 
(Igney and Krammer 2002a). A number of anti-apoptotic proteins, such as FLIP, Bcl-
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2, Bcl-x1, Mcl-1, Survivin and PI-9/SPI-6 have been identified in human cancers and 
are predictive of a poor diagnosis.  
Upregulation of soluble receptors and decoy receptors such as sCD95 and DcR3 
that lack functionality and compete for apoptotic signalling ligands in human and 
animal models have also been identified as a tumour escape mechanism (Igney and 
Krammer 2002a). Downregulation of pro-apoptotic molecules such as CD95 and 
various TRAIL receptors may impair tumour surveillance by NK and T cells (Igney 
and Krammer 2002a).   
Determining apoptosis 
There is a number of standard means of determining apoptosis in cells. During the 
earliest stages of apoptosis there is a loss of asymmetry of the cell membrane. This 
leads to exposure of the phosphatidylserine found on the intracellular leaflet of the 
plasma membrane that can then be bound by annexin V. In the very earliest stages 
of apoptosis the membrane remains impermeable to molecules such as propidium 
iodide (PI) and 7AAD but these molecules pass through in late stage apoptosis. 
Necrotic cells pass through PI but bind very little annexin V and this allows 
discrimination of early and late stage apoptosis from necrosis (Vermes et al 2000).  
The TUNEL assay (TdT-mediated dUtp Nick End Labelling) is another protocol to 
detect late stage apoptosis. The exposed 3’-hydroxyl ends of DNA breaks that occur 
in late stage apoptotic cells are labelled with the polymerase terminal 
deoxynucleotidyl transferase (TdT). TdT is an enzyme which then catalyses the 
incorporation of fluorochrome or biotinylated deoxyuridine triphosphate which can be 
detected by immunofluorescence (Obrien et al 1997, Vermes et al 2000).  
 Therapies to promote tumour apoptosis 
Understanding the ability of a specific tumour cell line to undergo or resist apoptosis 
would be critical to selecting appropriate anti-cancer therapies. The genes, proteins 
and pathways that regulate apoptosis are suitable targets for anticancer therapies. 
For example; if a specific tumour upregulates expression of Bcl-2 gene products, 
which inhibit apoptosis, administration of Ad-DF3-Bax to inhibit Bcl-2 may prove 
effective. Alternatively, the viral protein apoptin induces apoptosis and its activity is 
enhanced by Bcl-2 in tumour cells leaving healthy cells intact (Lowe and Lin 2000).     
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 Atypical regulation of NF-KB activity, which controls transcription of DNA, may 
promote tumour survival and the administration of a suitable inhibitor such as I-KB 
may induce tumour cell death. As well, the disruption of the survival signals 
generated by the PI-3 kinase/Akt pathway may reinstate apoptosis in the tumour. 
Inhibition of the Ras-GTPase activating protein appears to selectively promote 
apoptosis in human cancers and not affect normal cells. Restoring lost or mutated 
genes such as p53 is a strategy that has been adopted in clinical trials (Leblanc et al 
1999, Lowe and Lin 2000).  
Selective induction of apoptosis may be possible through TRAIL-induced apoptosis. 
TRAIL is a TNF related protein that binds to the DR4 and DR5 death receptors. 
Healthy human cells express decoy receptors for TRAIL proteins that minimise 
attachment of the TRAIL protein to functioning DR4 and DR5 receptors. Many 
human cancers demonstrate a loss of decoy receptors. This makes them more 
susceptible than healthy cells to induction of apoptosis by increased exposure to 
TRAIL protein as a cancer therapy (Lowe and Lin 2000).  
Most cytotoxic anti-tumour therapies succeed by promoting apoptosis; however, 
adverse effects are often linked to apoptotic death of normal cells because the 
apoptotic signalling extends beyond the tumour cell population (Lowe and Lin 2000). 
It may be that with apoptosis resistance cell lines the promotion of cell senescence 
would be an effective anti-cancer therapy (Lowe and Lin 2000). These treatments 
should prove more effective in synergy with other cancer therapies such as surgery, 
chemotherapy and radiation therapy (Leblanc et al 1999, Lowe and Lin 2000).   
1.4 Murine models for tumour immunology 
1.4.1 Mouse models 
Ideally tumour immunology should be studied in the host species and not a mouse 
model because the results from mouse models do not always correlate to the host 
species (Bierer 2009, Frese and Tuveson 2007). Nevertheless, it is often impractical, 
undesirable or unethical to conduct experiments in the host species in which case 
mouse models can provide valuable information and preliminary data prior to any 
clinical trials (Frese and Tuveson 2007).  
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While some would argue that promising in vitro trials should progress to the host 
species rather than an intermediary mouse model (Bailey 2011) all clinically 
approved agents for the treatment of human cancer have demonstrated positive 
activity in mice (Becher and Holland 2006). However, many agents that have 
therapeutic benefit in the mouse model do not translate into effective treatment in the 
human host (Becher and Holland 2006). 
The use of transgenic animals is intended to minimise the difference between the 
mouse and the host species and it has been noted in some genetically engineered 
mouse models that tumour growth is so similar to that in the host that clinical 
pathologists have difficulty telling them apart using a microscope (Becher and 
Holland 2006).  Xenografts obtained directly from patient tumours have replicated 
the histology and biology of the primary tumour more faithfully than cell lines, some 
of which may have passed through more than 100 passages (Becher and Holland 
2006, Borrell 2010).  
When using mouse models for the study of tumour regression or rejection it is 
paramount to consider the implications that the underlying rejection mechanism may 
be graft rejection rather than tumour specific rejection. In the case of DFTD this is 
less of an issue because in the wild the tumour is transmitted as an allograft which 
under normal circumstances should be rejected by a graft rejection mechanism 
(Azimzadeh et al 1996, Pearse and Swift 2006).  
The shorter lifespan of mice compared to human disease development is significant 
(Kim et al 2003); however, this may be less of a problem in the DFTD model as the 
disease is particularly virulent leading to mortality of the natural host within months of 
infection (Lachish et al 2007). 
There are usually differences in the progression of tumours between host species 
and mouse and this is often seen in variant cellular targets, size of tumour and 
metastatic disease progression. For example, the metastatic route in human breast 
cancer is usually lymphatic while in the mouse model the route is usually the blood 
vessels (Kim et al 2003). 
The study of metastatic disease can be difficult in mice because most implantations 
are done subcutaneously rather than orthotopic (Becher and Holland 2006). This 
1-25 
 
may be less of a problem in the study of DFTD as the implantation of cells in the 
natural host is through biting which implants the cells close to the skin surface in the 
dermis or submucosal connective tissue in the mouth (Loh et al 2006a).  
Mice consume higher amounts of oxygen per cell compared to larger animals and 
this may be significant in the tumour microenvironment were different expression of 
hypoxia-induced genes may occur altering proliferation and differentiation (Kim et al 
2003). The development of blood supply by the process of neovascularisation is 
determined by the host not the tumour itself (Becher and Holland 2006). The 
interaction between stroma cells and cancer is artificial since the stroma is murine 
(Becher and Holland 2006). Species or class specific differences in the binding of 
proteins and metabolism can be another variable in the mouse model experiments 
(Becher and Holland 2006). 
 Mouse models for CTVT 
Since the Russian veterinarian Norwinsky’s first experiments in 1876, CTVT has 
been studied experimentally by transferring viable cells into animals (Das and Das 
2000). Animal studies of CTVT have provided an understanding of how CTVT is 
transmitted as an allograft, accepted by the new host and ultimately regresses 
leaving the dog immune to re-infection (Harmelin et al 2001). Since dogs are not an 
endangered species most of these studies have been conducted in the host species 
(Das and Das 2000). 
Murine xenograft models for CTVT have also been used to reduce the need for 
maintaining allogeneic transfer in dogs (Harmelin et al 2001). Compared to dogs the 
murine model is relatively low cost to house and maintain. There would also be fewer 
problems with maintaining animal ethics approval and greater availability of 
antibodies to study immune responses (Bierer 2009, Harmelin et al 2001).  
CTVT has been engrafted into mice that have had their immune system suppressed 
with irradiation or into immunocompromised athymic nude mice and NOD/SCID mice 
(Harmelin et al 2001). The NOD/SCID model could be considered the model of 
choice as it allows CTVT to be established and progress with the typical 
characteristics of CTVT in the natural host (Harmelin et al 2001). An inoculation of 1 
x 106 cells will produce tumours within 47 days in the NOD/SCID model (Harmelin et 
al 2001).  
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The mouse models primarily can be used to test hypotheses and predict responses 
to treatments. Complex biological problems can be examined and predictive models 
focus on testing treatment responses including efficacy and toxicity (Coghlan 2013). 
The CTVT murine model provides a precedent and justification for using murine 
xenograft models to study the similarly infectious cancer DFTD. It could be expected 
that mouse models that have been successfully exploited for the study of CTVT 
would prove suitable for the study of DFTD since they are both transmissible 
neoplasms (Bierer 2009, Harmelin et al 2001, Loh et al 2006a). 
1.4.2 Xenograft tolerant mouse strains   
There is a variety of mice strains which have specific immunological impairments 
that clarify the immunological functions imperative to tumour engraftment, rejection, 
or regression (Frese and Tuveson 2007, Harmelin et al 2001).  
The three strains discussed in the following paragraphs all lack functional T cells. 
Lack of T cells would limit the protection offered by macrophages (Bancroft et al 
1986). As part of the surveillance of the innate immune system macrophages detect 
threats and present early signals to promote T cell proliferation and differentiation. In 
turn the T cells provide feedback signals that enhance the activity of the 
macrophages (Bancroft et al 1986).       
C.B-17 scid/scid mice  
C.B-17 scid/scid (scid) mice are homozygous for the severe combined 
immunodeficiency (scid) mutation and this results in a lack of functionality of B and T 
cells; however, some young adults might generate a few functional B and T cells and 
by 10 to 14 months nearly all the older adults have developed a limited number of 
functional T cells (Bancroft et al 1986). 
B and T cells are the only leukocytes that have impaired function in a scid mouse. 
NK cells, macrophages, APCs, monocytes, granulocytes and DCs are all normal in 
the scid mouse (Bosma and Carroll 1991). This would provide a model to study 
macrophage, NK cell and DC responses to DFTD cells independent of T and B cell 
interactions (Bancroft et al 1986). 
Lymphoid tissues are underdeveloped. The thymus is typically less than 10% of the 
normal size and the lymph nodes are minuscule and contain few lymphocytes. The 
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spleen presents with an unusual histology and contains macrophages and large 
granular cells but only low numbers of lymphoid cells and plasmacytes. Red blood 
cell levels are normal and serum Ig concentrations are less than 20 ng/ml (Bancroft 
et al 1986, Bosma and Carroll 1991). 
Xenogeneic tumours can be successfully engrafted into scid mice (Bancroft et al 
1986, Bosma and Carroll 1991). The scid mutation inhibits the early development of 
B and T cells but does not affect the ability of the mice to support normal lymphocyte 
proliferation and this has allowed the reconstitution of the immune system with 
functioning lymphocytes from other mice and humans (Bosma and Carroll 1991, 
Pearson et al 2008).   
NOD/SCID mice 
The NOD/SCID mouse strain has been created by backcrossing mice with the scid 
mutation and mice that have a diabetes-susceptible non-obese diabetic (NOD) 
background (Prochazka et al 1992). NOD/SCID mice have a more compromised 
immune system than athymic nude mice and CB-17-scid mice. NOD/SCID mice lack 
T and B cells, lack effective levels of serum antibody, have no complement activity, 
impaired development and function of macrophages and other APCs but do 
demonstrate limited NK cell function (Harmelin et al 2001).  
The lack of functioning T cells from the scid background makes the mice diabetes 
resistant (Prochazka et al 1992). The impaired immunity means these mice must be 
maintained in a pathogen free environment and have a short life expectancy of about 
eight months (Harmelin et al 2001). A single injection with broad spectrum antibiotics 
will usually prevent bacterial infection in NOD/SCID mice (Bastide et al 2002, 
Harmelin et al 2001).  
The NOD/SCID strain has proved suitable for studying certain human cancers 
because there is no evident tumour immunity (Bastide et al 2002). CTVT tumours 
have demonstrated the ability to undergo numerous passages in these mice 
providing a source of tumour cell lines maintained in-vivo (Harmelin et al 2001). The 
NOD/SCID xenograft model preserves the cytological, histological and molecular 
characteristics of CTVT. This facilitates the study of engraftment, disease 
progression including metastasis, diagnosis and treatments for CTVT (Harmelin et al 
2001).   
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Adoptive transfer of immune cells from competent mice to NOD/SCID mice can 
identify the contribution of individual components to effective immunity against 
challenges (Hicks et al 2006). It may be possible to apply this approach to DFTD 
engraftment in NOD/SCID mice to elucidate the ability and role of specific cell 
populations in rejection and or regression of DTFD.   
Athymic nude mice 
The nude mouse has an autosomal recessive mutation of the 11th chromosome that 
disrupts the FOXN1 gene resulting in failure to grow hair and lack of a functional 
thymus. The lack of a thymus means that nude mice are deficient in mature T cells 
including CD4 + and CD8+ cells which has negative implications for cell-mediated 
immune responses including the lack of CD4+ helper T cells to produce antibodies 
(Kim et al 2003).  
The lack of effective anti-tumour immunity makes this strain suitable as a xenograft 
model without the need of additional immune system suppression (Kim et al 2003). 
Human tumours can be maintained through more than fifty passages and still 
demonstrate the same morphology and phenotype with no species hybridization 
(Spangthomsen and Visfeldt 1976). 
Xenograft tumour growth is contained locally in a well defined capsule-like 
connective tissue that is not attached to the skin or underlying tissues. If the athymic 
nude mice did engraft DFTD cells they may because of their hairless nature and 
translucent skin make visual monitoring of tumour growth and precise intratumoural 
injections easier. Another advantage of the athymic nude mice is that they retain 
some functional components of the immune system including macrophages, DCs, B 
cells and NK cells (Spangthomsen and Visfeldt 1976) and these may be stimulated 
with therapeutic agents to target the DFTD cells.   
1.5 Evaluating immune responses  
By studying immune system responses to DFTD it is possible to infer how the 
immune system and the tumour cells respond to each other and this may provide the 
rationale for developing a cancer vaccine or immunotherapy. Antibodies are easily 
measured using flow cytometry. ELISA, ELISPOT, PCR and flow cytometry can be 
used to detect and measure cytokine production by cells in response to specific 
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tumour antigens or tumour cells. Cytotoxic responses against tumours can be 
evaluated by tumour rejection or regression in vivo or cytotoxic activity against the 
tumour cells in vitro (Clay et al 2001).  
The type and level of antibody produced can be informative about the cells and 
cytokines that are directing isotype switching from IgM to specific IgG isotypes. For 
example IFN-γ suppresses IgG1 and promotes IgG2a (Finkelman et al 1988). A low 
ratio of IgG1/IgG2a indicates a TH1-mediated antibody response while a high ratio 
indicates a TH2-mediated antibody response (Kanai et al 2007). T cells are required 
for isotype switching (Arrenbrecht and Mitchell 1975) but other cells can influence 
the process such as NK cells which promote IgG1 production, which mediates 
hyperacute rejection of xenografts (Yin et al 2004).  
Combining antibody responses with cytokine responses presents a more complete 
picture of the TH1/TH2 balance of the immune response. A TH1 response is 
associated with the upregulation of IL-2, IFN-γ and TNF-α cytokines while TH2 
responses are associated with the upregulation of IL-4, IL-5, IL-6, IL-10 and IL-13 
cytokines.  
In vitro cytotoxicity assays can be an important step in identifying cytotoxic function 
of specific cell types including T cells, NK cells and phagocytes (Clay et al 2001, 
Niles et al 2008). Cytotoxicity can be directly measured by enumerating dead cells or 
can be inferred from assays that measure viability (Niles et al 2008).  
Cytotoxicity assays are a direct measure of tumour cell death as a result of CD8+ T 
cells or NK cells lysing tumour cells. The technique can involve incubating effector 
cells with tumour cells that are labelled with radioactive 51Cr. When the tumour cells 
undergo apoptosis they release the 51Cr into the supernatant. The supernatant is 
harvested cell free and measured for 51Cr and this provides a quantitative measure 
of cytotoxicity. However, phagocytosis can be a very efficient form of eliminating 
tumour cells and 51Cr is retained by the phagocytes making this assay insensitive to 
this form of killing (Munn and Cheung 1990).   
Other assays such as calcein release assay, lactate dehydrogenase assay and 
Adenosine 5′-triphosphate (ATP) based assays are available based on similar 
principles. There are also fluorescent techniques that visualise dying cells or viable 
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cells to estimate cytotoxicity (Clay et al 2001, Hermans et al 2004, Lappalainen et al 
1994).  
An in vivo alternative may involve CFSE labelling of DFTD cells which can be 
injected and tracked for cytotoxic activity in vivo. CFSE labelling is reported to affect 
the viability and proliferation of certain cell lines and this may present an 
experimental artefact in any assay involving CFSE (Black et al 2006, Clay et al 2001, 
Hermans et al 2004, Lastovicka et al 2009).  
1.6 Cancer vaccines  
Fundamentally a vaccine exposes the host’s immune system to pathogen specific 
antigens in a non-infectious setting. The vaccine exploits the immune’s system ability 
to recognise, eliminate and remember antigens in the body (Abbas and Lichtman 
2003, Mackay and Rosen 2001, National Cancer Institute 2014).  
Most successful preventative vaccines target the viral aetiology of the cancer rather 
the cancer itself (Castellsagué et al 2011, National Cancer Institute 2014). However, 
there is no basis to suspect a viral link to DFTD disease transmission (Pyecroft et al 
2007).  
Therapeutic vaccines are used to treat established tumours and can be used as an 
alternative to, or in synergy with, treatments such as surgery, radiation and 
chemotherapy (Yang et al 2012b).  Development of therapeutic vaccines has proven 
more difficult than development of preventative vaccines against viral aetiologies. 
Therapeutic vaccines must target specific immune responses and these immune 
responses must be of a magnitude great enough to overcome the protective barriers 
utilised by the tumour cells to thwart the immune system (Yang et al 2012b). The 
vaccine must induce tumour specific CD8+ T CTLs to lyse the tumours and tumour 
specific CD4+  T cells to provide cytokines to enhance CTL activity (Schlom 2012).   
Most vaccines are effective because they stimulate antibody production resulting in 
antigen-specific immunity based on subsequent exposure to T cells (Clay et al 2001, 
National Cancer Institute 2014, Waldmann 2006). Passive immunisation with sera or 
whole blood from CTVT convalescent animals has been trialled (Ganguly et al 2013). 
Antibodies can modify tumours or help identify the tumour to other components of 
the immune system such as CTLs, NK cells or macrophages (Clay et al 2001, Yang 
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et al 2012b). With antibody-dependent cellular cytotoxicity (ADCC) tumour specific 
antibodies bind to the tumour cells and the Fc receptor on NK cells bind to the 
antibody triggering the NK cell to lyse the tumour cell (Waldmann 2006, Yang et al 
2012b).  
 Conventional vaccines 
Conventional vaccines can also be manufactured from killed or weakened cancer 
cells obtained from the patient themselves (autologous) or another person’s cancer 
(allogeneic) (Buonaguro et al 2011, Schlom 2012). The use of freeze-thaw lysates 
obtained from autologous tumour material demonstrates considerable potential to 
induce targeted T cell responses in cancer vaccines (Herr et al 2000). Active 
immunisation with CTVT tumour lysates has been used with some efficacy (Ganguly 
et al 2013). 
Irradiating tumour cells may be more effective than freeze thaw. Studies suggest 
irradiated tumour cells prime dendritic cell-mediated immunity while freeze thaw 
appear to inhibit in vitro killing by CTLs (Meng et al 2012). Irradiated cells present 
danger signals, increased MHC class I expression and express cytokines promoting 
DC and CTL activation for enhanced anti-tumour responses (Meng et al 2012). 
Subunit and conjugate vaccines  
Subunit vaccines present tumour specific surface peptide antigens to activate B and 
T cells via DCs (Black et al 2010). They require the addition of adjuvants to activate 
the immune system as peptides on their own are usually poorly immunogenic (Black 
et al 2010). Conjugate vaccines induce IgG responses by fusing T cell-independent 
antigens with proteins easily recognised by T cells (McCormick et al 2006, National 
Cancer Institute 2014). 
To date antigens have included proteins, carbohydrates, glycoproteins, 
carbohydrate-protein combinations (glycopeptides) and carbohydrate-lipid 
combinations (gangliosides) (Joshi et al 2012, Vigneron et al 2013). These antigens 
represent just part of the tumour being targeted by the vaccine and can be sourced 
from the tumour itself or synthesize based on sequencing data (Black et al 2010, 
Buonaguro et al 2011, Lakshminarayanan et al 2012). The advantages of synthetic 
peptide sequences include they are defined, stable and non-infectious; however, it 
may prove difficult to identify and mimic the correct sequences and sometimes the 
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epitopes recognised by the B-cells are in reality discontinuous sequences (Black et 
al 2010, Mackay and Rosen 2001).  
Dendritic cell vaccines 
Vaccines which depend on the immunogenicity of the vaccine alone without the 
presentation of antigens via DCs are predisposed to failure as they are unlikely to 
elicit a strong enough CTL response. Vaccine strategies aimed at loading DCs either 
in vitro or in vivo with tumour antigens are more likely to promote effective CTL 
responses against the tumour (Baar 1999).  
Dendritic-cell vaccines can be manufactured by growing DCs in vitro while feeding 
them tumour specific or tumour associated antigens. Antigen loading techniques for 
DCs include pulsing DCs with antigens, loading DCs with tumour lysates or whole 
tumour cells, transfecting  DCs with tumour DNA or RNA, or infecting DCs with 
bacterial, viral or yeast vectors. The DCs then manufacture and express the antigens 
on their surface (Baar 1999). Dendritic/tumour cell hybrid vaccines have been trialled 
with CTVT (Pai et al 2011).  
Dendritic cells have great potential as a cancer vaccine adjuvant because they 
promote both CD4+ and CD8+ T cell responses by presenting the tumour antigens 
to naïve T cells resulting in generation of short disease response and long term 
memory response (Herr et al 2000, Ma et al 2012).  
Transgenic vaccines  
Enhanced subunit vaccines can be produced using recombinant-DNA techniques 
that result in both humoral and cellular immune responses (Mackay and Rosen 
2001). Recombinant vaccines involve transgenic transfer of antigen expressing 
genes from the pathogen to another cell type. DNA can also be inserted into 
bacterial plasmids and this will stimulate a strong immune response because of the 
CpG motifs associated with bacterial DNA. Intramuscular injection of the transgenic 
plasmids will result in dendritic cell activation and maturation. Alternatively a gene 
gun could be used to blast the plasmids through the skin causing some plasmids to 
enter DCs directly (Mackay and Rosen 2001). This approach would have potential as 
a vaccine delivery method for Tasmanian devils caught through a trapping program.  
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1.6.1 Adjuvants  
Early attempts at cancer vaccines depended on tumour antigen presentation but 
failed to recognise the importance of co-stimulatory signals required to elicit a CTL 
response. This is a critical requirement of the immune system response to a cancer 
vaccine if it is to be effective. The use of suitable adjuvants may be required to 
provide the maturation signal to the DCs to cause the release of cytokines including 
IL-12 to promote T cell differentiation and activation as CTLs (Yong et al 2012). 
Without the addition of adjuvants many vaccines such as subunit vaccines lack the 
immunogenicity to engage the immune system adequately (Black et al 2010).  
Nearly every marketed vaccine utilises alum as an adjuvant. This has occurred 
because it was the only FDA approved adjuvant until recently (Vasievich and Huang 
2011). AS04 (monophosphorylated lipid A conjugated to aluminum hydroxide) was 
the second adjuvant approved by the FDA and is used in the Cervarix preventative 
vaccine. Granulocyte macrophage-colony stimulating factor (GM-CSF) is an 
(Cerkovnik et al 2010) adjuvant used in Provenge (Sipuleucel-T) which is the first 
FDA approved therapeutic cancer vaccine.  
GM-CSF is technically not classified as an adjuvant by the FDA for the purpose of 
approval as it is a cytokine but effectively is functioning as an adjuvant (Vasievich 
and Huang 2011). Other cytokines and molecules that can be employed as 
adjuvants include costimulatory molecules such as ICAM-1, B7-1 and LFA-3 and 
cytokines such as IL-2, IFN-α and GM-CSF (Vasievich and Huang 2011). These can 
be synthesized and added to treatment vaccines to boost the DCs and CTL 
responses (Vasievich and Huang 2011).  
PAMPs, DAMPs and TLR ligands as adjuvants 
The growing knowledge about the immune system has recognised the indispensible 
role of the innate immune system in presenting tumour antigens to the adaptive arm 
of the immune system. The innate immune system has evolved to produce strong 
and effective responses against bacterial, viral and fungal antigens (Mroz et al 2011, 
Ridnour et al 2013).  
Pathogen-associated molecular patterns (PAMPs) act as signals to the immune 
system to mount a response against infection. Various PAMPs from bacteria and 
viruses bind to Toll-like receptors (TLRs) and stimulate cytokine expression, promote 
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inflammation and recruits innate immune responses (Ridnour et al 2013). In addition 
to PAMPS are DAMPs that are intracellular proteins or nucleic acids released during 
necrosis serving as immuno-stimulants capable of promoting pro-inflammatory 
responses (Mroz et al 2011, Ridnour et al 2013).   
Toll-like receptors recognise PAMPs associated with microbes. Bacterial PAMPs are 
recognised by TLR2 (lipoprotein), TLR5 (flagellin) and TLR9 (CpG DNA motifs). Viral 
PAMPs are recognised by TLR3 (double-stranded RNA), TLR7/8 (single-stranded 
RNA) and TLR9 (CpG DNA motifs) (Sivori et al 2014).  
While NK cells can be directly activated by TLRs the synergy with the 
microenvironment can enhance their cytotoxic activity, direct their regulatory function 
and lead to recruitment of CTL responses (Sivori et al 2014). Recent research has 
also identified PAMPs and damage-associated molecular patterns (DAMPs) as 
molecules which switch on dendritic cell maturation resulting in a full-blown immune 
system response against the presented antigens (Ridnour et al 2013).   
The design of adjuvants has evolved with the understanding of the interaction of 
PAMPs with specific pattern recognition receptors (PRR) including toll-like receptors 
(TLRs) (Dubensky Jr and Reed 2010). TLR ligands are potentially adjuvants starting 
a cascade of events to promote anti-tumour responses (Yong et al 2012). TLR 
ligands induce maturation of DCs into effective APCs. At the same time TLR ligands 
upregulate the expression of costimulatory molecules on DCs and cytokine 
expression by DCs which are essential for the activation and differentiation T cells 
towards TH1 or TH2 responses (Yong et al 2012).  
Tumour cells typically fail to express PAMPs allowing immune system tolerance. 
Administration of TLR antagonistic PAMPS in some instances promote TH1 
responses by activating DCs and promoting production of inflammatory cytokines 
including TNF-α and IL-12.Administration of TLR antagonistic PAMPS needs to be 
localised as systemic administration is highly toxic (Lu 2014). Bacillus Calmette-
Guerin (BCG) and imiquimod are two FDA approved TLR agonists used as 
immunotherapies for treating cancer. Monophosphoryl lipid A (MPL) is a TLR agonist 
approved as a vaccine adjuvant (Adams et al 2012, Lu 2014).  
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On the occasion that TLR agonists are not effective it could be explained by the 
regulatory role of TLR agonists which suppress immune responses by inducing 
IL-10, Tregs and PD-L1 (Lu 2014). The TLR7 agonist imiquimod and the TLR9 
agonist CpG have induced IL-10 and Tregs in some studies (Lu 2014). TLRs 
including imiquimod, CpG and poly I:C have been shown in some studies to induce 
PD-L1 which is a protein that inhibits T cell activation by binding the programmed 
death-1 (PD-1) receptor on activated T cells (Lu 2014). The use of antibodies to 
blockade regulatory signals such as IL-10 is being considered in many of the latest 
trials with TLR agonists (Lu 2014).  
Necrosis of tumour cells tends to promote inflammatory responses and the chronic 
release of DAMPs by necrotic tumour cells can promote tumour survival through 
activation of TLR 1-9 receptors on tumour cells (Mroz et al 2011, Ridnour et al 2013). 
Activation upregulates NF-κB, inhibits apoptosis and generates pro-tumour cytokines 
to hijack immune system responses (Ridnour et al 2013). On the otherhand, 
apoptosis generally results in non-inflammatory disposal by phagocytes. Depending 
of the species of phagocyte recruited apoptosis can be immunogenic or non-
immunogenic and this is most likely linked to DAMPs (Mroz et al 2011). Inflammatory 
responses are required to promote anti-tumour immunity and the discovery of 
DAMPs explains why apoptosis can in some instances promote anti-tumour 
immunity.   
Cells of the immune system including DCs and B cells can be directly activated by 
bacterial DNA segments with 5’-Cytosine-phosphodiester-Guanin (CpG)-3’ motifs. 
The CpG oligodeoxynucleotide sequences are recognised by immune cells which 
express toll-like receptor (TLR9) and signalling through this pathway leads to innate 
immune responses from B cells and plasmacytoid DCs (pDCs). T cells, NK cells and 
monocytes express lower levels of TLR-9 in humans and are not the target of CpG 
immunotherapy strategies. The best CpG-ODN sequences vary between host 
species (Kawarai et al 2011, Vasievich and Huang 2011). 
When the TLR-9 pathway is activated in pDCs and B cells their production of TH1 
and pro-inflammatory cytokines is upregulated as well as TNF. These cells then 
differentiate into plasma cells and/or APCs which present antigens to T cells 
resulting in strong CTL activity against some cancers (Dubensky Jr and Reed 2010, 
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Kawarai et al). The addition of emulsified oils such as montanide can further 
enhance the immune response by maintaining the antigens at the site of injection for 
a prolonged period (Black et al 2010, Cerkovnik et al 2010).   
1.6.2 Vaccination protocols and immunisation routes 
Vaccination protocols usually involve repeated immunisation with the same vaccine. 
A prime-boost protocol may be better for promoting effective and long lasting CTL 
responses against tumours (Mackay and Rosen 2001).  
There are various immunisations routes including intramuscular, intravenous, 
intraperitoneal, subcutaneous, mucosal and epidermal. These are not always equal 
for inducing appropriate immune responses and what may be best for one pathogen 
may be ineffective for another (Fynan et al 1993). As an example, in one study 
immunity against Leishmania could be induced by immunisation with inactivated 
promastigotes administered intravenously or intraperitoneally (Liew et al 1985). In 
the same study subcutaneous or intramuscular immunisations not only failed to 
induce immunity but worsened the disease and resulted in earlier death (Liew et al 
1985).  
1.7 Potential immunotherapy options for DFTD 
Immunotherapy can be passive or active. Passive immunotherapy involves the 
transfer of donor lymphocytes and or antibodies to provide protection. Active 
immunotherapy’s, such as cancer vaccines, modulate the host’s own immune 
system to recognise and overcome tolerance of tumour cells. Promotion of tumour-
specific CTLs can provide life-long immunity (Yong et al 2012). 
1.7.1 Immunotherapy based on Coley’s toxins and bacteria 
Many would regard William Coley as the “Father of Immunotherapy” (McCarthy 
2005) but William Coley was ignorant of the underlying mechanisms of the immune 
system that made his “toxins” effective against cancer. The concept of the immune 
system only appears in the literature in the 1960s (Moulin 1988). He hypothesised 
that the bacteria produced toxins that directly attacked the tumour, believed the heat 
of fever was critical to the cure and even thought there was a ‘cancer bacillus’ 
responsible for the disease (Coley 1891).  
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William Coley was a New York surgeon frustrated by his ineffectiveness in treating 
cancer patients (Coley 1891). Through a search of hospital records he discovered 
over 40 cases of tumour remission following erysipelas infections. Erysipelas 
infections were a not uncommon post-operative infection caused by Streptococcus 
pyogenes in the late 19th Century (Hobohm 2009).  
Coley read the 1885 case notes of a German immigrant named Fred Stein. He had 
inoperable recurrent sarcoma of the neck which five operations had failed to control 
(Coley 1891). Stein contracted erysipelas and nearly died, but when he recovered 
the cancer had gone. In 1891, Coley found Stein who had remained cancer free 
(Coley 1891, Martin 2006, Nauts et al 1953). This inspired him to deliberately induce 
erysipelas in cancer patients to affect a cure (Starnes 1992).  
William Coley was not the first doctor to try treating cancer with deliberate erysipelas 
infections (Coley 1891, Van Arsdale 1886). Coley himself referred to the attempts by 
Bosh who tried patient to patient infection, Fehleisen who used cultured bacteria to 
infect patients and Bruns who reported 3 out of 5 cancer cures following inoculation 
with Streptococcus pyogenes (Coley 1891). 
Coley decided to treat a late-stage cancer patient named Zola with erysipelas. Zola’s 
case notes showed deliberate erysipelas resulted in lifelong remission (Hobohm 
2009, Martin 2006). Coley’s work over next two years with 12 late-stage patients 
demonstrated 2 full remissions, 6 partial remissions and 2 deaths (Hobohm 2009).  
Working with live Streptococcus pyogenes was abandoned due to the fatalities. 
Coley switched to inactivated bacteria and in 1893 treated his first patient with 
“Coley’s mixed toxins”. The first patient was a sixteen year old with malignant 
inoperable cancer. He was given heat sterilised Streptococcus pyogenes combined 
with Serratia marcescens and had complete remission and died of unrelated cause 
26 yrs later (Hobohm 2009, Nauts et al 1953).  
One of the most remarkable cures of cancer by Coley’s toxins took place in 1926. 
The patient had reticulum cell sarcoma and despite amputation of his leg at the hip 
metastatic disease took hold. The stump from the amputation increased to 31 inches 
in circumference due to tumour growth and metastases appeared above the 
umbilicus, in the scalp, vertebrae and cranial bones (Nauts et al 1953). The patient 
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was given 28 daily intratumoural injections into the stump by Dr Palmer and Dr 
Christian (Martin 2006, Nauts et al 1953). Sixty days later there was no signs of 
cancer and he died in 1959 from a heart attack and was cancer free (Martin 2006).  
Despite his impressive case histories his work continues to be ridiculed and mocked 
to this day. The American Cancer Society declared it was “quack medicine” and the 
FDA outlawed its use by classifying it as a new drug even though it had been in use 
for 60 years (Hoffer 1992). Currently it would be difficult to get Coley’s toxins 
approved as a vaccine adjuvant or treatment because the regulatory authorities 
would require a complete understanding of the mechanism of action before approval 
would be granted (Black et al 2010).   
It would be naïve to suggest that Coley’s toxins is a miracle cures all cancer 
treatment. Coley himself felt that his treatment was more effective against sarcomas 
than other cancers (Starnes 1992). Despite Coley’s dedication and determination he 
was not a methodical scientist and his treatment protocols and bacterial extracts 
were inconsistent and reflected in the patient outcomes (Nauts and Swift 1946). 
Coley recognised that he made a fundamental error in the route of administration of 
his toxins in many of his patients. He wanted to demonstrate the systemic benefits of 
his treatment to his peers and treated many of his patients with IV injections or 
injections at sites removed from the tumour. This was less successful than direct 
injections into the tumour (Nauts et al 1953).  
Coley lacked modern day immunological knowledge to interpret the effects he was 
observing. Coley believed Streptococcus pyogenes produced an anti-tumour product 
and we now know this product was not a toxin but a “perfect storm” of TLR and other 
PRR agonists (Decker and Safdar 2009). Coley’s heat inactivated toxins have 
recently been subjected to an immunological study by Maletzki et al (2012) where 
they showed that the effects are caused by activating the immune system through 
toll-like and other pattern recognition receptors. In fact they found the mixture 
contained CpG, lipoteichoic acid and lipopolysaccharide (LPS) which all engage 
TLRs switching immune system responses from one of tolerance to one of effective 
anti-tumour responses (Maletzki et al 2012).  
Commercial preparations such as MBV (produced by Bayer) and Vaccineurin 
(produced by Suedpharma) were produced in the 1960s and 70s which were similar 
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to Coley’s toxins but not identical. These preparations had a degree of mixed 
success and failures because 20th Century attempts to apply Coley’s toxins 
universally failed to recognise the importance of prolong treatment and high fever. 
Fever was considered undesirable and treatment has been modified to minimise 
fever (Hobohm 2009). Also many of the attempts to apply Coley’s toxins have been 
undertaken after the patient’s immune system had been compromised by radiation 
therapy and chemotherapy (Starnes 1992). Coley’s toxins commercially started 
being produced in 2005 by MBVax and exported to countries where regulators 
permitted it use. The company claims that regression was observed in about 70% of 
patients and complete remission in about 20% of patients (DeWeerdt 2013).  
Near the end of his life Coley reflected that it was not unreasonable to presume other 
forms of bacterial toxins could target different types of cancers (Starnes 1992). In 
recent years this has been shown to be true with intratumoural injection of 
Salmonella typhimurium causing tumour regression in human melanoma (Saccheri 
et al 2010, Yoon et al 2011) and injections of Bacillus Calmette-Guerin (BCG) have 
been shown to cause regression of CTVT (Hess et al 1977). In recent years the 
ability of various bacterial toxins to target and internalise within host cells has been 
studied as a means of eliminating cancer cells or enhancing immune responses by 
being included as an adjuvant in immunotherapies (Adkins et al 2012).   
1.7.2 LAK cell therapy 
LAK cells is the term applied to lymphokine-activated killer cells (Qian et al 2014). A 
similar phenomenon is observed with mitogen activated killer (MAK) cells and 
cytokine-induced killer (CIK) cells (Qian et al 2014). A common feature of all these 
activated killer cells is that they target tumours in a non-MHC restricted manner. This 
allows them to target cells which have downregulated MHC expression to avoid the 
immune system (Qian et al 2014).  
LAK cell therapy involves the activation of autologous killer cells populations by 
culturing in cytokines such as IL-2 (Lamb et al 2013). The preparation of LAK cells is 
highly irregular due to variability in the source and status of the autologous 
lymphocytes obtained for activation and inconsistency of protocols to activate these 
cells (Lamb et al 2013). Besides being difficult to produce to a consistent standard 
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they have only a transitory effect in vivo which is further complicated by the toxicity 
effects of IL-2 on return to patient (Lamb et al 2013).  
NK resistant tumours are sensitive to LAK cell lysis (Grimm et al 1983). Initially it was 
believed that LAK cells therefore represented a population of cytotoxic cells distinct 
from NK and CTLs (Grimm et al 1983) but it is now known that LAK cells are 
predominantly NK cells (Herberman et al 1987). The in vivo LAK killing phenomenon 
extends beyond NK cells and involves a cascade of events that recruits 
macrophages and CTL responses (Geldhof et al 2002). There is also evidence of a 
critical role of NKT cells in LAK and MAK cell activation and killing (Linn and Hui 
2010, Richards 1989). 
The cost of generating LAK cells in vitro and the short duration of anti-tumour activity 
following adoptive transferred to the patient has limited the clinical application of LAK 
cells (Ishikawa et al 2012). Inadequate cytotoxic activity against the tumour and 
limited effector cell numbers presents an obstacle in treating established metastatic 
disease (Cesano et al 1994). Both of which might be overcome by the establishment 
of allogeneic NK cell lines (Ishikawa et al 2012). 
In a LAK cell study performed on dogs it was found some tumour types, such as 
squamous cell or mammary carcinoma, impaired the ability of NK cells to be 
activated into LAK cells while melanoma tumours could be completely regressed 
(Funk et al 2005).   
LAK cells have been shown to not only target tumour cells but also M2 macrophages 
(Geldhof et al 2002). M2 macrophages express lower levels of MHC class I which 
inhibits NK lysis and higher levels of B7-costimulatory molecules and CD11b 
adhesion molecules which confer NK sensitivity (Geldhof et al 2002). By editing the 
macrophage population through depletion of the M2 macrophages and activation of 
M1 macrophages through cytokine signals CTL responses are enhanced by LAK 
cells (Geldhof et al 2002).  
1.7.3 Adoptive cell transfer therapy 
Tumour infiltrating lymphocytes (TILs) and CTLs recognise tumour antigens 
presented by MHC molecules (Qian et al 2014). These cells can be identified and 
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expanded in vitro before being reintroduced to the patient as adoptive cell transfer 
therapy (Butler et al 2011, Qian et al 2014). Clinical research has shown increased 
survival of lung cancer and gastric cancer patients through this approach (Wang et al 
2014).  
Several studies have shown the usefulness of mouse models to study the efficacy of 
adoptive transfer therapies such as LAK cell therapy and TIL therapy (Cesano et al 
1994, Malkovska et al 1992, Rosenberg et al 2008, Takahashi et al 1993). The 
mouse model revealed the need to deplete T-regs before the administration of TIL 
therapy. When this was done the TIL cells were seen to proliferate in vivo and persist 
for long periods resulting in primary and metastatic tumour regression in patients 
(Rosenberg et al 2008).  
1.7.4 In vivo activation of NK cells to enhance anti-tumour CTL responses  
Immature DCs present tumour antigens to T cells in a manner that promotes 
tolerance and supports tumour survival (Morandi et al 2012). Eliminating immature 
DCs and maximising the presentation of antigens by mature DCs would switch the 
tumour surveillance paradigm towards a protective response (Morandi et al 2012). 
Activated NK cells have been proposed as a mechanism to editing DC populations 
leaving a more mature DC population capable of promoting anti-tumour CTL activity 
(Morandi et al 2012). These NK cells can be activated in vivo by injecting MHC-
devoid cells as an NK target (Morandi et al 2012). In mice this has been achieved 
using YAC-1 cells (Morandi et al 2012). The NK cells become activated against the 
YAC-1 cells and as a bystander effect lyse immature DCs (Morandi et al 2012).   
1.7.5 Laser immunotherapy 
Laser immunotherapy has been proposed by Immunophotonics 
(www.immunophotonics.com) as a potential treatment for DFTD. Laser 
immunotherapy is an in situ autologous cancer vaccine (inCVAX) based on the same 
principle as photodynamic therapy (Li et al 2012). A near-infrared laser is used to 
create photothermal damage to the tumour and the injection of glycated chitosan (a 
proprietary immunoadjuvant) promotes systemic immune responses that can target 
the primary and metastatic tumours (Li et al 2012). The exact mechanisms providing 
the protection are still speculative but preliminary clinical trials in Peru have shown 
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great promise in treating breast cancer. The Peruvian Ministry of Health have 
requested that immunophotonics start a Phase III human breast cancer clinical trial 
with inCVAX (Chen 2014, Li et al 2012).  
The laser induces a gradient of heat damage to the tumour ranging from total 
destruction to the release of heat-shock proteins (HSPs) (Li et al 2012). It is believed 
that the inflammation, the HSPs and release of tumour antigens invokes an immune 
system response which sees DCs transport tumour antigens to CTLs in the lymph 
node (Li et al 2012). Effectively this is an in vivo generation of in situ whole-cells 
cancer vaccine (Li et al 2012).    
1.7.6 Plant and algae extracts 
Numerous plant extracts are being explored for their immuno-stimulatory effects and 
possible anti-tumour activities.  
Fucoidan  
Fucoidans are seaweed extracts that are complex sulphated polysaccharides with 
biological effects on mammalian cells (Araya et al 2011). Fucoidans constitute up to 
30% of the dry weight of specific seaweeds (Myers et al 2011). The structure and 
function of fucoidans varies between species of seaweed used to obtain the extracts 
(Kwak 2014).  
Fucoidans are well tolerated with low toxicity and no severe side effects in human 
clinical trials (Kwak 2014, Myers et al 2011). Excessive dosages exceeding 900 
mg/kg caused delayed blood clotting but no other signs of toxicity (Myers et al 2011). 
In animal studies, brown algae extracts have been shown to have anti-tumour effects 
when delivered intravenously, intraperitoneally or orally (Kar et al 2011, Kwak 2014, 
Myers et al 2011). 
In Japan, where seaweed consumption forms part of the regular diet, an 
epidemiological study associated dietary seaweed with numerous health benefits 
including lowered all-cause mortality and lower mortality to some cancers (Myers et 
al 2011).  
In a study of HTLV-1 patients treated with fucoidan there was little effect on the cells 
of the immune system. However, benefits were observed in patients and this was 
possibly the result of inhibition of cell-to-cell transmission of the virus (Araya et al 
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2011). In contrast, other researchers have shown fucoidans have an immuno-
modulating role as evident in vivo lymphocyte populations (Kwak 2014, Yang et al 
2013).  
There is empirical evidence that in vivo fucoidans modulate the immune system 
promoting maturation of bone marrow-derived DCs and mobilisation of hemopoetic 
stem cells to replenish immune cells within the body’s tissues and organs (Myers et 
al 2011). This was complemented in vitro with fucoidan induced changes to 
activation and function of lymphocyte populations (Kwak 2014).   
Many researchers suggest that fucoidan is an immuno-modulatory compound that 
induces TH1 cytokines including IFN-γ, TNF-α and IL-12 while suppressing TH2 
cytokines IL-10 and TGF-β (Kar et al 2011). Fucoidan also promotes the generation 
of nitric oxide and reactive oxygen species (Kwak 2014, Yang et al 2013). In one 
study, cytokine expression by monocyte-derived DCs was altered resulting in 
increased levels of TNF-α, IFN-γ and IL-12 while decreasing levels of IL-6 (Myers et 
al 2011). Fucoidan treated DCs also direct naïve T cells towards a TH1 differentiation 
(Myers et al 2011). Additional studies have also shown a modulation of TH1:TH2 ratio 
towards TH1 profiles, which are required for effective anti-tumour responses (Myers 
et al 2011).  
In vivo effect of fucoidan has also been demonstrated with mechanisms ranging from 
NK cell-mediated inhibition of angiogenesis, reduced tumour growth and prevention 
of metastasis (Kwak 2014). It has also been shown that fucoidan treatment can 
enhance NK cell activity (Myers et al 2011), significantly increase CTL numbers and 
phagocytic capacity of monocytes (Kwak 2014, Lu and Negrin 1994). Cancer cell 
apoptosis has been observed in vitro by fucoidan but this varied between tumour cell 
types species of fucoidan (Kwak 2014, Yang et al 2013). In clinical trials fucoidan 
has been reported as a strong selectin blocker demonstrating anti-inflammatory 
properties with osteoarthritis (Myers et al 2010).    
Fucoidan demonstrated an ability to eliminate Leishmania infection and promote 
extended protective response through immunomodulation (Kar et al 2011). Kar et al 
(2011) administered fucoidan orally and found 200 mg/kg/day (5 mg/mouse/day) 
gave maximum results in vivo in mice infected with Leishmania. Examination of 
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cytokine production revealed that the CD4+ T cell TH2 immune response was 
switched to a TH1 biased response by administration of fucoidan (Kar et al 2011). 
With in vitro experiments they used 50µg/ml for maximum response. They tested up 
to 150 ug/ml and had no adverse effect on cell viability but failed to enhance 
responses (Kar et al 2011).  
The difficulty with fucoidan is that, since it is a natural product, there is no 
standardisation between manufacturers and batches. This makes it difficult to 
determine the mode of action and mechanisms involved. What needs to be 
determined is which structural characteristics are responsible for anti-tumour activity 
(Kwak 2014).  
Withaferin A 
The traditional Indian medicine system, Ayurvedic Medicine, has used the medicinal 
plant Withania somnifera (Indian Winter Cherry) for many centuries to treat a variety 
of ailments. Withaferin A (WA) is a bioactive ingredient isolated from this plant which 
has been shown to have immuno-modulatory, anti-inflammatory, anti-angiogenic and 
anti-tumour properties (Yang et al 2012a). 
Withaferin A reduces proteasomal activity inhibiting synthesis of DNA, RNA and 
various pro-tumour proteins required for tumour cell growth and cycle (Kamath et al 
1999, Yang et al 2007, Yang et al 2012a). Analysis of gene expression following WA 
treatment showed downregulation of a number of cell growth and metastasis 
transducers including c-myc and vimentin (Patel et al 2013, Yang et al 2012a).  
Many cancers over express the Notch oncogene which activates the signal pathways 
of Akt, nuclear factor-kappa B (NF-κB) and mammalian target of rapamycin (mTOR) 
(Koduru et al 2010). This promotes proliferation and survival by regulating cell fate 
decisions (Koduru et al 2010). Withaferin A suppresses the Notch gene and 
ultimately this suppresses the Akt and mTOR growth and proliferation signalling 
pathways resulting in  a dose-dependent cell cycle arrest of susceptible tumours 
(Grogan et al 2013). Akt activation by Notch also plays a critical role in metastatic 
spread of cancer (Koduru et al 2010). Proliferation is halted at the G2/m phase cell 
cycle by modulating p53-dependent proteins (Munagala et al 2011). 
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The inhibition of proteasomal activity by WA also promotes apoptosis in tumour cells 
by disrupting mitochondrial functions (Yang et al 2007). Gene expression analysis 
following WA treatment showed an upregulation of Bax and downregulation of Bcl-2 
(anti-apoptotic protein) which causes a shift in Bax:Bcl-2 ratio that favours apoptosis 
an upregulation of pro-apoptotic Bax and IκB-α proteins (Koduru et al 2010, 
Munagala et al 2011, Patel et al 2013, Yang et al 2012a). 
STAT3 expression promotes proliferation, angiogenesis and apoptosis resistance 
(Munagala et al 2011). WA inhibits STAT3 activation and promotes p53-mediated 
apoptosis (Munagala et al 2011). Caspase-3 activation, poly (ADP-ribose) 
polymerase (PARP) cleavage and condensed nucleus which are characteristics of 
apoptosis have resulted from WA treatment of cancer cells (Yang et al 2012a). In 
human MPM cells WA has been shown to induce caspase-3 activation, PARP 
cleavage and condensed nucleus which are characteristics of apoptosis (Yang et al 
2012a). 
Upregulation of the Notch-1 gene results in downregulation of c-Jun and JNK 
resulting in suppression of apoptosis (Koduru et al 2010). Withaferin-A targets the 
cancer cells, downregulating Notch-1 which thereby permits JNK activation and 
ultimately induces c-Jun-NH2-kinase (JNK)–mediated apoptosis (Koduru et al 2010). 
JNKs are activated by stress and inflammatory signals which not only induce 
apoptosis but also inhibit proliferation (Fuchs et al 1998, Koduru et al 2010). 
Other anti-tumour activities of withaferin A include changing the architecture of the 
cytoskeleton by target vimentin (Grogan et al 2013, Patel et al 2013). Vimentin is a 
cytoskeletal protein responsible for cell shape, integrity and flexibility (Satelli and Li 
2011). Over expression of vimentin indicates an aggressive cancer associated with 
metastatic disease and poor diagnosis (Yang et al 2012a). 
Vimentin is present in the cytosol, nucleus and to a lesser degree as an extracellular 
protein (Satelli and Li 2011). Vimentin is a marker of epithelial–mesenchymal 
transition (EMT) that can be used in diagnosis (Satelli and Li 2011). During EMT the 
phenotype of epithelial cells changes to a mesenchymal phenotype which alters their 
shape and increases their motility promoting metastatic disease (Satelli and Li 2011). 
Withaferin A counteracts this by causing the accumulation of vimentin in the 
perinuclear space of cancer cells and then breaking it down (Patel et al 2013). 
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Vimentin has additional pro-tumour activities (Satelli and Li 2011). Secreted vimentin 
can protect the tumour by neutralising NK cell activity through blocking the NKp46 
receptors (Satelli and Li 2011). The breaking down of vimentin by WA not only 
prevents metastatic disease but promotes apoptosis (Satelli and Li 2011). The fact 
that withaferin A preferentially targets cancer cells over-expressing vimentin could 
partly explain the low toxicity towards normal cells which have lower vimentin levels 
(Satelli and Li 2011). 
The ability of WA to target tumours over expressing vimentin is relevant to DFTD 
since high vimentin expression is a characteristic of DFTD (Loh et al 2006b). Such 
expression is generally regarded as supporting a poor prognosis for cancers since it 
is correlated to metastatic disease. The ability of WA to selectively target vimentin 
suggests a mechanism to exploit against DFTD cells and warrants further 
investigation.   
Withaferin A is a natural product and is associated with fewer side effects and lower 
toxicity than synthetic options (Yang et al 2007). It can be administered orally as well 
as injected (Kamath et al 1999, Yang et al 2007). Intraperitoneal injection of 5 mg/kg 
of WA for 17 days following palpation of engrafted tumours has inhibited tumour 
growth in an in vivo murine model of malignant pleural mesothelioma (MPM). 10 µM 
doses of WA have been shown to be effective for in vitro trials. Withaferin A has also 
been shown to have anti-tumour effects against a variety of human cancers including 
prostate, breast and soft tissue sarcoma (Yang et al 2012a).   
The LD50 for withaferin A is ≈ 80 mg/kg with mortalities commencing around 60 
mg/kg (Sharada et al 1996). The toxic effect of withaferin A is cumulative while the 
tumour killing effect may not be. Tumour cells may be able to tolerate or recover 
from low levels of withaferin A whereas higher acute levels of withaferin A may be 
required for anti-tumour activity. Investigations by other researchers have revealed 
that individual doses should not exceed 40 mg/kg (Kamath et al 1999, Sharada et al 
1996). A protocol of three daily doses of 30 mg/kg is the maximum tolerated dose of 
withaferin A. Increasing the dose per fraction to 40 mg/kg was not tolerated when 
given twice and 30 mg/kg dose per fraction was not tolerated when given four or 
more times (Sharada et al 1996).  
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1.8 Chemotherapy option for DFTD 
Afatinib  
Afatinib has been shown to inhibit proliferation of DFTD cells in vitro by the Sanger 
Research Institute in Britain (Elizabeth Murchison, personal communication, 2012). 
Afatinib is a protein tyrosine kinase inhibitor (TKI). Tyrosine kinases are proteins 
which stimulate cells to grow. Afatinib inhibits ErbB1 (epidermal growth factor 
receptor – EGFR), ErbB2 (Her2) and ErbB4 (Her4). These receptors are often over 
expressed on tumours (Normanno et al 2006). Afatinib irreversibly binds to the 
intracellular tyrosine kinase domain of the ErbB family receptors interrupting 
downstream signalling inhibiting growth and promoting apoptosis (Yap et al 2010).  
The manufacturer recommends fasting three hours before and one hour after taking 
afatinib since high fat food prevents the uptake of afatinib by as much as 50% 
(Boehringer Ingelheim International 2014). Afatinib treatment is rarely without side 
effects ranging from minor to severe. In human trials these have seen most people 
suffering diarrhoea and skin changes (80%), loss of appetite (30%), sore mouth 
(60%) and nose bleeds (20%) (Yap et al 2010).  
Responders to afatinib in human trials tend to relapse after developing resistance to 
the treatment and methods to overcome this can be very toxic (Nanjo et al 2013). 
Resistance can be due to selection of resistant tumour cells or expression of 
hepatocyte growth factor (HGF) in the tumour microenvironment (Nanjo et al 2013). 
The HGF can be expressed by the tumour cells themselves or the surrounding 
fibroblasts (Nanjo et al 2013).  
  
 
 
 
 
 
 
 
 
Methods 
  
 
 
Methods 
2 Methods ....................................................................................... 2-1 
2.1 Laboratory equipment and consumables .............................................. 2-1 
2.1.1 Reagents ...................................................................................................... 2-1 
2.1.2 Antibodies ..................................................................................................... 2-3 
2.1.3 Consumables ................................................................................................ 2-4 
2.1.4 Laboratory equipment ................................................................................... 2-5 
2.1.5 Software........................................................................................................ 2-5 
2.1.6 Solutions and reagents ................................................................................. 2-6 
2.1.7 Mice .............................................................................................................. 2-7 
2.1.8 Cell lines ....................................................................................................... 2-7 
2.2 Methods ..................................................................................................... 2-8 
2.2.1 Camptothecin induced apoptosis .................................................................. 2-8 
2.2.2 TUNEL assay ................................................................................................ 2-9 
2.2.3 Standard protocol to detect DFTD specific antibodies in mouse serum ....... 2-11 
2.2.4 Standard biotin antibody labelling protocol for mouse lymphocytes ............. 2-12 
2.2.5 Conjugated antibodies for flow cytometry .................................................... 2-12 
2.2.6 Anti β2-microglobulin and anti-MHC+ DFTD cell antibodies ......................... 2-13 
2.2.7 51Cr cytotoxicity assay ................................................................................. 2-14 
2.2.8 CFSE and PI cytotoxicity assay .................................................................. 2-15 
2.2.9 CellTrace Violet and PI cytotoxicity assay ................................................... 2-17 
2.2.10 Measuring cytokines by ELISA .................................................................... 2-19 
2.2.11 Cytokine assay workflow for CBA TH1, TH2, TH17 micro bead array ............ 2-21 
2.2.12 EasySep NK enrichment per mouse spleen ................................................ 2-23 
2.2.13 EasySep CD4+ or CD8+ enrichment per mouse spleen .............................. 2-24 
2.2.14 Stimulation of Tasmanian devil monocytes with concanavalin A ................. 2-25 
2.2.15 Generation of concanavalin A supernatant (Con A sup) .............................. 2-25 
2.2.16 Separation of serum .................................................................................... 2-25 
2.2.17 Afatinib therapy ........................................................................................... 2-25 
 
 
2.2.18 Withaferin A therapy ................................................................................... 2-25 
2.2.19 Fucoidan therapy ........................................................................................ 2-26 
2.2.20 Imiquimod therapy ...................................................................................... 2-26 
 
 
  
2-1 
 
2 Methods 
2.1 Laboratory equipment and consumables 
2.1.1 Reagents 
Reagent Supplier Cat # 
Afatinib (BIBW2992) Boehringer 
Ingelheim 
Lot # 1040023 
Annexin V-FITC Miltenyi Biotec 130-092-852 
Annexin V-PE BioVision 1014-1000 
Antibiotic Antimycotic solution (Anti-Anti) Sigma Aldrich A5955 
Annexin Binding Buffer (x10) PharMingen 66121E 
BD™ CBA mouse TH1, TH2, TH17 cytokine kit BD Bioscience  560485 
Bovine Serum Albumin  Invitrogen  15561-020 
Camptothecin BioVision 1039-1 
CellTrace Violet™ Life Technologies C34557 
CpG 1585 GeneWorks  
CpG 1668 GeneWorks  
CpG 2395 GeneWorks  
51Cr  PerkinElmer NEZ030S001MC 
Dimethyl Sulphoxide (DMSO) Sigma Aldrich D2650 
EasySep™ Mouse CD8+ T cell Enrichment Kit Stemcell 19753 
EasySep™ Mouse CD4+ T cell Enrichment Kit Stemcell 19752 
EasySep™ Mouse NK cell Enrichment Kit Stemcell 19755 
Ethanol   Merck  4102309020 
Foetal Calf Serum Gibco 1099-141 
Fucoidan (Fucus vesiculosus) Marinova Lot # SK110199A 
Glutamax  Gibco 35050-079 
Histopaque®-1077 Sigma-Aldrich 10771 
Imiquimod AdipoGen AG-CRI-3569-M100 
In Situ Cell Death Detection Kit, Fluorescein  Roche 11 684 795 910 
Methanol Merck 901459020 
Montanide 71 Seppic  
Nuclear yellow (Hoechst S769121) Invitrogen N21485 
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Reagent Supplier Cat # 
NuPAGE®  Antioxidant Invitrogen NP0005 
NuPAGE® LDS Sample Buffer (4X)  Invitrogen NP0007 
NuPAGE® MOPS SDS Running Buffer (20X) Invitrogen NP0001 
NuPAGE® Novex® 4-12% BIS-Tris Gels Invitrogen NP0322BOX 
NuPAGE® Sample Reducing Agent (10X) Invitrogen NP0004 
NuPAGE® Transfer Buffer (20X) Invitrogen NP0006-1 
Paraformaldehyde Sigma-Aldrich P6148 
Phosphate Buffered Saline (PBS) tablets Oxoid BR0014g 
Potassium chloride  Calbiochem  529552 
Potassium dihydrogen phosphate  Sigma-Aldrich P9791 
Propidium iodide Sigma-Aldrich P4170 
RPMI 1640 Medium Gibco 224000-089 
Sodium Azide (NaN3) Sigma-Aldrich S2002 
Sodium Chloride  Sigma-Aldrich S6191 
Sodium citrate Sigma-Aldrich S-4641 
Spectra™ Multicolor Broad Range Protein 
Ladder 
Fermentas SM1841 
Triton X-100 BDH 30632 
Trypan Blue  Sigma-Aldrich  T6146 
In Situ Cell Death Detection Kit, Fluorescein Roche 11 684 795 910 
Withaferin A Sigma-Aldrich 89910-10MG 
7AAD Sigma-Aldrich A-9400 
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2.1.2 Antibodies 
Antibody Supplier Cat # 
Anti-mouse IgM (2 mg/mL) Invitrogen  A21042 (lot 898246) 
Anti-mouse IgG/IgM (2 mg/mL) Invitrogen  A10680 (lot 1008684) 
Anti-mouse IgG (2 mg/mL) Invitrogen  A31553 (lot 799225) 
Anti-mouse IgG1 (2 mg/mL) Invitrogen  A21121 (lot 845809) 
Anti-mouse IgG2a (2 mg/mL) Invitrogen  A21136 (lot 939316) 
Anti-mouse IgG2b (2 mg/mL) Invitrogen  A21146 (lot 948496) 
Anti-mouse IgG3 (2 mg/mL) Invitrogen  A21151 (lot 982318) 
Anti-mouse IL-4  BD PharMingen 554434 
Anti-mouse IL-10 PharMingen 554465 
Anti-mouse IL-12 PharMingen 18491D 
Anti-mouse IFN-γ BD PharMingen 554410 
Anti-mouse CD3e (AlexaFluor 488) Biolegend 100321 
Anti-mouse CD4 (PerCP/Cy5.5) Biolegend 100540 
Anti-mouse CD8 (Pacific Blue) Biolegend 100725 
Anti-mouse CD49b (APC) Biolegend 108910 
Anti-mouse CD69 (PE) Biolegend 104508 
Anti-mouse MHC-II I-A/I-E (APC) BD Bioscience 557000 
Anti-mouse CD19 (PE/Cy7) Biolegend 115520 
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2.1.3 Consumables  
Item Supplier Cat # 
0.1-20 µL pipette tips Eppendorf  022492012 
2-200 µL pipette tips Eppendorf  022492039 
50-1000 µL pipette tips Eppendorf  022492055 
25 cm3 cell culture flask Iwaki 3100-025 
75 cm3 cell culture flask Iwaki 3110-075 
10 mL centrifuge tube  Schering Plough LBSCT1203X 
15 mL centrifuge tube  Iwaki 3235-105 
50 mL centrifuge tube  Iwaki 2345-050 
Cryogenic freezing vials Iwaki 2712-002 
Disposable Pasteur pipette Samco 225-15 
Axygen MaxyClear Microtube Axygen Scientific MCT-175-C 
Eppendorf tube Quantum Scientific LAC11514 
Flow cytometry tubes BD Falcon  367 526 
24 well flat-bottom microplate  Iwaki 3820-024 
96 well round-bottom microplate Iwaki 655180 
40 µm  Cell Strainer  BD Falcon  352340 
10 mL syringe  Terumo SS+10ES 
 
  
2-5 
 
2.1.4 Laboratory equipment 
Equipment Supplier Model # 
-80°C freezer Sanyo MDF-U32V 
Centrifuge  Sorvall  RT 6000D 
Microcentrifuge Eppendorf 5415D 
Centrifuge  Eppendorf 5430R 
Class II biological safety cabinet Gelman Sciences BH-204 
Class II biological safety cabinet LAF Technologies  BCS 1200 
Fume hood Conditionaire HC-05 
Fluorescent microscope  Olympus BX 50 
Flow cytometer  BD Bioscience  FACSCanto II 
FACS cell sorter  Beckman Coulter Astrios 
Gamma radiation counter Laboratory Technologies Genesys Genii HE 
Haemocytometer Hawksley Improved neubauer 
Incubator 35°C  Heraeus BB15 
Incubator 37°C Binder 142489 
Platform Mixer  Ratek RPM5 
 
2.1.5 Software 
Software Supplier 
FCS Express 4 Research Edition De Nova Software (USA) 
Flowing Software vers. 1.6.0 Turku Centre for Biotechnology (Finland) 
GraphPad 5 GraphPad Software (USA) 
BD FACSArray Bioanalyzer BD Bioscience (USA) 
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2.1.6 Solutions and reagents 
FACS staining buffer (FSB) 
PBS with 1% BSA w/v and Sodium azide 0.1% 
PBS (pH 7.3)* 
Disodium hydrogen phosphate         1.15 g/L 
Sodium chloride                                8.0 g/L 
Potassium dihydrogen phosphate     0.2 g/L 
Potassium chloride                            0.2 g/L 
* Alternatively PBS tablets (Oxoid, Hampshire, England) were used  
RPMI-10 
500 mL RPMI medium (GIBCO, New York, USA), 50 mL Foetal Bovine Serum (Bovogen 
Biological, Victoria, Australia),  5 mL GlutaMax™ (GIBCO, New York, USA) and 5 mL 
Antibiotic-Antimycotic (GIBCO, New York, USA) 
TBS (pH 7.5) 
Tris base 2.42 g/L 
Sodium chloride 11.7 g/L 
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2.1.7 Mice 
Strain Supplier 
BALB/c Animal Services,  Menzies Research Institute Tasmania 
B6.Ighm/J Animal Services,  Menzies Research Institute Tasmania 
B6.raG2/J Animal Services,  Menzies Research Institute Tasmania 
B6.TNF Animal Services,  Menzies Research Institute Tasmania 
CBA/nu  Walter and Eliza Hall Institute of Medical Research (WEHI) 
C57/BL6  Animal Services,  Menzies Research Institute Tasmania 
NOD/SCID  Animal Services,  Menzies Research Institute Tasmania 
 
Unless specifically stated in the protocol the mice used in the experiments were at 
least 5 week’s old, mixed-sex and normal weight for the strain. Numbers of animals 
used in each trial stated in the results.   
2.1.8 Cell lines 
K562: Cell line sourced from liquid nitrogen store University of Tasmanian. They were 
maintained in culture in RPMI-10 medium.  
YAC-1: Cell line source from liquid nitrogen store University of Tasmanian. They were 
maintained in culture in RPMI-10 medium.   
C5065: DFTD cell line provided by A-M. Pearse and K. Swift , Tasmanian Department of 
Primary Industries, Parks, Wildlife and Environment (DPIPWE). They were maintained in 
culture in RPMI-10 medium. 
Incubation of cell lines: Cells were incubated at 35°C or 37°C (as stated in experiment 
protocol) in humidified incubator with 5% CO2  
Injections: Cells were washed in PBS (5 minutes at 500 rcf) and resuspended in PBS. Cell 
viability was determined using trypan blue exclusion and injections prepared at the viable 
cell concentration stated in protocol. Volumes between 100-200 µl were injected as stated in 
protocol.  
BALB/c and C57/BL6 mice were injected intraperitoneal or subcutaneously into the flanks as 
stated in the results. NOD/SCID, B6.Ighm/J, B6.raG2/J, B6.TNF and CBA/nu mice were 
injected subcutaneously into the flanks as stated in the results.  
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2.2 Methods 
2.2.1 Camptothecin induced apoptosis 
1. Camptothecin stock solution: 2 mM/mL in DMSO had previously been 
prepared 
 
2.  5 x 106  DFTD cells were harvested 
 
3. 4 µL Camptothecin stock solution (giving final concentration 4 µM/mL ) was 
added to  5x106 DFTD cells suspended in 2 mL complete media (placed in a 
10 mL centrifuge tube with a round base to minimize pelleting of cells). 
 
4. The cells were incubated for 4 hours at 22°C on a platform mixer  
 
5. Cell suspension transferred to 10 mL centrifuge tubes and washed twice with 
cold PBS and then resuspend cells in 2 mL of 1x Annexin V Binding Buffer 
(10x Binding Buffer diluted with distilled water) 
 
6. Transfer 100 µL of the cell suspension to each of 12 flow cytometry tubes 
labelled 1 to 12.Tubes 1 to 3 served as negative controls with no FITC 
Annexin V and Propidium Iodide stains*.  
 
7. In tubes 4 to 6 was added 5 µL of FITC Annexin V only. In tubes 7 to 9 was 
added 5 µL of Propidium Iodide only. In tubes 10 to 12 was added 5 µL of 
FITC Annexin V and 5 µL Propidium Iodide 
 
8. The tubes were gently vortex and incubated for 15 minutes at R/T (23°C) 
protected from light 
 
9. 100 µL of 1x Annexin V Binding Buffer was added to each tube and analysed 
by flow cytometry within one hour.  
 
*PE Annexin V and 7AAD were sometimes substituted for FITC Annexin V 
and propidium iodide using otherwise identical protocol 
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2.2.2 TUNEL assay 
TUNEL assay was performed using In Situ Cell Death Detection Kit, Fluorescein 
(Roche, Germany) as per manufacturer’s instructions  
https://cssportal.roche.com/LFR_PublicDocs/ras/11684795910_en_16.pdf  
1. C5065 DFTD cells were harvested and suspended in RPMI-10 medium  
2. Sterile cover slips were placed in the top two rows of two 24 well microplates 
and 500ul of the DFTD cell suspension was placed over the cover slips.  
3. The plates were incubated for 48 hours in 350C incubator.  
4. One plate was subjected to 5 minutes exposure of UV-B lamps estimated to 
be 8 kilojoules of radiation. The second plate was used as an untreated 
control to measure spontaneous apoptosis.   
5. Plates were incubated for an additional 24 hours in 350C incubator.  
6. Working in a fume hood the media was replaced with 500 µL of 4% 
paraformaldehyde in PBS (PFA) and incubated @ 23°C for 15minutes.  
7. The PFA was replaced with PBS and the well plates were stored in fridge for 
a few days.  
8. The cover slips were then lifted from the wells using a bent hypodermic 
needle and forceps and placed onto a marked out wax block. 
UV treated 
neg control 
UV treated 
pos control 
UV treated 
sample 1 
UV treated 
sample 2 
UV treated 
sample 3 
UV treated 
sample 4 
Untreated 
neg control 
Untreated 
pos control 
Untreated 
sample 1 
Untreated 
sample 2 
Untreated 
sample 3 
Untreated 
sample 4 
 
9. The cover slips were gently dried using tissues and then 50 µL endogenous 
peroxidase blocking solution (3% H2O2 in methanol) was placed onto the 
cover slip and incubated for 10 minutes.  
10. PBS wash x1 followed by 2 minute incubation in 40C room in permeabilisation 
solution ( 0.1% TritonX-100 in 0.1% sodium citrate) 
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11. PBS wash x2  
12. Removed 100 µL label solution from vial 2 and added 50 µL per each 
negative control cover slip.  
13. Prepared TUNEL reaction mixture by adding total volume (50 µL) of Enzyme 
solution (vial 1) to the remaining 450 µL Label solution in vial 2 to obtain 500 
µL TUNEL reaction mixture. Nuclear yellow was added as a counter stain at 2 
µM.   
14. Removed 100 µL of TUNEL reaction mixture and added 0.1 µL Dnase I. 50 µL 
of this mixture was placed on the two positive control cover slips.  
15.  50 µL of the remaining TUNEL reaction mix was added to the remaining 
cover slips.  
16. Incubated at 370C in a humidified atmosphere in the dark for 1 hour. 
17. Prepared slides with drops of Faramount aqueous mounting medium. Pick up 
cover slip; wash by dipping in milli-Q water, place cell surface down onto 
mounting medium, gently push cover slip down.  
18. Fluorescence microscope with excitation wavelength in the range of 450-500 
nm and detection in the range of 515-565 was used to detect TdT labelling. 
Nuclear Yellow counter stain was detected using ≈335/495 nm 
excitation/emission.  
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2.2.3 Standard protocol to detect DFTD specific antibodies in mouse serum 
1. Harvested C5065 DFDT cells, counted cells and re-suspended in FACS 
Staining Buffer (FSB)  typically at 106 cells per mL concentration 
 
2. Added 1 µL relevant thawed mouse serum sample to the appropriate wells of 
a 96 well round-bottom microplate. Added 50 µL of DFTD cell suspension to 
each well and incubated on ice for 30 minutes. Controls included target cells 
only, target cells and 2nd antibody, Target cells plus naïve mouse serum and 
target cells and known positive serum (see diagram below for typical layout).  
 
Row Column 1 
A Target cells only 
B Target cells + 2nd antibody  
C Naïve mouse serum  
D Known positive serum control 
E Sample being tested 
F Sample being tested 
G Sample being tested 
H Sample being tested 
 
3. Centrifuged 5 minutes  at 1500 rcf and then perform x2 PBS washes  
4. Briefly centrifuged conjugated antibody to eliminate protein aggregates which 
contribute towards background staining.  
 
5. Diluted 2nd antibody   
a. IgG1 488, IgG2b 633 and IgG/IgM 488 at 1:1000 in FSB 
b. IgM 488, IgG405, IgG488 and IgG3 at 1:500 in FSB 
c. IgG 488 at 1:100 to 1:1000 (as stated in experiment protocol) in FSB 
 
6. Placed 50 µL in each relevant well and incubated on ice for 30 minutes  
7. Washed twice in PBS and re-suspended in 200 µL of PBS for immediate 
reading on flow cytometry equipment 
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2.2.4 Standard biotin antibody labelling protocol for mouse lymphocytes   
1. Harvested mouse lymphocytes, counted cells and resuspended in FACS 
staining buffer (FSB) typically at 107 cells/mL.   
2. Added biotinylated  anti-mouse antibodies  
 Biotinylated rat anti-mouse CD49b  (≈ 1µL/107 cells) 
3. Incubated on ice for 30 minutes  
4. Added PBS, pelleted cells and then perform two more PBS washes 
5. Placed 107 cells in tube with 500 µL FSB with 1 µL Anti-biotin Strep-APC 
antibody and incubated on ice for 10minutes in dark.  
6. Washed cells and re-suspended in FSB for immediate sorting  
 
2.2.5 Conjugated antibodies for flow cytometry   
1. Harvested lymphocytes, counted cells and re-suspended in FACS staining 
buffer (FSB) typically at 107 cells/mL.  
2. Added conjugated anti-mouse antibody typically diluted between 1:300 to 
1:500 
 Anti-mouse CD3e (AlexaFluor 488) diluted 1:300 
 Anti-mouse CD4 (PerCP/cy5.5) diluted 1:500 
 Anti-mouse CD8 (Pacific blue) diluted 1:400 
 Anti-mouse CD49 (APC) diluted 1:300 
 Anti-mouse CD69 (PE) diluted 1:300 
 Anti-mouse MHC-II I-A/I-E (APC) diluted 1:400 
 Anti-mouse CD19 (PE/Cy7) diluted 1:300 
3. Incubated on ice for 30 minutes  
4. Filled tube with PBS, pellet and performed second PBS wash 
5. Re-suspended in PBS and run on flow cytometry equipment  
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2.2.6 Anti β2-microglobulin and anti-MHC+ DFTD cell antibodies   
To test upregulation of β2-microglobulin, DFTD cells obtained from culture or mouse 
xenografts (as stated in experiment protocol) were labelled with WEHI produced anti-
devil β2-microglobulin (#13-34-20). To test upregulation of MHC, DFTD cells were 
labelled with serum generated in a Tasmanian devil against MHC+ DFTD cells 
(Control serum accessed Tasmanian devil Missy’s serum 11-4-12).  
Protocol for testing upregulation of MHC in DFTD cells  
1. DFTD cells from xenograft tumours or cultured DFTD cells were re-
suspended as single cell suspension in FACS staining buffer (FSB)  
2. Treated cells were transferred to five micro-tubes. This will provide four 
sample controls no missy serum primary antibody, no WEHI anti-devil 
secondary antibody, no Alexa Fluor tertiary antibody, Missy pre-immune 
negative control and Missy’s serum (11-4-12) anti-MHC+ DFTD antibody*.  
3. Two more control tubes of cells from untreated DFTD xenograft and untreated 
cultured cells were placed in micro-tubes as negative controls. 
4. All tubes were washed in PBS (3min 750 rcf) and resuspend in 50 µL of PBS 
with 1:300 of Missy 4/11/12 serum. One control tube minus Missy’s serum 
and one with Missy’s pre-immune serum.  
5. Incubated at R/T (23° C) for 20 minutes and then wash x3 in PBS. 
6. Added 50 µL of 1:200 mouse anti-devil 42/11-A4-B1-2-1 2 mg/mL WEHI α-
devil antibody. One control minus mouse anti-devil Ab. Incubate 15 minutes at 
R/T.   
7. Washed x3 in PBS and re-suspended 1:1000 anti-mouse IgG 488 and 
incubated 20 minutes at R/T. One control minus anti-mouse IgG 488.  
8. Washed x2 PBS and re-suspended in 200 µL PBS for reading on flow.  
*To test for β2-microglobulin substituted Missy’s serum with WEHI produced anti-
devil β2-microglobulin (#13-34-20) and deleted Missy’s pre-immune control. 
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2.2.7 51Cr cytotoxicity assay 
1. Target cells were incubated with 100 uCi 51Cr for 2 hours, given two PBS 
washes and resuspended at 105/mL concentration  
 
2. 96 V bottomed well plate was prepared with effector cells (lymphocytes) doing 
100 µL serial halving dilutions of effector cells usually from 100:1 to 3:1. 
Dilution ratios varied between assays dependent on lymphocyte recovery.  
 
3. Control wells were prepared without any lymphocytes being added. Minimum 
control cells were prepared with 100 µL RPMI-10FCS and maximum control 
cells with 100 µL of Triton X 1%.   
 
4. 100 µL of 51Cr labelled DFTD cells at 105/mL concentration were added to 
wells 
 
5. Plate was centrifuged for 2 minutes at 1000 rcf  
 
6. Plate was incubated for 18 hours at 37°C with 5% CO2  
 
7. Plate was centrifuged for 4 minutes at 1000 rcf 
 
8. Being careful not to disturb the pellet, 100 µL of supernatant was transferred 
into 5 mL tubes and gamma measurements were obtained using a Genesys 
gamma radiation counter (Laboratory technologies Inc., Illinois, USA) 
 
9. Data analysis was undertaken using Microsoft Excel and/or GraphPad Prism  
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2.2.8 CFSE and PI cytotoxicity assay 
1. Added 2 µL of 5 mM CFSE to 5 mL of RPMI-10 then added media to target 
cells and incubated on a platform mixer for 10 minutes at R/T (23° C) or 30 
minutes on ice. (some target cells were retained unlabelled to set PMT 
voltages on flow cytometry) 
 
2. Performed two PBS washes before re-suspending in complete media and 
doing cell count and viability check.  Re-suspended CFSE labelled target cells 
at 105/mL concentration.  
 
3. Effector cells were prepared at 2 x 107 cells /mL if possible 
 
4. 96 round bottomed well plate was prepared doing 100 µL serial halving 
dilutions of effector cells to typically give a range from 200:1  to 3:1 effector to 
target cell ratio. This was achieved by placing 200 µL of lymphocytes at 2 
x107 cells/mL concentration in the 200:1 wells and 100 µL of RPMI media in 
the rest of the dilution wells. 100 µL was then transferred as a serial dilution 
through the relevant wells from 200:1 to 3:1.  
 
5. Minimum control cells were prepared with addition of 100 µL RPMI and no 
lymphocytes  
 
6. 100 µL of CFSE labelled target cells were added to all wells  
 
7. Incubated for 18 hours at 37°C with 5% CO2   
 
8. Diluted propidium iodide (PI) stock solution 1:25 in PBS and added 25 µL of 
PI working solution to each well. (7AAD can be substituted for PI) 
 
9. Place the following controls in flow cytometry tubes and set the PMT voltages 
on the FACSCanto II flow cytometer.  
a. Target cells unstained 
b. Target cells + PI only 
c. Target cells CFSE labelled only 
d. Target cells DFTD CFSE labelled and PI 
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10. Connected HST plate reader to FACSCanto II flow cytometer and analyse 
promptly  
 
11. Flow cytometry data was analysed to calculate the number of dead target 
cells as a percentage of the total target cells. The data was then normalised 
by subtracting the percentage of spontaneous cell death observed in the wells 
with target cells only. Data analysis was undertaken using Microsoft Excel and 
plotted using GraphPad Prism 5 
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2.2.9 CellTrace Violet and PI cytotoxicity assay 
1. Labelled target cells with CellTrace™ Violet  
a. The CellTrace Violet Cell Proliferation Kit contains single-use vials of dry 
dye. A 2.5 mM stock solution was prepared by dissolving the contents of a 
vial in 40 µL anhydrous DMSO prior to use 
b. Stock solution was used between 1:2500 and 1:250.  
c. To stain 106 cells in 1 mL of pre-warmed PBS added 1 µL of stock 
solution (1:1000). Cells were incubated for 20 minutes at R/T (23°C) with 
gentle agitation protected from light. 
d. Quenched any unbound dye remaining in solution by adding five times the 
volume of pre-warmed RPMI-10 media and incubating for 5 minutes. 
e. Pelleted cells and re-suspended in RPMI-10 media for assay at 105 
cells/mL. Cells could be kept growing in 37°C incubated for a number of 
days before use.    
2. Effector cells were prepared at 2 x 107 cells /mL if possible 
 
3. 96 round bottomed well plate was prepared doing 100 µL serial halving dilutions 
of effector cells to typically give a range from 200:1 to 3:1 effector to target cell 
ratio. This was achieved by placing 200 µL of lymphocytes at 2 x107cells/mL 
concentration in the 200:1 wells and 100 µL of RPMI media in the rest of the 
dilution wells. 100 µL was then transferred as a serial dilution through the 
relevant wells from 200:1 to 3:1.  
 
4. Minimum control cells were prepared with addition of 100 µL RPMI and no 
lymphocytes  
 
5. 100 µL of CellTrace labelled target cells were added to all wells  
 
6. Incubated for 18 hours at 37°C with 5% CO2   
 
7. Diluted propidium iodide (PI) stock solution 1:25 in PBS and added 25 µL of PI 
working solution to each well. (7AAD can be substituted for PI) 
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8. Placed the following controls in flow cytometry tubes and set the PMT voltages 
on the FACSCanto II flow cytometer.  
e. Target cells unstained 
f. Target cells + PI only 
g. Target cells CellTrace Violet labelled only 
h. Target cells labelled with CellTrace Violet and PI 
 
9. Connected HST plate reader to FACSCanto II flow cytometer and analysed 
promptly  
 
10. Flow cytometry data was analysed to calculate the number of dead target cells as 
a percentage of the total target cells. The data was then normalised by 
subtracting the percentage of spontaneous cell death observed in the wells with 
target cells only. Data analysis was undertaken using Microsoft Excel and plotted 
using GraphPad Prism 5 
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2.2.10 Measuring cytokines by ELISA  
1. Dilute IL-4 (cat #) 1:250, IL-10 (cat #), IL-12 (cat #) and IFN-γ (cat #) capture 
antibodies with coating buffer to give 50 µL per well. 
2. Add 50 µL per each well except for control well as per well plan which gets 
coating buffer instead. 
3. Cover plate with parafilm and incubate 4 °C overnight 
 IL-4 (or IL-12)  IL-10 (or IFN-α )  
 1 2 3 4 5 6 7 8 9 10 11 12 
A 
Standards 
20k 
No #1 
antibody 
200:1 200:1 200:1  Standards 
20k 
No #1 
antibody 
200:1 200:1 200:1  
B 
Standards 
10k 
No 
supernatant 
sample 
100:1 100:1 100:1  Standards 
10k 
No 
supernatant 
sample 
100:1 100:1 100:1  
C 
Standards 
5k 
No #2 
antibody 
50:1 50:1 50:1  Standards 
5k 
No #2 
antibody 
50:1 50:1 50:1  
D 
Standards 
2.5k 
No avidin 25:1 25:1 25:1  Standards 
2.5k 
No avidin 25:1 25:1 25:1  
E 
Standards 
1.2k 
 12:1 12:1 12:1  Standards 
1.2k 
 12:1 12:1 12:1  
F 
Standards 
600 
 MNC MNC MNC  Standards 
600 
 MNC MNC MNC  
G 
Standards 
300 
 DFTD    Standards 
300 
 DFTD    
H 
Standards 
zero 
     Standards 
zero 
     
 
4. Plate was washed twice in TBS (PBS + 250 µL Tween/500 mL) 
5. Added 200 µL blocking buffer to each well (PBS/FCS/BSA…%?) and incubate 
at room temp for 2 hours 
6. Defrosted samples and standards.  
7. Wash plate three times with TBS 
8. Add 200 µL of cytokine standard which has been prepared at 1:20000 dilution 
(Cat# and concentration) to the first standards well and then serially halving 
dilution with 100 µL of blocking buffer added to the next six wells. A zero 
standard is obtained in the eighth well by only having blocking buffer. 
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9. Added 100 µL of samples to relevant wells. 
10. Covered plate with parafilm and incubate 4°C overnight 
11. Washed plate four times with TBS 
12. Diluted IL-4 and IL-12 secondary antibodies 1:2000 with blocking buffer; and 
diluted IL-10 and IFN-γ secondary antibodies 1:1000 with blocking buffer. 100 
µL per well was required.  
13. Added 100 µL per each well except for control well as per well plan. 
14. Covered plate with parafilm and incubated for 1 hour at 22°C 
15. Washed plate six times in TBS 
16. Added 100 µL of avidin-HRP conjugate, which has been diluted 1:1000 from 
1mg/mL stock kept on bench fridge door shelf.  
17. Covered plate with parafilm and incubated for 30minutes at 22 ° 
18.  Washed eight times in TBS 
19. Added 100 µL of TMB pre-warmed to 22°C to each well and allowed colour to 
develop for 5-10 minutes.   
20. Stop reaction by adding 100 µL ELISA stop solution ( weak acid solution 1M 
HCl) 
21. Read within 30 minutes at OD 450nm 
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2.2.11 Cytokine assay workflow for CBA TH1, TH2, TH17 micro bead array   
Step 1: Preparing mouse cytokine standards 
a) Fresh cytokine standards were reconstituted and serially diluted immediately 
before mixing the capture beads and PE detection reagent.  
b) Transferred the ball of each lyophilized cytokine standard to flow tube 
(labelled 1:1), added 2 mL of Assay Diluent and allowed to sit for at least 15 
minutes at R/T (23° C) before mixing gently with a pipette. 
c) Added 300 µL assay diluent to each of 8 flow tubes (labelled 1:2 to 1:256) and 
performed a halving serial dilution by transferring 300 µL from the 1:1 tube to 
tube 1:2 and so on until tube 1:256.   
d) Prepare a 9th tube with 300 µL of diluent only as a zero value control. 
Step 2: Mixing mouse cytokine capture beads 
The capture beads were bottled individually (blue caps) and all bead reagents 
needed to be pooled immediately before using them in the assay. 1 µL of each 
concentrate was pooled with capture bead diluent to provide 50 µL mixed capture 
beads per test (see table for calculations).  
Capture Bead and Detection Reagent Diluent Calculations  
Number of flex sets 
used 
Volume of each 
Capture Bead or PE 
Detection Reagent/test 
Total Capture Bead 
volume/test 
Volume of Capture 
Bead or Detection 
Reagent Diluent/test 
Total volume of mixed 
capture Bead or PE 
Detection Reagent/test 
1 1 µL 1 µL 49 µL 50 µL 
2 1 µL 2 µL 48 µL 50 µL 
3 1 µL 3 µL 47 µL 50 µL 
4 1 µL 4 µL 46 µL 50 µL 
5 1 µL 5 µL 45 µL 50 µL 
6 1 µL 6 µL 44 µL 50 µL 
7 1 µL 7 µL 43 µL 50 µL 
8 1 µL 8 µL 42 µL 50 µL 
9 1 µL 9 µL 41 µL 50 µL 
10 1 µL 10 µL 40 µL 50 µL 
 
a) Calculated number of flex kits, number of tests (unknowns + 10 standards + 3 
extra) and added required volume of Capture Bead diluent to labelled tube.  
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b) Vigorously vortex each capture bead suspension for 15 seconds before use 
and added 1µL per test as calculated above. 
c) Vortex bead mixture thoroughly.  
Step 3: Performing mouse cytokine assay 
a) Added 50 µL of mixed capture beads to each assay tube 
b) Added  50 µL cytokine standards or unknowns to relevant tubes 
 
Tube label Concentration (pg/mL) Cytokine Standard dilution 
1 0 Assay Diluent only 
2 20 1:256 
3 40 1:128 
4 80 1:64 
5 156 1:32 
6 312.5 1:16 
7 625 1:8 
8 1250 1:4 
9 2500 1:2 
10 5000 1:1 
 
c) Mixed tubes gently and incubate for 1 hour at R/T 
d) Prepared Mixed PE Detection reagent in a similar manner to the mixed 
capture beads and stored protected from light in fridge.  
e) Added  50 µL of the PE Detection Reagent to all tubes and incubate for 1 hour 
at R/T protected from light (performed cytometer setup during this incubation 
period) 
f) Added 1 mL of wash buffer to each assay tube and centrifuged 200 rcf for 5 
minutes 
g) Gently tipped out supernatant and re-suspended bead pellet in 300 µL of 
wash buffer 
h) Run the samples on the flow cytometer. To assist analysis, started with zero 
standard to highest standard followed by unknowns.  
i) Data was analysed with manufacturer’s software BD FACSArray Bioanalyzer, 
Excel and GraphPad 5. 
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2.2.12 EasySep NK enrichment per mouse spleen  
1. Harvested spleen and run over histopaque. 
2. Pelleted and re-suspended in 1000 µL PBS + 2% FCS  + 1 mM EDTA and 
transfer to a 5 mL capped tube. 
3. Centrifuged  EasySep Negative Selection Mouse NK Cell Enrichment Cocktail 
and added 50 µL to cells, mixed well and incubated 15 minutes at R/T (23° C) 
4. Added EasySep Biotin Selection Cocktail 100 µL to cells, mixed well and 
incubated for 15 minutes at R/T   
5. Vortex EasySep D Magnetic particles for 30 seconds to ensure they were 
uniformly suspended and had no aggregates. Added 100 µL particles to cells, 
mixed well and incubated for 10 minutes at R/T   
6. Brought cell suspension to a total volume of 2.5 mL by adding PBS + 2% FCS  
+ 1 mM EDTA. Mixed gently with pipette x3. Placed tube without cap into 
magnet and stood for 5 mins.  
7. Picked up magnet and gently poured cell suspension into new tube without 
shaking magnet. Held inverted for 2 to 3 seconds. 
8. Removed the old tube which was NK depleted and placed the new tube into 
magnet for 5 mins and repeated the separation step 7.  
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2.2.13 EasySep CD4+ or CD8+ enrichment per mouse spleen  
1. Harvested spleen and run over histopaque. 
2. Pelleted and re-suspended in 1000 µL PBS + 2% FCS  + 1 mM EDTA and 
transferred to a 5 mL capped tube. 
3. Added 50 µL of Normal Rat Serum (code # 13551)  
4. Added 50 µL EasySep Mouse CD4+ or CD8+ Cell Enrichment Cocktail to 
cells, mixed well and incubated 15 minutes at 2 to 8° C 
5. Added 100 µL EasySep Biotin Selection Cocktail 2 to cells, mixed well and 
incubated for 15 minutes at 2 to 8° C (time was exceeded due to multiple 
samples) 
6. Vortex EasySep D Magnetic particles for 30 seconds to ensure they were 
uniformly suspended and there were no aggregates. Added 100 µL particles 
to cells, mixed well and incubated for 5 to 10 minutes at  2 to 8° C    
7. Brought cell suspension to a total volume of 2.5 mL by adding PBS + 2% FCS  
+ 1 mM EDTA. Mixed gently with pipette x3. Placed tube without cap into 
magnet and stood for 5 minutes.  
8. Picked up magnet and gently poured cell suspension into new tube without 
shaking magnet. Held inverted for 2 to 3 secs. 
9. Removed the old tube which was CD4+ or CD8+ depleted and placed the 
new tube into magnet for 5 mins and repeated the separation step 7.  
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2.2.14 Stimulation of Tasmanian devil monocytes with concanavalin A  
Cytotoxic cells (LAK cells) could be generated by 48 hours stimulation with 
concanavalin A.  As stated in the experiment protocols between 5 µg/mL and 20 
µg/mL concanavalin A in RPMI-10 media was used, however, 5 µg/ mL was 
sufficient. After 48 hours, the culture was harvested and centrifuged for 5 minutes at 
500 rcf then the cell pellet and supernatant were separated.  
2.2.15 Generation of concanavalin A supernatant (Con A sup) 
Following stimulation of Tasmanian devil monocytes with concanavalin A as 
described previously, the supernatant minus cells was collected. The residual 
concanavalin a was removed from solution by chelation with 15 mg/mL α-
-D-Mannose (Sigma Aldrich, New South Wales, Australia). Samples were then 
passed through 2 mm 0.8/0.2 µm filters (Pall Corporation, New York, USA) under 
sterile conditions. The resulting solution contained cytokines present after 
concanavalin A culture, with little residual mitogen or mannose.  
2.2.16 Separation of serum   
Blood was stored in microtubes and allowed to clot at R/T for at least 2 hours or 
overnight at 4°C. Sample was then spun down for 20 minutes at 10,000 rpm in 
Ependorf Microcentrifuge 5415D. Serum was aliquotted into microtubes and stored 
at -20°C or -80°C.     
2.2.17 Afatinib therapy 
Afatinib stock solution was prepared at 293 mg/ml concentration by dissolving in 
DMSO. A working solution of afatinib was prepared by diluting stock solution 1:10 
with sterile water. 10 µL of working solution, which equivalent to 293 µg, was 
concealed in peanut butter and fed to the mice.  
2.2.18 Withaferin A therapy 
Withaferin A stock solution was prepared at 50 mg/ml concentration by dissolving in 
DMSO. Working solution was prepared by diluting stock solution 1:200 in PBS and 
200 µL of working solution was injected in each mouse per dose.  
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2.2.19 Fucoidan therapy 
Fucoidan working-stock solution was prepared at 10 mg/ml concentration by 
dissolving fucoidan (Fucus vesiculosus species from Marinova, Tasmania) in sterile 
water. Mice were injected with 1.25 mg intraperitoneally as stated in protocol.  
2.2.20 Imiquimod therapy 
Imiquimod working-stock solution was prepared at 1 mg/ml concentration by 
dissolving initially in DMSO and then adding required sterile water. Mice were treated 
with 100 µg of imiquimod intratumoural injections as stated in protocol.  
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3 DFTD investigation using in vitro assays and a 
murine DFTD model 
3.3 Introduction 
The Tasmanian devil (Sarcophilus harrisii) faces possible extinction in the wild due to 
a transmissible cancer known as Devil Facial Tumour Disease. The unique and 
conserved chromosomal rearrangements of DFTD cells compared to the host’s, 
negate the possibility of transmission from a viral or bacterial agent, pollutants or 
toxins in the environment (Pearse and Swift 2006). The cancer cells are transmitted 
through facial biting of successive hosts (Murchison et al 2010, Murchison et al 
2012, Pearse and Swift 2006) and alongside the CTVT it is described as a clonal cell 
line immortalised as a parasitic infectious allograft (Murchison 2008). Genetic and 
chromosomal research has provided convincing evidence that the malignant 
neoplasm originated in an individual female Tasmanian devil (Murchison et al 2012). 
Not only did the DFTD cancer cells evade the original host’s immune system but the 
immune systems of subsequent devils.  
It was first considered that the limited MHC diversity of the population of devils, from 
which the DFTD founder was derived, enabled the establishment of DFTD 
throughout subsequent devil populations (Jones et al 2004, Siddle et al 2007). It had 
been hypothesised that since the tumour arose in a Tasmanian devil the tumour 
itself expressed normal MHC and was not perceived as a threat within the original 
host. It was further hypothesised that following transmission to another devil the 
MHC was so similar between hosts that it was not perceived as a foreign cell. 
Nevertheless, recent evidence reveals that genetically diverse animals are prone to 
the disease (Siddle and Kaufman 2013) while skin graft experiments showed MHC 
diversity was sufficient between individuals to result in graft rejection (Kreiss et al 
2011a). It is important to note that skin is one of the most immunogenic organs of the 
body and this skin graft rejection does not disprove the hypothesis of MHC 
bottleneck within the species contributing towards the transmission of DFTD.  
Siddle et al. (Siddle et al 2013) revealed that DFTD cells do not express cell surface 
MHC molecules in vitro or in vivo. The genes contributing to the essential 
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components of the antigen-processing pathway, such as β2-microglobulin and 
transporters associated with antigen processing are downregulated (Siddle et al 
2013). The loss of gene expression is not due to structural mutations, but to 
regulatory changes including epigenetic deacetylation of histones (Siddle et al 2013). 
By downregulating MHC, the tumour cells remain invisible to parts of the devil’s 
immune system. However, lack of surface MHC class I molecules should make 
DFTD cells targets for NK cells (Das and Das 2000) unless DFTD are non-
immunogenic. 
When tumours spontaneously occur in any animal they undergo random mutations 
that result in certain traits that promote escape from tumour surveillance. The lack of 
any identified resistant or immune wild Tasmanian devils suggests the pro-tumour 
mechanisms may hide the cells from the recognition of the immune system. One 
possible explanation could be that the DFTD cells have evolved to be non-
immunogenic and are therefore invisible to any immune system. The lack of 
interspecies transmission contradicts this possibility.  
To determine if DFTD cells are immunogenic and therefore potential targets for 
immunotherapy a xenograft mouse model was used to look for immune responses to 
DFTD. DFTD tumours successfully implant in immunocompromised NOD/SCID mice 
but do not implant in immunocompetent BALB/c mice (Kreiss et al 2011b).The aim 
was to determine if this rejection by immunocompetent mice was an active 
immunological response and not due to other factors such as preformed antibodies 
commonly associated with xenogeneic graft rejection. This was performed by 
examining specific antibody, cytokine and cell mediated cytotoxicity responses to the 
DFTD xenograft.  
In addition this xenograft model was used to investigate the possibility that DFTD 
evolved certain traits that modify appropriate immune responses to inappropriate 
responses which protect the tumour. Polarising the immune system towards a TH2 
response is a mechanism exploited by tumour cells to suppress anti-tumour CTL 
activity and promote ineffective humoral antibody responses (Singh et al 2011). This 
could be evaluated in the mouse model with the caution that results obtained may 
not directly translate to the Tasmanian devil.  
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Ideally an immunological study of an allograft tumour in the host species is 
necessary, but in the case of the Tasmanian devil conducting large scale 
immunological experiments are not possible due to the endangered species status. 
Therefore, since it is widely accepted that mouse models provide valuable insights 
into the study of human cancers this research exploits a mouse model to study 
DFTD. The particular advantage of a mouse model is the readily available antibodies 
to detect mouse immune responses while there is a paucity of equivalent antibodies 
currently available for the Tasmanian devil immune system. Developing an 
understanding of the mechanism and pathways used by immunocompetent mice to 
reject DFTD xenografts may provide insight into targeting DFTD cells for 
immunotherapy within the wild Tasmanian devil population.  
To complement the in vivo studies of DFTD in the mouse model in vitro studies could 
explore the question of whether or not DFTD cells can undergo apoptosis. 
Avoidance of apoptosis is known to contribute towards carcinogenesis, progression 
and resistance to treatment (Fulda 2009).   
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3.4 Results 
3.4.1 The intrinsic apoptosis pathway in DFTD cells 
Resistance to apoptosis is one mechanism employed by certain tumours to avoid 
killing by immune systems and drugs (Igney and Krammer 2002). Tasmanian devils 
with DFTD lack the ability to kill DFTD cells. This may be due to a lack of recognition 
of DFTD cells by the host. But there is also the possibility that DFTD cells can avoid 
immune destruction due to resistance of the DFTD cells to apoptosis. 
In this chapter flow cytometry was used to identify apoptosis in DFTD cells by 
Annexin V, propidium iodide (PI) and scatter analysis. Annexin V binds to the cell 
membrane of cells from the earliest stages of apoptosis. DNA labelling by PI occurs 
in later stages of apoptosis when the membranes become permeable and also as a 
result of necrosis.  
In late stage apoptosis the cellular contents are being condensed causing a more 
granular characteristic to the cell resulting in increased side scatter (SSC) of the 
laser. The condensing of the cellular contents during apoptosis also reduces the size 
of the cells resulting in a lower forward scatter (FSC). In comparison necrotic cells 
have both low FSC and SSC as the cellular contents are released (Darzynkiewicz et 
al 1997).  
Apoptosis can be induced by the cytotoxic drug camptothecin. Therefore, to evaluate 
the ability of DFTD cells to undergo apoptosis C5065 DFTD cells were incubated 
with camptothecin for four hours. The cells were then labelled with Annexin V-FITC 
and propidium iodide before being analysed by flow cytometry.   
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Based on cell morphology two populations were identified by flow cytometry (Figure 
3-1). Population 1, gated in blue, represents cells with lower FSC and relatively high 
SSC whereas Population 2, gated in red, represents cells with higher FSC and 
normal SSC.  Population 1 had a strong correlation to PI+ cells whereas Population 2 
correlated to PI- cells. Within Population 1, as analysed by Annexin V and PI, the late 
apoptotic cells were identified as Annexin V+ PI+ and in this example represented 
77% of the total cells. Within Population 2, Annexin V+PI- identified early stage 
apoptotic cells and represented 5% of the total cells. Annexin V-PI- identified viable 
cells and represented 16% of the total cells. Only 2% of the cells could be classified 
as necrotic based on being Annexin V-PI+.  Therefore, following four hours exposure 
to the cytotoxic drug, DFTD cells showed obvious signs of dying via apoptosis. 
 
 
Figure 3-1. Flow cytometry analysis of DFTD cells incubated with 4 µM camptothecin for four 
hours. Based on forward-scatter (FSC) and side-scatter (SSC) late apoptotic cells were 
identified as lower FSC and higher SSC values (represented by population 1 shown in blue). 
Population 2 (shown in red) represents viable and early stage apoptotic cells. 82% of the cells 
are Annexin V positive and 77% of the cells were positive for both Annexin V and propidium 
iodide (right panel).     
  
FSC-A
S
S
C
-A
0 256 512 768 1024
0
256
512
768
1024
Population 2
Population 1
Annexin V-FITC 
P
ro
p
id
iu
m
 I
o
d
id
e
10
0
10
1
10
2
10
3
10
4
10
0
10
1
10
2
10
3
10
4
5%16%
77%2%
Camptothecin treated DFTD cells 
 3-6 
 
Necrosis is a non-apoptotic cell death that disrupts the membrane in a way that 
makes it permeable to dead cell markers such as PI but does not expose the 
membrane’s phosphatidylserine for Annexin V binding. As camptothecin only 
produced 2% necrotic cells, C5065 DFTD cells were induced to undergo necrosis by 
rapid freeze thawing. This was used to confirm that the previously described Annexin 
V binding to DFTD cells was specific for apoptosis and not resulting from non-
specific binding to necrotic cells.  
There were two distinct populations, Annexin V- PI- and Annexin V- PI+. There was no 
evidence of Annexin V+ cells. Necrotic cells incorporated PI while viable cells 
excluded PI (Figure 3-2).  As none of the necrotic cells, induced by freeze thawing, 
were Annexin V+ this provides support that the assay is specific for detecting 
apoptosis in DFTD cells and that DFTD cells have the ability to die via apoptosis.    
 
 
Figure 3-2. Annexin V-FITC and PI were used to label DFTD cells following freeze-thaw 
treatment. Dead cells have labelled positive for PI and negative for Annexin V-FITC.     
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A further verification of specificity of the assay for apoptosis was performed with 
K562 cells and resting lymphocytes. These cells are resistant to camptothecin 
induced apoptosis (Ferraro et al 2000, Tian et al 2011) and were selected as 
negative controls to further validate the use of Annexin V. K562 cells, devil 
lymphocytes and DFTD cells were incubated with camptothecin, labelled with 
Annexin V-PE and 7AAD and then analysed by flow cytometry.  
Following exposure to camptothecin, K562 cells and devil lymphocytes were not 
positive for Annexin V. In contrast, 42% of the DFTD cells were Annexin V+ of which 
16% were Annexin V+ 7AAD+  (late apoptosis) and 26% of the cells were Annexin V+ 
7AAD-   (early apoptosis) (Figure 3-3). The lack of Annexin V binding in the K562 
cells and devil lymphocytes confirms that the Annexin V binding to DFTD cells was 
specific for camptothecin mediated apoptosis.   
 
 
   
Figure 3-3. Following two hours incubation with camptothecin there is only limited binding of 
Annexin V to K562 cells (A) and no significant binding to resting lymphocytes (B) while there 
was binding of Annexin V to C5065 DFTD cells (C). 7AAD has bound to dead cells (A, B & C).  
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UV-radiation (UV-R) was used as an alternative treatment to induce apoptosis to 
further corroborate apoptosis in DFTD cells. Since K562 cells are sensitive to UV 
induced apoptosis (Ujvarosi et al 2007) they were used as a positive control cell line. 
The cells were exposed to 4 kj/m2 of UV-R and Annexin V-FITC and PI were used to 
detect apoptosis following 24 hours in culture.  
Following UV-R exposure apoptosis was detected in both K562 and C5065 DFTD 
cells. Various stages from viable cells to apoptotic cells are evident for both cell 
lines. The bottom left hand corner of each panel shows viable cells, which are 
Annexin V- and PI-. To the right of this population are Annexin V+ cells ranging from 
PI- to PIdim  to PIbright as they progress from early to late stage apoptosis (Figure 3-4). 
In the example shown 59% of the K562 cells  and 26% of the DFTD cells have 
undergone apoptosis.  
 
  
 
Figure 3-4. Following exposure to 4 kj/m
2
 of UV-R radiation apoptosis was evaluated using 
Annexin V-FITC and PI. Bottom left quadrant contains viable cells, bottom right quadrant 
contains cells in early stage apoptosis and top right quadrant contains cells in late stage 
apoptosis.    
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Another indicator of apoptosis is DNA fragmentation. DFTD cells were exposed to 4 
kj/m2 of UV-R and cultured for 24 hours. DNA fragmentation was then evaluated with 
TUNEL assay, which labels the exposed 3’-hydroxyl ends of DNA breaks that occur 
in late stage cell apoptosis. Nuclear yellow staining was included to identify all cells.  
Cells positive for nuclear yellow and TUNEL appear yellow in the overlaid images. In 
the representative images shown (Figure 3-5) 26% and 43% of the DFTD cells were 
TUNEL positive confirming apoptotic damage is occurring to the DNA of C5065 
DFTD cells following UV-R exposure. This result correlates with the 26% apoptotic 
cells evaluated by Annexin V following similar UV-R irradiation (Figure 3-4).  
From these combined observations it can be concluded that DFTD cells can undergo 
apoptosis. This verifies the intrinsic apoptosis pathway in DFTD cells has remained 
functional and this does not explain the lack of immune response to DFTD cells in 
infected Tasmanian devils.  
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Figure 3-5. Following exposure to 4 kj/m
2
 of UV-R radiation apoptosis in DFTD cells was 
evaluated using TUNEL assay. Positive control was treated with DNase and Nuclear Yellow 
labelling shown in A, TUNEL labelling shown in B and overlay shown in C. Two replicates of 
C5065 cells (D to F and G to I) demonstrate apoptosis in 26 and 43% in these examples.  
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3.4.2  Antibody responses by mice following immunisation with DFTD cells 
In the wild Tasmanian devil population there is no evidence of immune responses or 
resistance to DFTD. Having shown that DFTD cells have the capacity to undertake 
apoptosis this leads to the hypothesis that DFTD cells are not immunogenic and 
therefore invisible to any immune system. To test this hypothesis, immunocompetent 
C57/BL6 mice were subcutaneously immunised one to four times with 106 viable 
DFTD cells into the flanks. This cell number was selected based on observations of 
DFTD tumour establishment in BALB/c mice by Kreiss et al (2011b).These injections 
included 50 µg CpG1668 and 50 µl Montanide 71 as adjuvants designed to enhance 
immune responses.  
Indirect immunofluorescence was used to identify IgG anti-DFTD antibodies in the 
serum. As shown in Figure 3-6, six of eight immunised mice produced varying levels 
of DFTD specific antibody. Of the two non-responders one had received three 
immunisations. This result established that DFTD cells can induce an immune 
response but individual responses are variable. Multiple subcutaneous 
immunisations did not guarantee that an IgG immune response would be detected.  
 
Figure 3-6. Goat anti-mouse IgG (H+L) Alexa-fluor 488 conjugated antibodies were used to test 
mouse serum for DFTD specific antibodies. Naïve mouse serum shown in black was used as a 
negative baseline control. Mice were immunised subcutaneously and received one (shown in 
red), two (shown in blue), three (shown in green) or four (shown in pink) immunisations.   
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To determine which antibody isotypes were produced subsequent to subcutaneous 
immunisations with DFTD cells, sera from C57/BL6 mice were screened for IgM, 
IgG1, IgG2a, IgG2b and IgG3 isotype production following immunisation. Comparing 
mean fluorescence intensity level of sample against serum from naïve mice 
facilitated calculation of relative anti-DFTD antibody responses as a fold increase 
(Table 3-1).  
IgM anti-DFTD was detected in 4/15 mice whereas IgG anti-DFTD was detected in 
14/15 mice at varying levels. IgG1 was the isotype detected in all responders. IgG1 
alone was detected in 5/15 while in 2/15 mice IgG1 and IgG2b were detected and all 
IgG isotypes in 7/15 mice. When IgM was detected all isotypes were identified.   
These results indicate that IgM/IgG isotype switching is occurring in C57/BL6 mice 
following immunisation with DFTD cells and that IgG1 is the dominant response.  
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Table 3-1. Relative anti-DFTD antibody levels in serum from C57/BL6 mice that had been 
immunised by subcutaneous injection with DFTD cells (ND represents no change from naïve 
serum) 
Relative anti-DFTD isotype antibody levels 
Mouse ID# IgM IgG1 IgG2a IgG2b IgG3 
100219-g ND 5 ND 2 ND 
100219-h ND 5 ND ND ND 
100219-i ND 2 ND ND ND 
100219-j ND 7 ND ND ND 
10419-a-38 2 4 2 3 2 
10419-b-39 ND 3 ND ND ND 
10419-c-10 ND 3 ND ND ND 
10419-d-12 ND 11 ND ND ND 
10419-e-11 2 52 2 5 2 
10419-f-18 2 67 7 51 6 
10419-g-19 ND 9 ND 2 ND 
10419-h-17 4 112 12 44 7 
100823-207 ND 10 5 30 8 
100823-208 ND 15 5 20 10 
100823-209 ND 6 5 10 5 
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BALB/c mice were injected subcutaneously with 106 DFTD cells from the same 
culture either into a single site or divided between multiple sites in the flanks. This 
was performed to investigate if distributing the same number of DFTD cells between 
multiple injection sites rather than concentrating the cells into a single site enhanced 
responses to subcutaneous injections. The serum were screened for IgG and IgM 
anti-DFTD isotypes.     
Multiple site subcutaneous injections produced higher relative levels of 
immunoglobulins compared to single site subcutaneous injections (Figure 3-7). IgM 
was not detected in any of the serum samples screened. IgG1 was detected 
following 4/4 single site injections and 4/4 multi-site injections. IgG2a was detected 
following 3/4 single site injections and 4/4 multi-site injections. IgG2b was detected 
following 1/4 single site injections and 3/4 multi-site injections. IgG3 was detected 
following 1/4 single site injections and 2/4 multi-site injections.  These results 
indicate that distributing the same number of cells over multiple sites significantly 
enhances the anti-DFTD antibody response in BALB/c mice.   
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Figure 3-7. Comparison of antibody responses of BALB/c mice inoculated subcutaneously 
(SC) with DFTD cells on days 0 and 16. Serum was collected day 25. IgM was not detected. 
Higher levels of IgG1 were detected for mice immunised by injections into multiple sites. (Data 
are expressed as mean of four mice ± SEM, probability calculated by Student’s unpaired t-test 
* P < 0.05, ** P < 0.01)   
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Intraperitoneal injections were compared to subcutaneous immunisations. C57/BL6 
mice were injected with 10
6
 DFTD cells from the same culture either into a single 
intraperitoneal site or divided between two subcutaneous locations by injections to 
the neck and rump. The mice were immunised on day 0 and day 16 and serum 
collected on day 25. The serum was then analysed by indirect immunofluorescence 
for relative anti-DFTD antibody levels.  
Intraperitoneal injections produced significantly higher levels of immunoglobulins 
compared to multi-site subcutaneous injections (Figure 3-8). For the intraperitoneally 
immunised mice all tested isotypes were detected in all three mice. For multi-site 
subcutaneous immunised mice IgG, IgG1 and IgG2b were detected in all four mice 
while IgM was detected in two of the four mice and IgG3 in one of the four mice.  
These results indicate that intraperitoneal immunisations produced stronger and 
more consistent anti-DFTD antibody responses following immunisation.   
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Figure 3-8. Comparison of antibody responses for intraperitoneal (IP) and subcutaneous (SC) 
injections of DFTD cells. Relative antibody levels were determined in serum samples obtained 
from C57BL/6 mice immunised with DFTD cells on day 0 and 16. Serum was collected on day 
25. The SC immunisations were given as two injections divided between the neck and rump 
region to target multiple draining lymph nodes. (Data are expressed as mean of three IP and 
four SC immunised mice ± SEM, probability calculated by Student’s unpaired t-test * P < 0.05, 
** P < 0.01, *** P < 0.001)   
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   Mouse strain 
    C57/BL6  
    BALB/c  
 
Having determined that intraperitoneal immunisations were more effective than 
subcutaneous immunisations, a protocol described by Elsawa et al (2003) was 
evaluated to determine if two intraperitoneal injections spaced 14 days apart would 
enhance antibody responses against DFTD cells. A similar procedure produced 
rapid and reliable responses against viruses in mice within 21 days (Elsawa et al 
2003). 106 viable DFTD cells were intraperitoneally injected into mice with a second 
injection 14 days later. Serum was collected 7 days after the second injection and 
IgG antibody levels analysed. All the immunised mice produced detectable antibody 
responses with variability between individuals (Figure 3-9).   
   
Figure 3-9. Mice were given two intraperitoneal injections of 10
6
 C5065 DFTD cells 14 days 
apart and serum collected 7 days after the second immunisation. Naive C57/BL6 mouse serum 
(shown in black) was used as a negative baseline control.  
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To determine if antibody responses could be enhanced further and variability 
between individual mice minimised the relative IgG levels were compared for 
C57/BL6 mice given two versus three intraperitoneal 106 DFTD immunisations. All 
mice produced IgG antibody responses following immunisation with DFTD cells. The 
mice immunised three times had less variability in antibody levels but not higher 
antibody levels than those with two immunisations. There would be little advantage 
gained by prolonging the immunisation protocol. 
 
   
Figure 3-10. Mice were given two (shown in blue) or three (shown in green) intraperitoneal 
injections of C5065 DFTD cells. Serum were collected 7 days after the last immunisation. 
Pooled naïve C57/BL6 mouse serum (shown in black) was used as a negative baseline control.      
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Two strains of immunocompetent mice were analysed because of their reportedly 
opposing TH1 (C57/BL6) or TH2 (BALB/c) dominated immune responses (Mills et al 
2000, Reiner and Locksley 1995). Since TH1 and TH2 responses can be 
discriminated based on IgG isotype polarisation, C57/BL6 and BALB/c mice that 
were immunised against 106 DFTD cells with a second injection on day 14 and 
serum collected on day 21 were compared for IgG and IgM profiles.   
Both strains of mice produced all of the tested antibody isotypes. Levels of IgM, IgG1 
(TH2 antibodies) and IgG3 (TH1 antibody) were similar for the two strains (Figure 
3-11). BALB/c mice produced significantly higher levels of IgG2a (TH1 antibody) and 
significantly lower levels of IgG2b (TH1 antibody) compared to C57/BL6 mice. The 
relevance of these findings is that immunisation with DFTD cells did not polarise the 
immune system of either strain towards a TH1 or TH2 response. The difference in 
IgG2 isotypes between the two strains suggests a disparity in the immune response 
between the strains.  
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Figure 3-11. Cohorts of BALB/c and C57/BL6 mice were injected with 10
6
 DFTD cells by 
intraperitoneal injection on day 0, with a second injection day 14 or 16; serum was collected 7 
or 8 days later. While anti-DFTD antibody expression varied between individuals there was a 
consistent trend that BALB/c mice were skewed towards higher levels of IgG2a and lower 
levels of IgG2b compared to C57/BL6 mice. (Data are expressed as mean ± SEM, probability 
calculated by Student’s unpaired t-test ** P < 0.01) 
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Although DFTD transmissibility in the Tasmanian devil population did not show any 
gender bias it was unknown if this was the case for DFTD responses in the mouse 
model. Therefore to investigate if there was any significant gender bias, serum from 
male and female BALB/c siblings were compared for antibody levels following 
immunisation with the same preparation of 106 DFTD cells. All tested isotypes were 
produced by both genders with no skewing of the antibody isotypes.  
 
Anti-DFTD antibody responses BALB/c male and female siblings
To
ta
l I
gG
-Ig
M
 (M
)
To
ta
l I
gG
- I
gM
 (F
)
Ig
G
 (M
)
Ig
G
 (F
)
Ig
M
 (M
)
Ig
M
 (F
)
Ig
G
1 
(M
)
Ig
G
1 
(F
)
Ig
G
2a
 (M
)
Ig
G
2a
 (F
)
Ig
G
2b
 (M
)
Ig
G
2b
 (F
)
Ig
G
3 
(M
)
Ig
G
3 
(F
)
0
50
100
150
Antibody Isotype
R
e
la
ti
v
e
 a
n
ti
b
o
d
y
 l
e
v
e
ls
Figure 3-12. Four male and five female BALB/c mice were injected with the same DFTD cell 
preparation and protocol. Unpaired Student’s two tailed t-test revealed that there was no 
statistically significant difference between genders. 
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To investigate how long after immunisation it took to induce detectable antibody 
responses and timing of IgG isotype switching, C57/BL6 mice were injected 
intraperitoneally with 106 DFTD cells and bled four and seven days post 
immunisation. Four days following immunisation with DFTD cells two mice had 
produced detectable levels of IgM and the mouse with the highest IgM level (shown 
in red) was the only mouse with detectable IgG at this time.  Seven days following 
immunisation all four mice produced both IgM and IgG. The mouse producing the 
highest level of IgM at day seven (shown in green) also had the highest level of IgG 
at this time (Figure 3-13). The significance of this result is that four days is 
insufficient to produce reliable antibody responses and seven days will produce both 
IgM and IgG antibodies following DFTD immunisation.   
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Figure 3-13. C57/BL6 mice (shown in individual colours) were immunised intraperitoneally with 
10
6
 DFTD cells and serum collected 4 and 7 days post injection. All samples were analysed in 
the same flow cytometry experiment to permit direct comparison of mouse anti-DFTD IgM and 
IgG levels in the serum.  
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Primary and secondary responses were compared to determine if secondary 
responses were enhanced as a result of recall or memory. C57/BL6 mice were 
immunised once intraperitoneally with 106 DFTD cells and serum samples collected 
4 (n=4), 7 (n=4), 16 (n=3) or 24 (n=3) days later to evaluate the fluctuation of 
antibody levels following primary immunisation. Other C57/BL6 mice (n=3) were 
given a second injection on day 95 and serum collected 7 days later to evaluate 
secondary responses.  
Figure 3-14 shows that for the primary response peak detection levels for IgM were 
at day 7 and 16 following immunisation and subsided by day 24. IgM levels were 
restored to levels similar to the primary response 7 days following a second 
immunisation at day 95.  
IgG1, IgG2a and IgG2b primary response levels were highest at day 16 and had 
subsided by day 24. IgG1 had higher levels 7 days after the second immunisation 
compared to seven days after the first immunisation. The error bars for the 
secondary response at day 7 were large indicating variability in individuals but the 
response was not significantly higher than the peak primary response observed on 
day 16. The enhanced speed of the secondary response is consistent with a memory 
response.  
Ig2a primary response peak levels were also the highest at day 16 and had subsided 
by day 24. Seven days after the second immunisation IgG2a was higher than 7 days 
after the first immunisation. This was equivalent to the peak primary response 
observed on day 16. The enhanced speed of this secondary response is consistent 
with a memory response.  
IgG2b primary response levels also peaked at day 16 and subsided by day 24. 
Seven days after the second immunisation IgG2b was higher than 7 days after the 
first immunisation. This was significantly higher than the peak primary response 
observed on day 16. The secondary response was both more rapid and stronger 
suggesting a memory response had occurred.  
IgG3 primary response levels were the highest at days 7 and 16 and subsided by 
day 24. The response 7 days after the second immunisation was higher than 7 days 
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after the first immunisation. The secondary response was both more rapid and 
stronger than the primary suggesting a memory response had occurred.  
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Figure 3-14. Comparison of primary and secondary antibody responses following 
immunisation with DFTD cells. Primary antibody responses were measured as MFI fold 
increase compared to naïve serum. Serum samples were collected on days 4, 7, 16 and 24 
(results shown in black). Secondary immunisation occurred on day 95 and serum was 
collected 7 days later (results shown in blue). (Data are expressed as mean ± SEM, probability 
calculated by Student’s unpaired t-test * P < 0.05, ** P < 0.01, *** P < 0.001)   
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3.4.3 Development of a cytotoxicity assay for DFTD  
One of the aims of the research into DFTD is to induce cell-mediated cytotoxic 
responses. This research requires a sensitive, robust and repeatable in vitro 
cytotoxicity assay. The 51Cr assay is one of the most commonly used cytotoxicity 
assays but it is expensive and has inherent safety concerns associated with 
radioactive isotopes. For this reason a non-radioactive assay needed to be 
developed and validated specifically for DFTD cells.  
The non-radioactive cytotoxic assay involved labelling the target cells with CFSE or 
CellTrace Violet™. This allowed discrimination of target cells from unlabelled effector 
cells. Then following the required incubation period a dead cell marker such as 
propidium iodide (PI) or 7AAD was used. Flow cytometry was used to analyse the 
percentage of dead target cells.    
Validation for this assay was undertaken using human lymphocytes as effector cells 
against K562 target cells and also mouse lymphocytes against YAC-1 target cells. 
The human leukaemia cell line K562 is a known cytotoxic target for human NK cells 
while YAC-1 cells are a known target for murine NK cell-mediated cytotoxicity. The 
non-radioactive assay technique detected cytotoxicity for both of these effector target 
cell combinations as a dose response curve was evident. Human lymphocytes 
showed greater cytotoxicity than mouse lymphocytes, hence the use of lower 
effector to target cells ratios (Figure 3-15).   
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Figure 3-15. To test the cytotoxicity assay K562 and YAC-1 cytotoxicity was calculated 
following 18 hours incubation with effector cells. (Data points represent the mean of 
duplicates (K562) or triplicates (YAC-1) and error bars represent SEM) 
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The 51Cr radioactive assay has long been regarded as the gold standard of 
cytotoxicity assays. To compare the sensitivity and reproducibility of the non-
radioactive assay a direct comparison of the 51Cr assay to the non-radioactive 
cytotoxicity assay was undertaken. YAC-1 tumour cells from the same culture and 
mouse lymphocytes from the same mouse were used in these parallel assays to 
minimise variability.  
The 51Cr and CellTrace Violet assay results closely correlated (Figure 3-16). The 
main difference being the CellTrace Violet plot had smaller error bars indicating 
smaller variance between replicate wells than 51Cr.  The exception was the 3:1 E:T 
ratio when CellTrace Violet had the highest variability in replicate wells which 
included negative values. CellTrace Violet assay is cheaper, easier and safer than 
the 51Cr assay and is not inferior to 51Cr for repeatability and sensitivity. 
Consequently, the non-radioactive assay was deemed as a suitable replacement for 
the 51Cr assay.   
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Figure 3-16. Splenocytes from a C57/BL6 mouse were used as effector cells against 
51
Cr 
labelled YAC-1 target cells and CellTrace Violet labelled YAC-1 target cells in 18 hour in vitro 
cytotoxicity assays. (Data points represent mean of three replicate wells and error bars 
represent SEM) 
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3.4.4 In vitro murine cell-mediated cytotoxic responses to DFTD  
Splenocytes from naïve and immunised C57/BL6 mice were compared for 
cytotoxicity responses against DFTD cells following 18 hours in vitro incubation. The 
immunised mice had been injected intraperitoneally with 2 x 106 C5065 DFTD on 
days 0 and 25 with the splenocytes harvested on day 33. 
The magnitude of killing from naïve mice was equivalent to that of immunised mice. 
This indicated that the killing was mediated by unprimed cells of the immune system 
(Figure 3-17). There were varying amounts of background killing at low effector to 
target cell ratios. All mice in this experiment demonstrated a dose response 
cytotoxicity against DFTD cells.  
However it should be noted that cytotoxic responses by mouse splenocytes were not 
always observed in other experiments. This is evaluated in more detail in Chapter 6.   
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Figure 3-17. Splenocytes from immunised and naïve C57/BL6 were compared for cytotoxicity 
against DFTD cells following 18 hours in vitro co-incubation. (Data points represent mean of 
four replicate wells with error bars representing SEM)  
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3.4.5 In vitro cytokine responses to DFTD cells by murine lymphocytes  
As upregulation of certain cytokines in the tumour microenvironment can enhance or 
suppress tumour rejection, cytokines from immunised C57/BL6 mice were evaluated 
to provide an additional assessment of immune responses to DFTD cells. Two 
C57/BL6 mice were subcutaneously immunised with DFTD cells and lymphocytes 
from the lymph nodes were co-cultured with DFTD cells for five days to allow time for 
cytokines to be produced. Five days culturing in 96 well plates proved problematic in 
terms of nutrient exhaustion and evaporation from the plate edges. The supernatant 
was analysed in an ELISA assay for IFN-γ, IL-4, IL-10 and IL-12 cytokines as these 
would allow discrimination between TH1 or TH2 dominated immune responses.  
Lymphocytes from both immunised mice produced IL-4, IL-10 and IFN-γ but IL-12 
was not detected (Figure 3-18). IFN-γ is a principal TH1 cytokine and IL-10 is the 
most important TH2 cytokine to downregulate TH1 responses. The presence of both 
of these cytokines suggests the immune system is not polarised to either a TH1 or 
TH2 response.  
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Figure 3-18. Cytokine levels detected by ELISA assay following five days co-culturing of DFTD 
cells and lymphocytes from two immunised C57BL/6 mice. (Data points represent the mean of 
duplicates)    
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Since five days incubation was problematic when incubating lymphocytes with DFTD 
cells to produce cytokines an investigation was undertaken to determine an optimal 
incubation period. As a consequence, lymphocytes and DFTD cells were cultured 
together for 72 hours at a ratio of 50:1 and supernatant sampled at 24 hour time 
points to measure cytokine production.  
There was increasing IFN-γ and IL-10 levels in the culture supernatant as culture 
time was extended to 72 hours. Shorter culturing times of 48 hours or less 
significantly reduced the cytokine levels in the supernatant (Figure 3-19). IL-4 and 
IL-12 was not detected at any time point (data not shown).  Based on these results 
72 hours was selected for the incubation period for future cytokine assays.  
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Figure 3-19. Evaluation of cytokine levels following various incubation periods for 
lymphocytes and DFTD cells in 96 well plates. (Horizontal bars represent the mean)    
  
In vitro cytokine responses 
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Having determined 72 hours as a suitable incubation time for detecting cytokine 
levels in the supernatant the best effector to target cell ratios for cytokine production 
needed to be determined. One of the limiting factors was the availability of effector 
cells as these were also required for other experiments conducted concurrently. For 
this reason the maximum ratio of effector to target cells tested was 100:1 and a 
series of doubling dilutions to 3:1 were cultured together for 72 hours.   
An effector to target cell ratio of 100:1 produced the highest level of IFN-γ and IL-10 
while 12:1 was ineffective at producing detectable levels of cytokines (Figure 3-20). 
IL-4 and IL-12 was not detected at any ratio (data not shown). Based on these 
results an effector to target cell ratio of 100:1 with 72 hours incubation would become 
standard protocol for future cytokine assays. 
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Figure 3-20. Evaluation of cytokines levels following 72 hours incubation at various effector to 
target cell ratios. (Data points represents mean of three immunised C57/BL6 mice and error 
bars SEM) 
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To evaluate cytokine responses in more detail the cytokine analysis was switched 
from an ELISA based technique to a CBA TH1, TH2, TH17 micro-bead array kit. The 
micro-bead assays have the advantage of being able to evaluate multiple cytokines 
in a single sample. Also, by using 96 well plates multiple samples can be analysed in 
the same experiment using high throughput analysis on flow cytometry equipment. 
This allows direct comparison of relative cytokine levels without experimental 
variability between ELISA plates confounding the results.     
The micro-bead assay was used to compare splenocytes from naïve and immunised 
mice to see if the cytokine response varied depending on previous exposure to 
DFTD cells. BALB/c and C57/BL6 mice were injected intraperitoneally with viable 
DFTD cells on day 0 and 15 with splenocytes harvested on day 22. Splenocytes 
from naïve mice were harvested at the same time.  
Immunisation altered the cytokine responses in BALB/c and C57/BL6 mice. 
Splenocytes from naïve BALB/c and C57/BL6 mice produced higher levels of the 
inflammatory cytokine IL-6, the anti-tumour cytokine TNF-α and the TH1 cytokine 
IFN-γ. Splenocytes from immunised mice produced higher levels of the TH2 
regulatory cytokine IL-10 (Figure 3-21).  
Naïve NOD/SCID mice had been included in the experiment because it was 
predicted that they would be non-responders to the DFTD cells. However, the 
NOD/SCID mice produced levels of TNF-α and IL-6 equivalent to the levels 
produced by naïve BALB/c and C57/BL6 mice. There was no significant production 
of IL-10 and IFN-γ from the NOD/SCID mice (Figure 3-21). 
IL-2, IL-4 and IL-17a were not detected in any of the samples (data not shown). 
DFTD cells alone and splenocytes alone did not produce detectable levels of 
cytokines (data not shown). 
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Figure 3-21. Evaluation of cytokine levels obtained in culture supernatants of splenocytes from 
naïve and immunised mouse cultured in vitro for 72 hours with C5065 DFTD cells. Supernatant 
analysed using CBA TH1, TH2, Th17 micro-bead array kit. (Horizontal bars represent mean and 
individual points raw data)  
 
  
Cytokine profiles for naïve and immunised mice 
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To further assess the effect of priming the immune system with DFTD cells, various 
intraperitoneal immunisation strategies were compared in C57/BL6 mice and 
cytokine responses analysed. The first involved injections on day 0 and 15 with the 
splenocytes harvested on day 22. This protocol was chosen to replicate the 
previously described work in Figure 3-21. The next involved a series of three 
immunisations on day 0, 47, 75 and splenocytes harvested on day 81. This protocol 
was chosen to see if repetitive exposure modified responses. The third involved 
injections on day 0 and 95 with the splenocytes harvested on day 102. This protocol 
was to evaluate if a memory immune response to DFTD cells developed in the 
C57/BL6 mice following primary exposure.  
The cytokine production by mice immunised day 0, day 15 and splenocytes 
harvested on day 22 were equivalent to the previous results for comparable 
immunised C57/BL6 mice as shown in Figure 3-21. This immunisation schedule 
resulted in cytokine production dominated by the TH2 regulatory cytokine IL-10 
(Figure 3-22).  
Immunisation on days 0, 47 and 75 resulted in the highest levels of IL-6, IL-10, TNF-
α and IFN-γ. There was no skewing towards a TH1 or TH2 profile (Figure 3-22).   
Compared to two injections 15 days apart, two injections 95 days apart produced 
higher levels of IL-6 and TNF-α, lower levels of IL-10 and similar levels of IFN-γ 
(Figure 3-22).  
IL-2, IL-4 and IL-17a were not detected in any of the samples (data not shown).   
Priming the immune system altered the cytokine responses to subsequent DFTD 
exposure. Repetitive exposure increased all detected cytokine levels however there 
is no evidence that this effect is maintained over prolong periods as a 95 day interval 
between DFTD exposure did not produce enhance cytokine responses compared to 
naïve mice (Figure 3-21,Figure 3-22)  
 
  
 3-32 
 
 
IL-6
D
ay
 0
, 1
5,
 H
=2
2
D
ay
 0
, 4
7,
 7
5,
 H
=8
1
D
ay
 0
, 9
5,
 H
=1
02
0
500
1000
1500
2000
Days of IP injection and spleen harvest (H)
C
y
to
k
in
e
 p
g
/m
l
IL-10
D
ay
 0
, 1
5,
 H
=2
2
D
ay
 0
, 4
7,
 7
5,
 H
=8
1
D
ay
 0
, 9
5,
 H
=1
02
0
1000
2000
3000
Days of IP injection and spleen harvest (H)
C
y
to
k
in
e
 p
g
/m
l
TNF-
D
ay
 0
, 1
5,
 H
=2
2
D
ay
 0
, 4
7,
 7
5,
 H
=8
1
D
ay
 0
, 9
5,
 H
=1
02
0
1000
2000
3000
Days of IP injection and spleen harvest (H)
C
y
to
k
in
e
 p
g
/m
l
IFN-
D
ay
 0
, 1
5,
 H
=2
2
D
ay
 0
, 4
7,
 7
5,
 H
=8
1
D
ay
 0
, 9
5,
 H
=1
02
0
2000
4000
6000
8000
Days of IP injection and spleen harvest (H)
C
y
to
k
in
e
 p
g
/m
l
 
Figure 3-22. C57/BL6 mice were injected intraperitoneally with 10
6
 C5065 DFTD cells and 
splenocytes harvested 6 or 7 days after the last injection. The splenocytes were cultured for 72 hours 
in vitro with the DFTD cell line C5065. The supernatant was analysed using CBA TH1, TH2, Th17 
micro-bead array kit. (Horizontal bars represent mean and individual points raw data)  
  
Cytokine profile subsequent to priming immune system 
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As shown in Figure 3-21 immunised mice produced higher levels of IL-10 while naïve 
mice produced higher levels of IFN-γ. This lead to the hypothesis that early immune 
responses were TH1 dominated and later responses switched to TH2 dominated 
responses. To test this hypothesis, cytokine responses were compared for C57/BL6 
mice four and 21 days after a primary immunisation, as well as C57/BL6 mice given 
a secondary immunisation 57 days after the primary.  
The primary responses for IL-6, IL-10, TNF-α and IFN-γ increased from day 4 until 
day 21. IFN-γ dominated IL-10 primary responses while this was reversed as a 
secondary response. The secondary response for IL-10 was more rapid and stronger 
than the primary response but IFN-γ secondary and primary responses were 
equivalent. Secondary responses for IL-6 and TNF-α were enhanced compared to 
the primary response (Figure 3-23). IL-2, IL-4 and IL-17a were not detected in any of 
the samples (data not shown).  The greatest variation in the cytokine response was 
the domination of IL-10 as a secondary response supporting the hypothesis that later 
responses switch towards a TH2 response.   
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Figure 3-23. Cytokine production by splenocytes from DFTD immunised C57/BL6 mice, 
cultured in vitro with DFTD cells for 72 hours. Primary responses refer to mice given a single 
injection of 2 x 10
6 
DFTD cells and day refers to time post immunisation. Secondary responses 
refer to mice immunised with 2 x10
6
 DFTD cells, rested 57 days, given a second immunisation 
of 2 x 10
6
 DFTD cells and splenocytes collected 5 days later. (Data expressed as mean of five 
mice and error bars SEM)  
  
Primary and secondary cytokine responses to DFTD 
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To further test the hypothesis that early immune responses were TH1 dominated and 
later responses switched to TH2 dominated responses IL-10 and IFN-γ levels were 
compared 4 days after DFTD primary immunisation and either 5 or 7 days after 
secondary DFTD immunisations. The secondary immunisations were performed on 
either day 27, day 57 or day 95. Serum was collected 5 days after the day 26 or 57 
immunisations and 7 days after the day 95 immunisation.     
IFN-γ production was unaltered between primary and secondary responses; 
however, IL-10 response was greatly enhanced as a secondary response on day 27 
and diminished to similar levels as a primary response by day 95 (Figure 3-24).  
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Figure 3-24. IFN-γ and IL-10 responses compared for primary responses four days post DFTD 
immunisation and responses five days post-secondary DFTD immunisations given at day 27 or 
57 and seven days post-secondary DFTD immunisations given at day 95. (Columns represent 
mean of five mice except for day 95 is mean of three mice and error bars SEM) 
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It was important to determine if any gender bias occurred in the murine immune 
responses to DFTD as this variable would need to be factored for in future 
experimental designs.  Following identical immunisations on days 0 and 15 the 
splenocytes were harvested and cultured with DFTD cells for 72 hours. The 
supernatant was then analysed for cytokine levels and no significant gender biases 
were detected (Figure 3-25).    
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Figure 3-25. Cytokine levels were compared for male and female BALB/c mice immunised 
twice with 2 x 10
6
 DFTD cells. (One way ANOVA with Bonferroni’s multiple comparison tests 
used to analyse significance. Horizontal bars represent mean and individual points raw data).   
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3.4.6 Maintaining immunogenicity while inactivating DFTD cells 
Vaccine trials and immunotherapy experiments with Tasmanian devils require the 
injection of inactivated DFTD cells to induce immune responses without the risk of 
infection. To evaluate how inactivating DFTD cells affected immunogenicity the 
BALB/c mouse model was used. Relative antibody responses were compared 
between mice immunised with viable cells, irradiated cells, sonicated cells or 
freeze/thawed cells.   
Both IgG and IgM antibody responses were reduced when BALB/c mice were 
immunised with sonicated and freeze/thawed inactivated cells. Using irradiated cells 
for immunisations maintained similar levels of antibody responses compared to 
viable cells (Figure 3-26).  
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Figure 3-26. BALB/c mice were injected intraperitoneally with 10
6 
viable, irradiated, sonicated 
or freeze/thaw inactivated C5065 DFTD cells on day 0, given a second injection day 14 and 
serum collected day 21. (Columns represent mean of five mice and error bars SEM. Statistical 
analysis by one way ANOVA with Bonferroni’s multiple comparison test * P < 0.05, ** P < 0.01 
and *** P < 0.001.)  
  
Relative antibody responses to DFTD 
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To examine in more detail the IgG responses following immunisations with 
inactivated DFTD cells the mouse sera were analysed for IgG1, IgG2a, IgG2b and 
IgG3 isotypes levels. Following immunisation with irradiated cells all tested IgG 
isotype responses remained similar to viable cell immunisations. There was a trend 
for all tested IgG isotypes to be lower following immunisations with sonicated or 
freeze/thaw cells and this was statistically significant in the case of IgG1 and IgG2a 
(Figure 3-27). This provided further evidence that sonication and freeze/thawing cells 
for immunisations reduces the subsequent immune responses while irradiation of 
cells has no significant effect on subsequent immune responses.   
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Figure 3-27. BALB/c mice were injected intraperitoneally with 10
6 
viable, irradiated, sonicated 
or freeze/thaw inactivated C5065 DFTD cells on day 0, given a second injection day 14 and 
serum collected day 21. (Columns represent mean of five mice and error bars SEM. Statistical 
analysis by one way ANOVA with Bonferroni’s multiple comparison test * P < 0.05.)  
  
Relative IgG isotype responses to DFTD 
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In vitro cytokine levels were examined following immunisation with inactivated cells 
as cytokine levels are informative about the efficacy of immune responses against 
tumours. The anti-tumour cytokines IFN-γ and TNF-α response were suppressed 
when DFTD cells were inactivated by sonication or freeze/thawing. IFN-γ production 
was maintained at normal levels when DFTD cells were inactivated by irradiation. IL-
2 and IL-4 cytokines were also suppressed when DFTD cells were inactivated by 
sonication or freeze/thawing. Results for IL-6 and IL-10 were highly variable and not 
statistically significant but responses from irradiated cells tended to be higher than 
those from sonicated or freeze/thaw inactivated cells (Figure 3-28). The cytokine 
responses are consistent with the antibody responses providing further evidence that 
immunisation with sonicated or freeze/thaw cell preparations produced lower 
immune responses compared to viable or irradiated cells.  
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Figure 3-28. BALB/c mice were injected intraperitoneally with 10
6 
viable, irradiated, sonicated 
or freeze/thaw inactivated C5065 DFTD cells on day 0, given a second injection day 14 and 
serum collected day 21. (Columns represent mean five mice and error bars SEM. Statistical 
analysis by one way ANOVA with Bonferroni’s multiple comparison test * P < 0.05, ** P < 0.01 
and *** P < 0.001.)   
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During the experiments described in this results chapter and the experiments 
described in the proceeding chapters BALB/c and C57/BL6 were injected with DFTD 
cells. The DFTD xenograft development kinetics in NOD/SCID mice are described in 
chapter four (Figure 4-2). In consideration of the time to tumour development in 
relationship to number of DFDT cells injected at least 71 BALB/c or C57/BL6 were 
injected with DFTD cells of sufficient numbers and given sufficient time to establish 
DFTD xenografts and none developed tumours.  
Table 3-2. Summary table of DFTD cell injections into BALB/c and C57/BL6 mice 
Mouse Strain Injected cells 
Number of mice 
Tumour No Tumour 
BALB/c mice ≥106 DFTD cells 0 35 
C57/BL6 5 x105 DFTD cells 0 8 
C57/BL6 ≥10
6 DFTD cells 0 28 
Overall 0 71 
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3.5 Discussion  
Devil Facial Tumour Disease is a cancer that is transmitted from host to host with a 
lack of allo-recognition. An inability to trigger an immune response suggests that 
DFTD cells are non-immunogenic and could be imperceptible to any immune 
system. Using a mouse model this chapter analysed whether DFTD cells can induce 
an immune response and if so can they be targets for cytotoxic cells and be killed by 
apoptosis.  
3.5.1 Apoptosis 
The ability of DFTD cells to undergo apoptosis was investigated because if an 
immune response could be generated against DFTD, it would be ineffective if DFTD 
cells could not be killed. Some tumours can undermine immune responses by the 
inactivation of the apoptotic pathway. Apoptosis resistance is not only relevant to 
immunosurveillance but could impact on possible interventions including 
chemotherapy, radiotherapy and immunotherapy. These therapies primarily depend 
on inducing apoptosis (Igney and Krammer 2002). Resistance to apoptosis would 
present a major hurdle in developing effective treatments and would have 
implications for protocols to inactivate the DFTD cells for potential vaccine 
development. For these reasons, very early priorities in this project aimed to 
determine if DFTD cells could undergo apoptosis.     
Apoptosis had not been shown in DFTD cells. A well established protocol for 
assessing apoptosis in mammalian cells involves Annexin V, which labels the 
membrane of apoptotic cells and propidium iodide (PI), which labels the DNA of cells 
at late stages of apoptosis and necrosis. In both the early and late stages of 
apoptosis the intracellular leaflet in the cell membrane becomes exposed facilitating 
Annexin V binding to the phosphatidylserine located there. This does not occur if 
cells undergo necrosis. Cells that have undergone necrosis, or have entered late 
stage apoptosis, will be labelled with DNA stains such as PI or 7AAD because the 
cell membranes have become permeable to these molecules while viable cells and 
cells in early stage apoptosis exclude these molecules.  
Following four hours exposure to the cytotoxic drug, camptothecin, 82% of DFTD 
cells showed obvious signs of dying via apoptosis and only 2% by necrosis based on 
Annexin V and PI analysis. K562 cells and lymphocytes, which are known to be 
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resistance to camptothecin mediated apoptosis, were Annexin V- when incubated 
with camptothecin while DFTD cells were positive. As camptothecin only produced 
evidence for 2% necrotic cells DFTD cells were induced to undergo necrosis by rapid 
freeze thaw. None of the necrotic cells, induced by freeze thawing had Annexin V 
binding. This provides support that the assay is specific for detecting apoptosis 
rather than necrosis in DFTD cells and that DFTD cells have the ability to die via 
apoptosis.    
Further evidence of apoptosis in DFTD cells was provided by scatter analysis in flow 
cytometry. In late stage apoptosis the DFTD cellular contents were condensed 
causing a more granular characteristic to the cell resulting in increased side scatter 
(SSC) of the laser. The size of the cells also decreased resulting in a lower forward 
scatter (FSC). In comparison, necrotic DFTD cells released their cellular contents 
and the SSC was low, consistent with necrosis as described by Darzynkiewicz et al.  
(1997). Scatter analysis, which evaluates cell morphology should complement 
Annexin V binding which is less ambiguous and detects early and late stage 
apoptosis.  
UV-radiation (UV-R) was used as an alternative treatment to induce apoptosis to 
further corroborate apoptosis in DFTD cells. Since K562 cells are sensitive to UV 
induced apoptosis (Ujvarosi et al 2007) they were used as a positive control cell line. 
Following UV-R exposure, apoptosis was detected in DFTD cells. The TUNEL assay 
was another means to evaluate apoptosis by labelling DNA breaks, which occur 
during late stage apoptosis. Following UV-R exposure DFTD cells were TUNEL 
positive confirming apoptotic damage was occurring to the DNA of the DFTD cells. 
These results further validated the ability of DFTD cells to undergo apoptosis. 
From these combined observations it can be concluded that DFTD cells undergo 
apoptosis. This suggests that DFTD cells do not avoid immune responses by 
inactivating the apoptotic pathway. Further investigations are required to determine if 
the appropriate signalling receptors are present on the cell surface to initiate 
apoptosis by cellular ligands, including cytotoxic cells.  
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3.5.2 Antibody responses 
Having shown that DFTD cells have the capacity to undertake apoptosis led to the 
hypothesis that DFTD cells are not immunogenic and therefore invisible to any 
immune system. However, the ability to establish DFTD xenografts in 
immunocompromised NOD/SCID mice but not in immunocompetent BALB/c and 
C57BL/6 mice (Kreiss et al 2011b) suggests that the DFTD cells are immunogenic. 
To confirm that the failure to establish DFTD xenografts in immunocompetent mice 
was a specific immune response, BALB/c and C57BL/6 mice were challenged with 
viable DFTD cells and antibody responses were evaluated.  
Both BALB/c and C57BL/6 mice consistently rejected the DFTD cells as no tumours 
developed. Naïve mice lacked anti-DFTD antibodies while immunisation resulted in 
production of both IgM and IgG anti-DFTD antibodies. The significance of this is two-
fold. Firstly, since naïve mice lacked DFTD specific antibodies rejection was not as a 
result of hyperacute xenograft rejection, which depends on preformed antibodies. 
Secondly, since immunisation induced DFTD specific antibody production this 
provided evidence that viable DFTD cells are immunogenic.   
Having demonstrated that DFTD cells were immunogenic and therefore could be 
targeted by the immune system the next stage of this project evaluated means of 
enhancing immune responses following immunisation. Since access to Tasmanian 
devils is limited due to their endangered status and there are limited reagents such 
as monoclonal antibodies, this work continued in the DFTD mouse model.    
Detection by flow cytometry of antibodies specific to DFTD cell surface antigens in 
the serum of BALB/c and C57BL/6 mice provided the most robust method for 
evaluating immune responses following immunisation with DFTD cells. The 
subcutaneous injection route for immunisations had originally been selected because 
of its similarity to the transfer of DFTD cells in the Tasmanian devil population. 
Adjuvants such as CpG and Montanide were also added to the immunisations. 
Following a single injection of DFTD cells immunocompetent mice did not develop 
tumours. This did not always induce a detectable antibody response. Three 
consecutive immunisations always produced a detectable antibody response but 
further immunisations did not enhance antibody levels.  
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The use of adjuvants was discontinued and future immunisations were with viable 
DFTD cells, which is what Tasmanian devils are infected with and therefore more 
biologically relevant. Adjuvants might alter the cells from their natural state or cause 
cell death independent of immune responses.  
Single site versus multiple sites subcutaneous injections were compared and it was 
established that multiple site injections produced a higher relative antibody response. 
This was most likely due to the targeting of an increased number of draining lymph 
nodes and thereby establishing more germinal centres for the production of 
antibodies. Although implantations at a single site may occur frequently in wild 
Tasmanian devils, multiple site injections would be more effective in a vaccination 
program.  
When intraperitoneal injections were compared to multiple site subcutaneous 
injections, the result was even greater and more reliable antibody response with all 
of the mice responding. The enhanced immunological response via the 
intraperitoneal route in the mouse model may have implications for the induction of a 
protective immune response in Tasmanian devils. Vaccination of Tasmanian devils 
with intraperitoneal may prove more effective than subcutaneous injections.  
Intraperitoneal immunisations generated both IgM and IgG responses to the DFTD 
cells with the switch from IgM to IgG detected between four and seven days after 
immunisation. The isotype switching of B cell antibody production is T cell dependent 
and directed by T cell derived cytokines resulting in antibody isotypes characteristic 
of either a TH1 or TH2 profile (Isakson et al 1982, Kanai et al 2007, Tangye et al 
2002). Immunisation with DFTD cells induced all tested IgG isotypes and did not 
polarise the immune response to a TH1 or TH2 antibody response.  
To further optimise the immunisation of mice a protocol known to produce rapid and 
reliable responses against viruses in mice within 21 days was trialled (Elsawa et al 
2003). This protocol involved a primary immunisation with a second immunisation 
two weeks later when IgG antibodies would be established and cytotoxic T cells 
would be activated. When mice were intraperitoneally immunised with DFTD cells 
using this two week prime-boost protocol antibody responses were consistently 
observed by the third week. This was not significantly enhanced by further 
immunisations. Evaluation of secondary versus primary responses in the mouse 
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DFTD model confirmed a T cell dependent immunological memory response with 
rapid production of high levels of IgG on subsequent exposure to DFTD cells. This 
memory response was long lasting and still present 95 days after the first 
immunisation.  
3.5.3 Cytokine responses 
The cytokine profile developed by the two week prime-boost protocol saw an 
upregulation of the TH2 cytokine IL-10, which dominated the immune response at 
day 21. In comparison, a single immunisation induced an immune response at day 
21 dominated by IFN-γ, which is a TH1 cytokine. However, since the two week prime-
boost protocol produced all tested IgG isotypes which included both TH1 and TH2 
associated isotypes this protocol did not polarise the immune response.  
To further understand cytokine responses, primary and secondary responses to 
DFTD cells were analysed. This was achieved by co-culturing splenocyte effector 
cells obtained from mice and DFTD cells at a 100:1 ratio for 72 hours and measuring 
the cytokines produced. When MNC effector cells were obtained from mice 
immunised once these profiles were regarded as primary responses and from mice 
immunised twice as secondary responses.  
A number of cytokines were not detected in the assays including IL-2, IL-4 and IL-
17a. These may have been produced and consumed within the assay. IL-2 is a 
cytokine used by cells for proliferation and it is likely that this was consumed within 
the assay.  IL-6, TNF-α and IFN-γ were produced at similar levels for both the 
primary and secondary responses. The expression of these cytokines indicates an 
inflammatory response typical of anti-tumour activity.  
IL-6 is a pro-inflammatory cytokine which enhances T cell, B cell and NK cell activity 
and promotes lymphocyte proliferation (Dranoff 2004, Fassati and Mitchison 2010). 
TNF-α induces apoptosis in tumour cells, promotes maturation of DCs increasing 
their antigen presenting abilities to elicit CTL anti-tumour responses (Dranoff 2004, 
Yong et al 2012). IFN-γ is produced by T cells, NK cells, NKT cells, macrophages 
and DCs. It can increase immunogenicity of tumour cells by upregulating MHC 
expression. IFN-γ is the principal cytokine to define a TH1 response leading to 
cellular immune responses by CD8+ T cells, macrophages and NK cells. It induces 
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the production of TH1 antibodies IgG2a and IgG3 (Dranoff 2004, Finkelman et al 
1988, Snapper et al 1992).  
IL-10 was the only cytokine observed to significantly alter as a secondary response. 
IL-10 is the principle cytokine to define a TH2 response and its upregulation is a 
mechanism employed by some tumours to permit tumour surveillance escape by 
suppressing TH1 anti-tumour responses (Salazar-Onfray 1999, Schulte et al 2008, 
Singh et al). However, the pro-tumour immunoregulatory suppression role of IL-10 is 
most evident in the priming phase of the immune response. This results in 
suppressed activation of macrophages, DCs and T cells. IL-10 responses to DFTD 
cells peaked as a secondary response rather than during the priming phase of the 
immune response. However, the significance may be that previously activated CTLs 
increase their IL-10 receptors and become reactivated rather than suppressed by IL-
10 in secondary responses and this can function against the tumour (Emmerich et al 
2012).  
IL-10 also promotes the activation and proliferation of antigen-specific B cells (Singh 
et al 2011). The timing of IL-10 upregulation in the primary response was consistent 
with the production of IgG antibodies against DFTD cells in the mice. It can therefore 
be concluded that the primary response is a balance between TH1 and TH2 cytokines 
with dominance by IFN-γ. However, secondary responses showed a strong 
upregulation of IL-10 that dominated the IFN-γ responses which had remained at 
similar levels to the primary response. This observation held true for secondary 
immunisations up to 57 days after the primary but was not observed in secondary 
immunisations 95 days after the primary. Secondary responses 95 days after the 
primary had returned to cytokine levels equivalent the primary responses. The 
relevance of this is the immune system is being primed by primary exposure to 
DFTD cells and the initial TH1 response is being directed towards a TH2 response 
which remains enhanced for at least 57 days but has subsided by 95 days.   
The exact roles of IFN-γ and IL-10 in DFTD cell rejection by immunocompetent mice 
are not fully understood. Nevertheless, the significance of these observations in the 
mouse is to suggest that the study of IFN-γ and IL-10 responses in the Tasmanian 
devil should become a priority. This would require the production of anti-devil IFN-γ 
and anti-devil IL-10 antibodies which are currently not available.  
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3.5.4 Cytotoxic responses 
Cytotoxicity responses were evaluated using in vitro cytotoxicity assays to see if 
cytotoxic responses against DFTD cells could be detected and if primed splenocytes 
were more effective than naïve splenocytes. This required the optimisation and 
validation of a non-radioactive assay suitable for DFTD cells since DFTD cells label 
poorly with 51Cr. This meant the 51Cr assay, which is regarded as the gold standard 
cytotoxicity assay (Kane et al 1996), was not optimal for studying DFTD cells. As 
well 51Cr is expensive, has a short half life and has inherent safety concerns 
associated with the use and disposal of radioactive isotopes.  
The use of a fluorometric assay based on propidium iodide to determine NK cell 
function has been validated for clinical use and has been found to be a viable 
alternative to 51Cr assay. Fluorometric assays have the advantages that they can be 
standardised between laboratories and since not all research facilities are licensed to 
for radioactive isotope use of fluorometric assays have more universal application 
(Kane et al 1996). Labelling target cells with CFSE or CellTrace Violet™ allowed 
discrimination from unlabelled effector cells. Then following the required incubation 
period a dead cell marker such as propidium iodide (PI) or 7AAD discriminated 
viable and dead cells and flow cytometry facilitated evaluation of cytotoxicity.   
In our laboratory, further validation for this fluorometric cytotoxicity assay was 
undertaken using the human leukaemia cell line K562, a target for human NK cells 
and YAC-1 cells, a target for murine NK cells. There was a dose-response curve for 
both these cell lines. Then using YAC-1 cells a direct comparison of 51Cr assay and 
the fluorometric assay revealed that the fluorometric assay was not inferior to the 
51Cr assay and would be a sensitive and robust cytotoxicity assay that could be 
adapted to DFTD cells.  
Cytotoxic responses against DFTD cells by mouse splenocytes did not provide 
evidence for CTL activation as splenocytes from DFTD immunised mice produced 
the same level of cytotoxicity as splenocytes from naïve mice. This is not unexpected 
as CTL responses are MHC dependent and Tasmanian devil MHC would be too 
foreign to bind mouse CD8. It is more likely that the observed cytotoxicity may have 
been mediated by a combination of APCs, NK cells, NKT cells or unprimed T cells 
responding to xenogeneic determinants (Fox et al 2001). In light of these results it is 
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unlikely that an immunisation protocol in mice would enhance the cytotoxic 
responses against DFTD.  
3.5.5 Comparison of BALB/c and C57/BL6 mouse strains 
Two strains of immunocompetent mice were selected for the DFTD mouse model 
based on their reportedly opposing TH1 (C57/BL6) and TH2 (BALB/c) dominated 
immune responses (Mills et al 2000, Reiner and Locksley 1995) . The comparison of 
both immunised and naïve BALB/c and C57/BL6 mouse cytokine responses 
revealed no significant difference between the strains.  
Further evaluation of the TH1 TH2 responses in BALB/c and C57/BL6 mice involved 
the analysis of IgG isotypes, which discriminate between TH1 and TH2 responses 
(Schulte et al 2008). Both strains of mice expressed high levels of IgG1, which is 
regarded as a TH2 response. They also expressed IgG2a, IgG2b and IgG3 which are 
regarded as TH1 cytokines.  There was some skewing towards IgG2a in the BALB/c 
mice and towards IgG2b in the C57BL/6 mice, but this is a strain specific observation 
and not necessarily due to exposure to DFTD cells. The relevance of these findings 
is that the DFTD cells do not polarise either mouse strain towards a TH1 or TH2 
immune response.  
The antibody and cytokine responses for both genders were compared in BALB/c 
mice and there was no gender bias in the responses. The conclusions that can be 
drawn from these observations is that both strains and genders are equally suitable 
for experiments studying immune responses to DFTD cells.    
3.5.6 Inactivating DFTD cells for vaccine trials 
Vaccine trials and immunotherapy experiments with Tasmanian devils require the 
injection of inactivated DFTD cells to induce immune responses without the risk of 
infection. The BALB/c DFTD mouse model facilitated direct comparison of the 
immunogenicity of DFTD cells inactivated by gamma radiation, sonication or freeze-
thawing and compared these with viable DFTD cells.   
Freeze-thawing and sonication significantly reduced the immunogenicity of DFTD 
cells. This was evident in reduced levels of IgG and IgM antibodies and suppression 
of the anti-tumour cytokines IFN-γ and TNF-α. Inactivation of DFTD cells by 
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irradiation did not reduce antibody or cytokines responses and therefore would the 
better method of inactivating DFTD cells for vaccine and immunotherapy trials.  
3.5.7 Conclusions 
The main findings of this chapter are that DFTD cells are immunogenic, undergo 
apoptosis, can be targeted and killed by immune systems. Both BALB/c and 
C57/BL6 mice of either gender can be used similarly for studying immune responses 
against DFTD. Cytotoxic responses against DFTD cells by mice did not reveal 
evidence for CTL activation and were most likely mediated by unprimed cells. The 
most robust method of detecting immune responses in mice was by serum antibody 
levels specific for DFTD. The use of intraperitoneal prime-boost immunisations in the 
mice produced the most reliable immune responses and may prove more effective 
than subcutaneous immunisations in the Tasmanian devil.  
Cytokine and antibody responses against DFTD demonstrated a balance of TH1 and 
TH2 responses showing the mouse immune system is not being polarised following 
immunisation with DFTD cells. The development of anti-devil IFN-γ and IL-10 
antibodies to study the role of TH1 and TH2 immune response in Tasmanian devils 
should be a priority. The inactivation of DFTD cells for vaccine and immunotherapy 
trials would be best done using gamma radiation as it has no significant impact on 
the immunogenicity of the cells.      
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4 Immunocompromised mouse models to evaluate 
DFTD establishment, adoptive protection and 
xenograft rejection 
4.1 Introduction 
Devil Facial Tumour Disease is an infectious cancer. It could be described as an 
infectious parasitic clonal cell line that survives as an allograft transmitted between 
Tasmanian devils. There is only one other infectious cancer cell line known to exist 
in nature and that is CTVT. There have been very few laboratory models used to 
study these transmissible cancers. A NOD/SCID murine xenograft model has 
previously been used to study CTVT (Harmelin et al 2001). Models of this kind are 
essential to further understand the pathology or epidemiology of such diseases.  
The NOD/SCID model is useful for studies concerning anti-tumour immunity and 
tumour progression in CTVT. The model provides a means to test treatments, 
chemotherapy and immunotherapy in a biologically relevant setting. Advantages 
include cost, reproducibility, analogy to natural disease and decreased need for dogs 
to study CTVT (Harmelin et al 2001, Rivera et al 2005).  
NOD/SCID mice were developed by crossing the SCID mutation into the NOD 
background. Due to genetic mutations SCID mice lack functional B and T cells and 
do not produce functional immunoglobulin and T cell receptors. NOD mice have 
immune defects including low NK cell activity, defective macrophages and a 
deficiency in the C5 component of complement system (Shultz et al 1995, Vormoor 
et al 2001). These combined defects in the NOD/SCID mouse prevented any 
immunity to CTVT and facilitated an in vivo model that reproduced the main features 
of tumour establishment, progression and metastasis (Harmelin et al 2001). 
In this chapter the NOD/SCID mouse model was applied to the study of DFTD 
because of DFTD similarities to CTVT. There were three main objectives in this 
chapter. The first was to study DFTD establishment in NOD/SCID mice as an 
alternative to using Tasmanian devils. The second was to evaluate adoptive 
protection of NOD/SCID mice by transfer from immunocompetent mice. The third 
was to identify cells and mechanisms of rejection by immunocompetent mice through 
adoptive transfer to genetically modified mice.  
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DFTD is highly infectious but the number of cells needed to be transmitted between 
Tasmanian devils to establish tumours in the new host is unknown. The period of 
disease latency between an individual becoming infected to them being infectious is 
also uncertain. This information is important to biologists trying to model and manage 
the spread of the disease in Tasmanian devils (Hamede et al 2012a). However, it is 
not practical to comprehensively investigate this in the Tasmanian devil due to their 
endangered status. Such questions can be investigated using the NOD/SCID mouse 
model.  
The inability of Tasmanian devils to mount an immune response against DFTD is not 
fully understood. The previous chapter of this thesis used immunocompetent mice to 
demonstrate that DFTD cells are immunogenic and can be killed by the immune 
system. Further understanding the mechanisms by which the mice rejected the 
DFTD cells may lead to a revelation of mechanisms which can be exploited in the 
Tasmanian devil.   
To study biological mechanisms associated with tumour rejection, the NOD/SCID 
mouse has been widely used because of its ability to accept adoptive transfer of 
immune cells from mice and other species including humans (Belizário 2009, 
Feuerer et al 2001, Xue et al 2005) .This chapter explored the possibility of co-
transplanting lymphocytes from immunocompetent mice and DFTD cells into 
NOD/SCID mice to study the effect of competent immune cells in rejecting DFTD 
cells. The adoptive transfer experiments were augmented by evaluation of the ability 
of genetically modified mice with specific defects to reject or engraft DFTD tumours.  
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4.2 Results 
4.2.1 DFTD xenograft model to study disease establishment 
In the previous chapter, immunocompetent BALB/c and C57/BL6 mice were shown 
to consistently reject DFTD cells (Table 3-2). This rejection was a specific immune 
response that produced anti-DFTD antibodies and cytokines such as IFN-γ, TNF-α, 
IL-6 and Il-10.  In vitro analyses revealed killing by unprimed cells. In comparison, 
the work presented in this chapter demonstrates NOD/SCID mice did not reject the 
tumour. This is most likely because of their compromised immune system, which is 
absent of T cells, B cells, macrophages, DCs and functional NK cells (Belizário 2009, 
Lapidot et al 1997). NOD/SCID mice therefore provide an in vivo platform to study 
DFTD in a xenograft setting. This mouse model will provide an alternative to in vitro 
assays to advance our understanding of the kinetics of infection including disease 
latency. The model would also facilitate determination of the minimum number of 
cells required to infect a new host, if there is a direct dose response and provide 
indication to the shortest and longest time to clinical manifestation following 
implantation.  Such information is not possible with in vitro assays. The DFTD cells 
can be implanted subcutaneously and typically develops as a nodule that can be 
palpated and measured non-invasively in a living mouse (Figure 4-1). The DFTD 
tumour can be removed at necropsy for measurement of size, mass or fluid 
displacement.  
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Figure 4-1. Subcutaneous DFTD xenograft in NOD/SCID mouse being measured with Vernier 
calipers (panel A). Typical subcutaneous DFTD xenograft growing as a nodule (panel B).  
4.2.2 Kinetics of DFTD xenograft establishment 
The period to detection and the minimum number of cells required to consistently 
establish DFTD xenografts in NOD/SCID mice was unknown. As a consequence, 
NOD/SCID mice were injected with DFTD cells ranging from 2.5 x 103 to 1 x106 cells 
and for up to 20 weeks the mice were monitored by palpation for the first sign of 
tumour development.  
Palpation of tumours as small as 2mm diameter was the first evidence of DFTD 
xenograft establishment. In the absence of any pre-clinical marker this was the best 
available method to measure earliest sign to detection. There was a direct 
correlation between the number of DFTD cells injected and the period latency. The 
number of days to detection increased as the number of cells injected decreased. 
Implantation of 106 cells resulted in the establishment of DFTD xenografts within 32 
days and when 104 cells were implanted this was up to 99 days (Figure 4-2). 
To determine the minimum number of cells required to ensure xenograft 
establishment all mice that failed to develop DFTD tumours were carefully examined 
in autopsy to confirm that the tumour had not established in cryptic locations.  
Xenograft failure was observed in four of 28 mice injected with 104 DFTD cells or 
less. Xenografts were established in all mice implanted with 5 x 104 DFTD cells (n=5) 
and 2.5 x 104 DFTD cells (n=17). Xenografts also established in 30 of 31 mice 
implanted with 1 x105 DFTD cells and all mice implanted with 106 DFTD cells (n=18) 
(Figure 4-2).  
The more cells injected the more consistent the time to tumour development. 
Decreasing the number of cells injected increased the chance of xenograft failure. 
Time to detection ranged, in a dose dependent response, from 17 days with 106 cells 
to 130 days with 105 cells. From this it was determined that 106 cells should be 
injected to ensure tumour engraftment and fast tumour establishment.    
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Figure 4-2. Varying quantities from 2.5 x 10
3 
to 1 x 10
6
 C5065 DFTD cells were SC injected into 
NOD/SCID mice. The mice were monitored by visualisation and palpation for tumour 
development. The day of first detection was recorded. Horizontal lines represent mean and red 
crosses failure to establish xenograft.  
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4.2.3 C57/BL6 splenocyte adoptive transfer to NOD/SCID mice  
To extend our understanding of DFTD rejection by immunocompetent mice, 
splenocytes from DFTD immunised C57/BL6 mice were adoptively transferred to 
NOD/SCID mice to determine if the immune system could be partially reconstituted 
and an immune response against DFTD established. The splenocytes obtained from 
whole spleens were combined with 106 DFTD cells and injected subcutaneously into 
eleven NOD/SCID mice. Within 11 days the recipient mice showed symptoms 
consistent with graft versus host (GVH) rejection. As a consequence all mice were 
euthanised within 11 to 18 days of rejection; serum was collected and tested for 
DFTD specific antibodies.  
Eight of the 10 NOD/SCID mice had varying levels of DFTD specific IgG antibodies 
detectable in their serum (Figure 4-3). The only IgG isotype detected was IgG1; 
IgG2a, IgG2b and IgG3 were not detected (Figure 4-4).  
 
 
Figure 4-3. NOD/SCID mice were injected with splenocytes from immunised C57/BL6 mice and 
10
6
 C5065 DFTD cells. Serum was collected between  day 11 and day 18 after reconstitution 
and compared to serum from a naïve C57/BL6 mouse (indicated in grey shading). Eight of 10 
mice produced DFTD specific IgG antibodies.  
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Figure 4-4. Alexa Fluor conjugated anti-mouse antibodies were used to screen serum collected 
from NOD/SCID mice, which had been reconstituted with splenocytes from an DFTD 
immunised C57/BL6 mouse. Plots shown are representative of responses showing a serum 
that tested positive for IgG1 isotypes but negative for IgG2a, IgG2b and IgG3 isotypes.  
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4.2.4 BALB/c splenocyte adoptive transfer to NOD/SCID mice  
C57/BL6 donor mice had proven unsuitable for adoptive transference of splenocytes 
to NOD/SCID mice because of GVH rejection. BALB/c mice splenocytes were 
subsequently used and did not promote GVH rejection in NOD/SCID mice. Both 
naïve and immunised BALB/c splenocytes were compared. Furthermore, 
splenocytes from immunised mice were used with and without the addition of 
autologous serum and CpG 2395.   
Splenocytes from 14 naïve BALB/c mice were used for adoptive transfer to 
NOD/SCID mice. Firstly this involved adoptive transfer to four NOD/SCID mice and 3 
of 4 developed tumours. Tumours were not detected before 88 days which suggests 
delayed tumour growth compared to the DFTD xenograft development kinetics 
discussed in Figure 4-2. In a second experiment transferring naïve splenocytes from 
BALB/c mice to NOD/SCID mice 10 of 10 mice did not develop tumours.  
Splenocytes from immunised BALB/c mice prevented tumour establishment in 15 of 
15 mice. This included cells alone or cells plus either immune serum or CpG. All 
control mice that received only DFTD cells established tumours (n=10) (Table 4-1).  
Table 4-1. Adoptive transfer of splenocytes from BALB/c to NOD/SCID mice. NOD/SCID mice 
received splenocytes from naïve or immunised BALB/c mice as indicated co-injected with 
10
6
DFTD cells. As indicated some received 50 µl serum from the same immunised BALB/c 
mice and some mice also received the adjuvant CpG 2395. Mice were monitored up to 20 
weeks or until tumours were observed.  
NOD/SCID mice injected with 106 
DFTD cells plus  
Challenged 
mice Tumour development 
Splenocytes from naïve BALB/c mice n=14 
Tumours n=3/14 
No tumours n=11/14 
Splenocytes from immunised BALB/c 
mice 
n=5 No tumours n=5 
Splenocytes and serum from immunised 
BALB/c mice 
n=5 No tumours n=5 
Splenocytes and serum from immunised 
BALB/c mice plus CpG 2395 
n=5 No tumours n=5 
DFTD cells only with no serum, 
splenocytes or CpG  
n=10 Tumours n=10 
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To demonstrate that rejection of DFTD cells in NOD/SCID mice following adoptive 
transfer of donor splenocytes from BALB/c mice was a specific immune response 
two NOD/SCID mice were subcutaneously co-injected with splenocytes from 
immunised BALB/c mice and 106 DFTD cells. After 33 days the mice were sacrificed 
to collect the spleens and serum. The mice had no detectable tumours. The 
splenocytes were used for an in vitro cytotoxicity assay against DFTD cells. The 
serum was analysed for IgM, IgG1, IgG2a, IgG2b and IgG3 DFTD specific 
antibodies.  
The cytotoxicity assay demonstrated a dose response curve following 18 hours in 
vitro incubation and anti-DFTD IgG1 antibody was detected in both mice (Figure 4-5) 
but IgM, IgG2a, IgG2b and IgG3 isotypes were not detected (data not shown). These 
results demonstrate a DFTD specific immune response following adoptive transfer of 
BALB/c splenocytes. 
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Figure 4-5. Two NOD/SCID mice received splenocytes from DFTD immunised BALB/c mice co-
injected subcutaneously with 10
6
 C5065 DFTD cells. The mice were sacrificed after 33 days 
and had no detectable tumours. The splenocytes were recovered and incubated for 18 hrs in 
vitro with CFSE labelled C5065 DFTD cells. (Each data point represents the mean of four 
replicate wells and error bars the SEM). Serum was collected and screened for IgG1 antibodies 
specific to DFTD. The same serum had no detectable IgM, IgG2a, IgG2b or IgG3 (data not 
shown).  
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Adoptive transference of protection to NOD/SCID mice could be achieved when 
splenocytes were co-transplanted with DFTD cells. However, it was unknown if naïve 
splenocytes could be induced in vivo to produce anti-DFTD immune responses 
following transfer to NOD/SCID mice if they were not co-injected with the DFTD 
cells. Consequently, NOD/SCID mice were injected with 2 x 106 DFTD cells either 
seven days prior to or seven days after adoptive transfer of naïve BALB/c 
splenocytes. There was no evidence of an immune response to DFTD cells injected 
at a different time point. Tumours developed in all eight mice and no antibodies were 
detected in their serum (Figure 4-6).  
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A  Tumour cells 7 days before adoptive transfer 
 
 
 
  
 
 
 
 
 
B Adoptive transfer 7 days before tumour cells 
 
 
 
 
 
 
 
 
 
 
Figure 4-6. Adoptive transfer of splenocytes from naive BALB/c mice to NOD/SCID mice (A) 
schema of five NOD/SCID mice which were injected subcutaneously with 10
6
 DFTD cells 
followed seven days later with adoptive transfer of splenocytes from naïve BALB/c mice . (B) 
schema of three NOD/SCID mice which had adoptive transfer of splenocytes from naïve 
BALB/c mice followed seven days later by subcutaneous injection of 2 x 10
6
 DFTD cells. All 
mice grew tumours and no anti-DFTD specific antibodies were detected in their serum which 
was collected at necropsy.  
Day 0 
2 x106 DFTD cells 
Day 7 
Naïve splenocytes 
Day 43 
Serum collected  
no antibody detected 
Tumours detected 
in all mice  
x 5 
Day 0 
Naïve splenocytes 
Day 7 
2 x 106 DFTD cells 
Day 56 
Serum collected  
no antibody detected 
Tumours detected 
in all mice 
x 3 
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4.2.5 Adoptive enrichment and depletion splenocyte transfer trials 
Splenocytes transferred from DFTD immunised BALB/c mice to NOD/SCID mice 
consistently protect against DFTD tumour engraftment. To investigate if a specific 
population of cells such as NK, NKT, CD4+ or CD8+  cells was responsible for 
protection these populations were either enriched or depleted using either magnetic 
bead separation or flow cytometric cell sorting. The enriched or depleted populations 
were then co-injected subcutaneously into NOD/SCID mice with 5 x 104 DFTD cells. 
Control mice were injected with DFTD cells of the same number from the same 
culture. 
EasySep™ magnetic bead sorting kits were used to establish enriched and depleted 
populations of CD4, CD8 or NK cells as stated in methods. Purity was at least 85% 
and checked using flow cytometry detecting CD4, CD8 or CD49b (NK cells) for the 
respective cell types being enriched or depleted. Both the enriched and depleted 
populations from magnetic bead sorting prevented establishment of DFTD tumours 
in treated mice while all the controls established tumours (Table 4-2).  
Flow cytometry sorting was used to establish enriched and depleted populations of 
CD4, CD8, CD49b or NKT cells. CD4 and CD8 cells were positively selected based 
on their respective CD marker combined with CD3e T cell marker. NK cells were 
positively selected for using CD49b and NKT cell subset was selected for using 
CD49b and CD3e.  
Flow cytometry provided at least 95 % purity. Populations depleted of just CD49b  
(n=8), CD4+ T cells (n=4) or CD8+ T cells (n=4) all rejected the DFTD cells. Enriched 
populations of CD8+ T cells (n=6) and NKT cells (n=3) all rejected the DFTD cells. 
However, 3 of 16 CD49b enriched and 1 of 5 CD4+ T cell enriched populations was 
not protective against the DFTD cells and tumours established.  This result suggests 
that CD49b and CD4+ T cells are less effective than CD8+ T cells at protecting the 
recipient mice from DFTD cells.  
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Table 4-2. Adoptive transference of enriched and depleted splenocyte populations. 
Immunised splenocytes from BALB/c mice had specific populations enriched or 
depleted by magnetic bead separation or using an Astrios cell sorter. These cells were 
then co-injected with 5 x 10
4 
DFTD cells. Control mice were also injected with the same 
number of DFTD cells only.   
  
 Donor splenocytes Observation 
 Magnetic bead enrichment/depletion 
N
K
 
NK enriched (>85% purity) Rejected DFTD cells (n= 5/5) 
NK depleted (>85% purity) Rejected DFTD cells ( n=5/5) 
Controls  Tumours (n= 3/3) 
 Magnetic bead enrichment/depletion 
C
D
4
 
CD4 enriched (>85% purity) Rejected DFTD cells (n= 5/5) 
CD4 depleted (>85% purity) Rejected DFTD cells ( n=5/5) 
Controls  Tumours (n= 4/4) 
 Magnetic bead enrichment/depletion 
C
D
8
 
CD8 enriched (>85% purity) Rejected DFTD cells (n= 5/5) 
CD8 depleted (>85% purity) Rejected DFTD cells ( n=5/5) 
Controls Tumours (n= 5/5) 
 Flow cytometry cell sorter enrichment/depletion 
C
D
4
9
b
 
 
CD49b enriched (>95% purity) 
Rejected DFTD cells (n= 13/16) 
Tumour (n=3/16) 
CD49b  depleted (>95% purity) Rejected DFTD cells ( n=8/8) 
Controls  Tumours (n= 16/16) 
 Flow cytometry cell sorter enrichment/depletion 
C
D
4
 
CD4 enriched (>95% purity) 
Rejected DFTD cells (n= 4/5) 
Tumour (n=1/5) 
CD4 depleted (>95% purity) Rejected DFTD cells ( n=4/4) 
Controls  Tumours (n= 5/5) 
 Flow cytometry cell sorter enrichment/depletion 
C
D
8
 
CD8 enriched (>95% purity) Rejected DFTD cells (n= 6/6) 
CD8 depleted (>95% purity) Rejected DFTD cells ( n=4/4) 
Controls  Tumours (n= 5/5) 
 Flow cytometry cell sorter enrichment 
N
K
T
 NKT cell enriched (>95% purity) Rejected DFTD cells ( n=3/3) 
Controls  Tumours (n= 3/3) 
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4.2.6 Evaluating DFTD engraftment in congenic and knockout mouse strains 
To further investigate which murine immune cells protect against the DFTD cells 
congenic and knockout mice were challenged with DFTD cells and monitored for 
tumour growth or rejection. Ighm/J, a B cell knockout strain, rejected 106 DFTD cells 
(Table 4-3). A TNF knockout strain, B6.TNF, rejected 106 DFTD cells (Table 4-3). 
DFTD tumours established in the B and T cell knockout strain, Rag/2 (n= 8/10) and 
the congenic T cell deficient strain, CBA/nu mice (n=9/9) following a challenge with 
106 DFTD cells (Table 4-3). Significantly, the tumours in the Rag/2 mice grew to one-
tenth the size of the tumours of the athymic CBA/nu mice within the same time 
period (Figure 4-7). Both strains of mice had been injected with the same number of 
cells from the same cell culture on the same day.   
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Table 4-3. DFTD challenge of knockout mice strains. Genetically modified mice were injected 
subcutaneously with 10
6
 DFTD cells and monitored for up to 20 weeks or until tumours 
developed.  
 
Strain Deficiency Observation 
Ighm/J  B cell knockout  
Rejected 106 DFTD cells 
(n=5/5) 
B6.TNF TNF knockout 
Rejected 106 DFTD cells 
(n=10/10) 
Rag/2  B cell and T cell knockout  
Small tumours in 8/10 mice 
at day 52 
CBA/nu T cell deficient 
Tumours in 10/10 mice at 
day 53 
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Figure 4-7. 10 Rag/2 and 9 CBA/nu mice were injected with 10
6
 identical C5065 cells at the 
same time. They were sacrificed on day 52 and 53 respectively. The xenograft established in 
9/9 Nude mice but only 8/10 Rag mice. Furthermore the Nude mice grew tumours more than 
tenfold larger. (Horizontal bars represent mean and probability calculated by unpaired two-
tailed t test *** P < 0.001) 
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4.2.7 Rag/2 versus CBA/nu mice immuno-phenotyping 
The significant (P < 0.001) size difference between DFTD xenografts grown in Rag/2 
and CBA/nu mice over the same time period suggested that the Rag/2 mice have an 
immune response that inhibits tumour growth more than CBA/nu mice. 
Understanding the difference between the two strains would provide insight into the 
protective mechanisms used by immunocompetent mice to reject DFTD cells. 
Consequently, the immunophenotypes of the splenocytes obtained from these two 
strains were evaluated using flow cytometry. FITC anti-mouse CD3e antibodies 
confirmed that mature T cells were absent in both strains (Figure 4-8). APC anti-
mouse CD49b antibodies confirmed both strains had NK cells but the percentage of 
NK cells was more than twice as high in the Rag/2 mice compared to the CBA/nu 
mice (Figure 4-8). PE/Cy7 anti-mouse CD19 antibodies confirmed that only the 
CBA/nu mice had mature B cells (Figure 4-9). PE anti-mouse MHC II antibodies 
confirmed both strains had APCs. However, the Rag/2 mice had more than twice the 
percentage of APCs compared to the CBA/nu mice (Figure 4-9).  
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Anti-mouse CD3e (FITC) Mature T Cell marker 
 
Anti-mouse CD49b (APC) NK cell marker 
 
Figure 4-8. Splenocytes from CBA/nu and Rag/2 mice were labelled with FITC anti-mouse CD3e 
and APC anti-mouse CD49b and analysed by flow cytometry.  
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Anti-mouse CD19 (PE/Cy7) mature B cell marker 
 
Anti-mouse MHC II (PE) antigen presenting cell marker 
 
 
Figure 4-9. Splenocytes from CBA/nu and Rag/2 mice were labelled with PE/Cy7 anti-mouse 
CD19 and PE anti-mouse MHC II antibodies and analysed by flow cytometry.  
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4.3 Discussion 
The previous chapter used BALB/c and C57/BL6 immunocompetent mice to 
demonstrate that DFTD cells are immunogenic and can be rejected by murine 
immune systems. In this chapter, NOD/SCID immunocompromised mice were used 
to evaluate various aspects of DFTD establishment to avoid the risk of harming 
endangered Tasmanian devils. An evaluation of adoptive transfer of protection from 
immunocompetent mice to the NOD/SCID mice was undertaken to reveal the 
components of the immune system affording protection to mice. Fluorescence-
activated cell sorting (FACS) combined with genetically modified mice was used to 
further investigate which components of the immune system contribute towards the 
protection against DFTD in mice.   
4.3.1 DFTD establishment 
In vitro assays are indispensible tools for the study of cancer but some investigations 
require an in vivo setting. There is a wealth of evidence that many critical clinical 
developments such as drugs, treatments and cures for human diseases and cancer 
have been developed with the use of animal models (Sausville and Burger 2006, 
Suggitt and Bibby 2005). There are many aspects of disease that cannot be 
recapitulated in an in vitro setting and in this instance the establishment and 
progression of DFTD in the Tasmanian devil is one aspect. The environment of cells 
grown as a monolayer on a plastic substrate lacks the complexity of a dynamic 
three-dimensional in vivo environment, which includes epigenetic changes to gene 
expression that can alter tumour growth and influence results (Luca et al 2013). The 
limited access to Tasmanian devils and difficulties associated with housing them in a 
biosecure environment hindered in vivo studies in the host species. As a 
consequence mouse models were used as substitutes for Tasmanian devils to 
minimise the use of Tasmanian devils and complement in vitro studies.  
NOD/SCID mice can be used as surrogates for Tasmanian devils as both have no 
known immune response to DFTD cells (Kreiss et al 2011, Siddle and Kaufman 
2013). The Tasmanian devil immune system fails to recognise the DFTD cells while 
NOD/SCID mice lack an effective immune system to generate an immune response 
and also fail to recognise DFTD cells. NOD/SCID mice engraft DFTD tumours and 
provide a physiological microenvironment that preserves the three-dimensional 
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tumour structure with cell to cell interactions and angiogenesis that is biologically 
relevant for the study of DFTD establishment and growth.  
Following subcutaneous injection of DFTD cells into NOD/SCID mice the first 
evidence of tumour development was the identification of a small nodule about the 
size of a pinhead (1-2 mm diameter) near the injection site. In some mice two or 
more nodules established near the site of injection. Metastatic disease was not 
observed in any of the mice injected, which suggests that the DFTD cells do not 
migrate from the injection site and proliferating cells clump together to create the 
nodules.   
It was unknown how many DFTD cells are required to establish a tumour in 
NOD/SCID mice and if DFTD tumour development is cell dose-dependent. To 
evaluate this, DFTD cells ranging from 2.5 x 103 to 1 x 106 were subcutaneously 
injected into NOD/SCID mice.  Tumours always established when 106 DFTD cells 
were injected but below these levels there was an increasing rate of mice without 
tumour establishment. This ranged from 3% when 105 cells were injected to 30% 
when 5 x 103 or fewer cells were injected. When 106 DFTD cells were injected 
tumours of approximately 2mm diameter were observed within 32 days in all mice. 
Reducing the number of cells implanted extended the period to detection and 
increased the probability of not establishing a DFTD tumour in the mouse.  
One possible explanation for lack of tumour establishment at low cell numbers could 
relate to the cancer stem cell hypothesis. This hypothesis suggests that not all 
cancer cells are capable of self renewal and only a limited number of cancer stem 
cells drive tumour growth and development (Clevers 2011). The results in the mouse 
model suggest only a small percentage of the cells transferred were responsible for 
tumour establishment. While this result is consistent with the hypothesis of cancer 
stem cells, this has not been investigated in the cultured DFTD cell lines used in 
these trials.    
An alternative explanation to account for the small percentage of cells that establish 
as tumours may be that all DFTD cells are capable of proliferation but there is a 
reduced rate of engraftment as a consequence of the xenogeneic environment. 
Tumour cell growth requires synergy with supporting cells such as fibroblasts, 
endothelial cells, mesenchymal cells and tumour infiltrating macrophages (Rahman 
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et al 2011). CTVT cells are known to express TGFβ1 which suppresses the immune 
system, induces proliferation of the surrounding stromal cells and promotes 
angiogenesis (Morris and Belov 2013). If a similar scenario occurs with DFTD it is 
unlikely that the cytokines and receptors that promote these interactions are 
compatible between mouse and Tasmanian devil. Increased DFTD cell densities 
may overcome these barriers by promoting cell to cell signalling between the DFTD 
cells.  
It is unknown if the observations concerning the cell numbers associated with DFTD 
establishment and period of latency until detection in mice reflects the situation with 
the Tasmanian devils. In the wild the disease appears to be spread by biting 
between devils with cells being transmitted into cuts and open wounds in the oral 
cavity (Hamede et al 2013). There have been no published data on the number of 
DFTD cells transferred between individuals as a result of biting. It would be 
reasonable to presume that just hundreds or at most a few thousand cells are 
transferred. It therefore appears likely that just a few cells in a Tasmanian devil are 
sufficient to establish a DFTD tumour.  
While there is a paucity of evidence to support this statement there is a single 
anecdotal case of a wild devil in captivity developing DFTD more than 40 weeks after 
capture (Hamede et al 2013). In preliminary transmission trials undertaken by 
Department Primary Industries Parks Water Environment (DPIPWE) it was shown 
that 1 x106 DFTD cells established tumours between 2 and 4 weeks (Kreiss 2009). 
In trials utilising 25,000 DFTD cells tumour establishment took between 12 to 38 
weeks (Kreiss 2009).  Explanations for the long latency period could be a slow 
replicating strain of DFTD or host resistance. But in light of the observation that 
tumour development is cell dose-dependent in mice it is likely that the wild devil was 
infected with a very low number of cells and following engraftment cell replication 
was exponential and it took ten months for the tumour mass to be large enough for 
detection. The seasonality of disease detection in the wild combine with field 
observations has been extrapolated to suggest a latency period of 6 to 9 months in 
the wild population subsequent to transmission (Hamede et al 2013).     
To guarantee the maximum number of mice that develop tumours this study 
revealed that at least 105 or 106 DFTD cells need to be injected. Cell numbers of 105 
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or less were transferred with the intention of establishing tumours with a small 
number of cells that could be targeted effectively in cell transfer experiments. This 
resulted in 3% to 60% of NOD/SCID mice not establishing tumours while 106 DFTD 
cells always resulted in tumour establishment. Too high a number of cells will 
overwhelm the immune system and prevent cell transfer experiments efficacy. 
Conversely too low a number will see an increasing number of failures to engraft 
tumours which will confound the results of cell transfer treatments. To overcome this, 
the number of replicate mice for each experiment would have to be substantially 
increased to ensure statistical significance between control and treatment groups.  
Another negative aspect of reducing the number of DFTD cells injected is the 
increased time to tumour detection and which extends the duration of the 
experiments. In the mouse model a one hundred-fold decrease in cell numbers 
extended the time to detection by three-fold. The longest time to detection in the 
mice was 81 to 130 days when 5000 cells were transferred. Such long latency times 
are detrimental with NOD/SCID mice since they are prone to develop metastatic 
thymic lymphomas by 20 weeks of age (Shultz et al 1995). The implications for 
experimental design are that young mice 5 to 8 weeks old need to be selected at the 
commencement of experiments and duration of experiments should be no greater 
than 12 weeks.  
There is an unknown period when disease is undetectable because of a lack of pre-
clinical markers or antibody responses to identify infected Tasmanian devils. For the 
purpose of disease management and monitoring in the wild defining this period 
between exposure until detection would be useful. Understanding the period of 
latency would benefit decisions about how often diseased animals need to be culled 
from the populations to interrupt transmission. The latency period combined with 
seasonality of transmission has implications on scheduling monitoring trips.  The 
best evidence so far suggests a seasonal pattern associated with transmission that 
means infrequent sampling of sites may be skewing the data between different 
populations of Tasmanian devils.  
Given that Tasmanian devils and the NOD/SCID mice generate no immune 
response to inhibit the establishment and growth of DFTD it is not unreasonable to 
expect that the results obtained in the mouse model would translate to the 
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Tasmanian devil. As a consequence, period from exposure to detection of DFTD 
was assessed in NOD/SCID mice with the intention of extrapolating this to what 
might be occurring in the Tasmanian devil. It was found that when 5 x 103 DFTD cells 
were transferred time to detection was between 81 and 130 days. However, this was 
in a mouse where injection site was known and detection was by palpation of a 2 
mm diameter tumour. Therefore detection for a Tasmanian devil in the field would 
require extended growth of the tumour. The current estimate for disease latency by 
field biologist is 6 to 9 months (Hamede et al 2013) and extrapolation of results from 
the mouse model agrees with this estimate.    
4.3.2 Adoptive protection 
The next stage of the project involved taking splenocytes from immunocompetent 
mice and transferring them to NOD/SCID mice to see if protection could be 
adoptively transferred. This would facilitate analysis of immune responses in mice to 
identify if components such as antibodies, primed cells or unprimed cells of the 
immune system were critical to protection in mice. Evaluating the pathways and 
mechanisms used by immunocompetent mice to reject DFTD cells would reveal 
suitable targets of DFTD cells that could be exploited by the immune system in 
developing a vaccine or treatment for DFTD in Tasmanian devils.  
C57BL/6 mice were immunised with DFTD cells and their spleens harvested for 
splenocytes which were then subcutaneously co-transplanted with DFTD cells into 
NOD/SCID mice. Blood was collected between 11 and 18 days post transfer and 
antibody responses against DFTD were detected in eight of ten (80%) of the 
NOD/SCID mice. This result is evidence that transferred cells were functional against 
DFTD targets within the new host.   
NOD/SCID mice lack B cells and do not produce antibody responses against DFTD. 
That means the source of the antibody had to be B cells from the C57/BL6 mice that 
had survived and maintained function following adoptive transfer. Furthermore, since 
only IgG1 was detected in the absence of IgM this suggests memory B cells had 
previously been generated following the immunisation of the C57BL/6 donor mice 
prior to adoptive transfer and were responsible for the antibody response in the 
NOD/SCID mice.  
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Following adoptive transfer the mice became unwell, developed puffy eyes, body 
shakes and respiratory problems. This was most likely as a consequence of graft 
versus host (GVH) rejection as NOD/SCID mice are H-2g7 MHC class and C57BL/6 
are H-2d MHC class (Hu et al 2012). This meant the experiments had to be 
terminated within 18 days which was insufficient time to evaluate DFTD engraftment 
or rejection. But the observation of GVH like symptoms and detection of antibody 
responses provided proof of concept that immune cells could be adoptively 
transferred and retain function. 
To overcome the GVH limitation the adoptive transfer model was switched to BALB/c 
donors for the NOD/SCID recipient mice. BALB/c mice have immune responses 
biased more towards TH2 and for this reason were not the first choice for adoptive 
transfer trial. However, BALB/c mice did not promote GVH rejection in NOD/SCID 
mice and the mice could be monitored for prolonged periods following adoptive 
transfer. Splenocytes from both immunised and naive BALB/c mice were compared 
in the adoptive transfer trial to determine if primed cells from immunised mice were 
superior to unprimed cells for adoptive protection. The addition of autologus serum 
from the immunised BALB/c donor and inclusion of CpG adjuvant was also assessed 
to see they were necessary for protection.   
Adoptively transferred splenocytes from immunised BALB/c donors protected 15 of 
15 (100%) recipient mice from DFTD. Five of these mice had received splenocytes 
only, five received splenocytes and autologus serum and five received splenocytes, 
autologous serum and CpG 2395. When splenocytes from naïve BALB/c mice were 
transferred to NOD/SCID mice only 11of 14 mice were protected from DFTD. This 
suggests that immunised cells benefit from a priming effect that enhances the 
protection when the cells are adoptively transferred. This is in contrast to the in vitro 
cytotoxicity assay result which found equal killing by naïve and immunised 
splenocytes. This suggests that in vitro assay is not as informative as the in vivo 
challenge.  
There are various primed cells that may have worked in synergy to produce the 
enhanced result in the in vivo challenge. Primed B cells may have produced 
antibodies to opsonise the DFTD cells in vivo where the overnight in vitro assay 
would be too short to generate such a response. CTL cells and other cytotoxic cells 
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targeting the DFTD cells may have had the opportunity to clonally expand in vivo 
where in vitro assay was too short a time to induce this enhanced activity. Another 
factor would be the contribution to the response by the NOD/SCID mouse itself. 
Even though it is severely compromised it is capable of producing reduced levels of 
cytokines and other factors which may have contributed to the synergy of the 
response by primed cells.  
The failure to establish DFTD tumours was evidence of successful adoptive 
protection in the NOD/SCID mice. Further evidence that the transferred cells had 
survived and retained function was evident in detection of IgG1 antibodies in the 
serum of NOD/SCID recipient mice. As well, the splenocytes harvested from 
NOD/SCID recipient mice used in in vitro cytotoxicity assays against DFTD cells 
demonstrated dose dependent killing of DFTD cells.  
Adoptive protection is enhanced when DFTD cells are co-transplanted with the 
splenocytes. Adoptive transfer of naïve splenocytes prior to or after DFTD cells did 
not induce antibody responses and tumours established. This suggests that if the 
tumour cells are transplanted at a different time the transferred splenocytes have 
limited opportunity to interact with the DFTD cells. Future experiments will require 
co-transplantation for analysis of cell types. This could be viewed as the equivalent 
of in vitro responses in an in vivo setting which has many advantages over in vitro 
assays. The environment within the mouse is a complex environment in which 
tumour growth is not restricted and angiogenesis can supply nutrients and oxygen as 
the tumour expands in a biologically relevant setting. As previously alluded to, the 
NOD/SCID mouse to a limited degree can also contribute to the response by 
producing low levels of cytokines and other stimulatory factors.   
The next stage of the project evaluated which specific immune cells were 
responsible for the protection. The rationale being that by understanding which 
specific cells of the immune system induced protection following adoptive transfer it 
may be possible to identify targets of DFTD cells that could be exploited in the 
development of a vaccine or treatment for DFTD in Tasmanian devils. To evaluate 
this, spleens from BALB/c mice were divided into enriched or depleted populations of 
NK, CD4, CD8 and NKT (enriched only) populations. These cells were then co-
transplanted with DFTD cells into NOD/SCID mice.  
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With the CD4, CD8 and NK cells sorted by magnetic beads both the enriched and 
depleted populations rejected the DFTD cells while all the control mice grew 
tumours. The purity by magnetic bead sorting was greater than 85%. This result 
suggests that even a small percentage of contaminating cells was protective or the 
individual populations tested were not the sole population providing protection and 
were therefore redundant.  
Fluorescence activated cell sorting (FACS) was an alternative method of enriching 
and depleting populations of cells. When this was used the purity was at least 95% 
which was higher than magnetic beads. While the results were not conclusive 3 of 16 
(19%) NOD/SCID mice with NK enriched cells and 1 of 5 (20%) NOD/SCID mice 
with CD4 enriched cells established DFTD tumours following co-transplantation.  
This result suggests that that NK cells and CD4 cells may not be critical to rejection 
of DFTD cells in vivo. In contrast to this result co-transplantation of even small 
numbers of NKT cells proved protective in 3 of 3 (100%) mice suggesting that that 
NKT cells may be capable of killing DFTD cells.  
With regards to NKT cells, they are known to be activated by glycolipid antigens 
presented by CD1d molecules on the target cell (Godfrey and Rossjohn 2011, Joyce 
et al 2011). However DFTD cells have β2-microglobulin downregulated which is an 
obligatory molecule associated CD1d molecules making NKT cells unlikely effector 
cells. However, as β2-microglobulin expression can be restored in the presence of 
cytokines (Siddle and Kaufman 2013) NKT cells could have contributed to the 
immune response. Another possibly could be non-classical NKT cells which are 
CD1-independent and have been implicated in anti-tumour responses in human 
cancers (Konishi et al 2004).  
Additional evidence of which cells contributed to a protective response to DFTD cells 
was undertaken using congenic and knockout mice. Ighm/J, a B cell knockout strain, 
rejected DFTD cells revealing B cells are not critical to DFTD tumour rejection in the 
mouse model. This is important since antibody responses against DFTD have been 
the principal method of detecting and measuring immune responses to DFTD in both 
mice and Tasmanian devils thus far. So while antibodies are produced by fully 
competent mice such as BALB/c and C57BL/6 they are not essential for the killing of 
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DFTD cells but may still contribute towards the response by opsonising the targets 
cells.  
A TNF knockout strain, B6.TNF, rejected DFTD cells indicating TNF expression by 
cells was not essential to DFTD rejection in the mouse model. TNF was one of the 
cytokines produced in response to DFTD cells by C57BL/6 and BALB/c mice 
splenocytes in in vitro cultures. The role of TNF in DFTD rejection in mice, while not 
apparently critical, may still contribute to DFTD rejection. Inflammatory responses 
are promoted by TNF and this may contribute towards recruiting effective anti-DFTD 
immune cells to the site of infection in fully competent mice.   
To assess the role of T cells in DFTD rejection two strains of T cell deficient mice 
were evaluated. CBA/nu is an athymic mouse that lacks T cells but maintains B cell, 
macrophage, dendritic and NK cell activity. The Rag/2 mouse has a thymus but lacks 
T cell receptors and therefore does not have functioning T cells or B cells but 
maintains macrophage, dendritic and NK cell activity. The DFTD tumour established 
in 80 % of the Rag/2 mice (n= 8/10) and 100% of CBA/nu mice (n=9/9). Significantly, 
the tumours in the Rag/2 mice grew to one-tenth the size of the tumours of the 
CBA/nu mice within the same time period following injection with the same number 
of cells from the same cell culture on the same day.  
Understanding the differences in the immune responses by these two strains would 
provide insight into the protective mechanisms used by immunocompetent mice to 
reject DFTD cells. Consequently, the immunophenotype of the splenocytes obtained 
from these two strains was evaluated. The lack of T cells in both strains was 
confirmed using antibodies for CD3e. This means that T cells had not contributed to 
the rejection in 20% of the Rag/2 mice or slower growth in the 80% of Rag/2 mice 
which grew tumours. The use of CD19 antibodies confirmed the CBA/nu had mature 
B cells and these were absent in the RAG/2 mice. This result combined with the 
previous observation in the Ighm/J mice confirms B cells are not critical in anti-DFTD 
responses in mice.  
CD49b antibody confirmed both strains had NK cells. The rag/2 mice had over 10% 
of the spleen being NK cells while the CBA/nu had less than 5% NK cells. Using 
MHC II antibody to discriminate APCs such as macrophages and DCs the RAG/2 
mice had over 30% of the spleen composition as APCs while the CBA/nu had just 
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13%. This suggests that the increased percentage of NK cells and APCs may 
contribute towards anti-DFTD responses in the Rag/2 mice.     
Conclusions 
The NOD/SCID mice provided an informative model to facilitate study of DFTD 
tumour transplantation and growth kinetics, which required an in vivo setting. The 
use of mice as a substitute for Tasmanian devils protects a rare and endangered 
species and has the benefit of reduced husbandry costs and readily available 
antibodies to study the mouse immune system.  
Biologists concerned with the management of DFTD in the wild population need 
information about the latency of the disease. This information is hard to obtain in the 
wild so the NOD/SCID mouse provides a biologically relevant platform to conduct 
experiments to determine latency and growth rates of DFTD. In the future this may 
prove particularly valuable as the tumour evolves into different strains. It has been 
hypothesized that DFTD will evolve into a less virulent strain which will facilitate co-
existence of the host species and the pathogen. The growth kinetics of evolving 
strains could be evaluated in the reproducible setting of NOD/SCID mice and provide 
evidence of changes to virulence of DFTD in the wild.  
It is difficult to know in the wild how many cells are transferred between devils and 
what the threshold number of cells to induce infection is. The NOD/SCID mice 
revealed that as few as 2.5 x 103 DFTD cells could induce tumours. The model also 
revealed tumour latency till detection was cell dose-dependent and extrapolation of 
the data agrees with the best estimates from the field of a latency period of 6 to 9 
months in the wild and suggests that this is due to inoculation with a very small 
number of cells, possibly a few hundred.  
There was a negative correlation of tumour engraftment as injected DFTD cell 
numbers declined and time to detection increased. In the NOD/SCID mice 106 DFTD 
cells always resulted in engraftment which could be detected within five weeks. This 
information should be used to guide immunisations of Tasmanian devil for vaccine 
trials. If too low a number are used tumours may fail to engraft and this could 
confound the results.  
Elucidating the mechanisms of rejection and killing of DFTD cells in mice is ongoing 
research to identify targets for DFTD in vaccine and immunotherapy trials. This 
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chapter has shown adoptive transfer of protection from BALB/c mice to NOD/SCID 
mice is practical and can contribute towards our understanding of anti-DFTD 
responses. Caution should be applied if alternative strains of mice are used in the 
future due to GVH rejection and MHC matching would minimise this risk.  
The results from the current adoptive transfer study suggested CD4+ T cells and NK 
cells did not have a critical role in killing DFTD cells. NKT cells are implicated, 
despite difficulties understanding how they could be activated, as even a small 
number transferred appeared to be protective. The role of CD8+ T cells was not able 
to be determined but primed splenocytes from immunised BALB/c donors were more 
protective than unprimed splenocytes suggesting CD8+ T cells could be involved.  
Further evidence that T cells were implicit in DFTD rejection came from two different 
strains of T cell knockout mice which engrafted the tumour. The response difference 
between these strains, CBA/nu and Rag/2, demonstrated that another cell type was 
augmenting the T cell protection. Ighm/J, a B cell knock strain, had already revealed 
B cells were not critical and the addition of B cells to the CBA/nu mouse repertoire 
had not enhanced its protective response. It was significant that Rag/2 mice had a 
higher percentage of NK cells and APCs than CBA/nu and grew tumours just 10% 
the size of CBA/nu mice. This suggests that NK cell activity and or antigen 
presenting cell activity levels may have been higher in the Rag/2 mice and slowed 
the initial growth of the DFTD tumour and prevented DFTD establishment in 20% of 
the Rag/2 mice while all CBA/nu mice grew DFTD tumours. This suggests that both 
innate and adaptive immune responses can kill DFTD cells and ongoing research 
will continue to study the different responses in these strains.   
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5 Evaluation of Tasmanian devil LAK cells 
5.1 Introduction 
In the wild, the Tasmanian devil faces extinction because of the lack of effective 
immune rejection of DFTD cells on transmission. The disease, which is 100% fatal, 
fails to engage any cells of the immune system. What is indicated from recent 
research is that the lack of MHC expression by DFTD cells explains the absence of T 
cell recognition but fails to explain why NK cells have not targeted the DFTD cells for 
destruction. There are three possible explanations; DFTD cells are not immunogenic, 
are resistant to apoptosis or are resistant to NK cells.  
In the previous chapters of this work, it was noted that immunocompetent mice 
provided evidence that DFTD cells are immunogenic and can be targeted and killed 
by the immune system. In vitro studies in these chapters also revealed camptothecin 
and UV-radiation induced apoptosis in DFTD cells. Therefore DFTD cells are 
immunogenic and can undergo apoptosis but still fail to be recognised and killed by 
the Tasmanian devil immune system. This highlights the third possibility above, that 
DFTD tumours are NK cell resistant. 
One of the promising therapies with human and animal tumours that are NK-resistant 
is the generation of autologus lymphokine activated killer (LAK) cells. This was first 
described using recombinant IL-2 to stimulate cytotoxic activity in human PBMNC 
and mouse splenocytes. In those studies, LAK killing targeted autologous, allogeneic 
and cultured tumour cell lines (Herberman et al 1987). In a similar fashion, culturing 
with concanavalin A also promoted cytotoxic activity equivalent to LAK cells (Miyagi 
et al 2004).   
When lymphocytes are cultured with concanavalin A lymphokines (cytokines) are 
released into the culture medium (Fidler et al 1976). The culture medium retains 
lymphokines which act as activation factors for numerous cell types including 
macrophages, NK and NKT cells in the same manner achieved by recombinant 
cytokines such as IL-2 (Fidler et al 1976, Funk et al 2005). Once the lymphokines 
have been produced there is no continuing need for concanavalin A and the 
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supernatant from the culture medium (Con A sup) can also promote activation, even 
with the remaining concanavalin A inactivated (Fidler et al 1976, Palacios 1982).  
LAK cells from humans and mice have been shown to be cytotoxic against tumour 
cells in vitro (Funk et al 2005). This cytotoxicity was predominantly the result of NK 
and NKT cells (Herberman et al 1987, Ishikawa et al 2012, Miyagi et al 2004). 
Concanavalin A does not directly activate NK cells but induces IFN-γ production by 
NKT cells, which in turn promotes activation of NK cells (Miyagi et al 2004). 
Macrophages are also not directly activated by concanavalin A (Palacios 1982) but 
Con A sup contains macrophage-activating factor (MAF) that induces cytotoxic 
responses by macrophages that target syngeneic, allogeneic and xenogeneic 
tumours while leaving normal tissues alone (Fidler et al 1976). 
LAK cell therapy has been used with some efficacy in the treatment of human 
patients with tumours (Rosenberg et al 1985). LAK cells preferentially target 
cytotoxicity against tumour cells and are not harmful to normal cells (Linn and Hui 
2010, Richards 1989). While the mode of action is not fully understood, the evidence 
is consistent with innate immune cells including NK, NKT and macrophages targeting 
the tumours. This sort of therapy has never previously been applied to Tasmanian 
devils.  
In this chapter, the efficacy of LAK cell therapy against DFTD cells was evaluated in 
in vitro and in vivo. Because of the endangered status of the Tasmanian devil the in 
vivo work was conducted in NOD/SCID mice. This chapter evaluated if it was 
possible to confer protection in NOD/SCID mice by adoptive cell transfer of 
Tasmanian devil LAK cells. The most important purpose of these in vivo trials was to 
prove that these in vitro activated LAK cells can kill DFTD tumours in vivo.  
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5.2 Results 
5.2.1 Activation of Tasmanian devil lymphocytes 
There is no evidence in nature for Tasmanian devil immune cells targeting or killing 
DFTD cells. There is currently no way to activate Tasmanian devil lymphocytes to 
induce specific immune responses against DFTD cells. In our laboratory we have 
demonstrated Tasmanian devil lymphocytes can be non-specifically activated to 
induce cytotoxic cells capable of killing DFTD cells (Brown 2013). This was 
demonstrated using an in vitro 51Cr cytotoxicity assay. In this chapter these results 
were confirmed using the non-radioactive CellTrace Violet and propidium iodide 
fluorometric assay. The activation protocol was optimised prior to in vivo trials of 
adoptively transferring activated Tasmanian devil lymphocytes into NOD/SCID mice.  
Concanavalin A has the ability to activate peripheral blood mononuclear cells 
(PBMNC) and causes them to secrete cytokines that promotes further activation 
(Qian et al 2014). These cells could be called mitogen activated killer cells (MAK) but 
in this thesis they will be referred to as LAK cells. Cells that are activated by the 
cytokines secreted into the culture medium during concanavalin A stimulation will 
also be referred to as LAK cells. This study revealed these LAK cells are capable of 
killing DFTD cells. To evaluate cytotoxicity and the requirement for activation, fresh 
PBMNC were obtained from five Tasmanian devils and used as effector cells in an 
18 hour cytotoxicity assay against DFTD cells. Non-activated PBMNC had no 
cytotoxicity against DFTD cells (Figure 5-1panel A).  When PBMNC were stimulated 
for 48 hours in RPMI-10 medium supplemented with 20 µg/ml concanavalin A and 
used as effector cells in an 18 hour cytotoxicity assay, cytotoxicity against DFTD 
cells was observed (Figure 5-1panel B). At the highest effector to target cell ratios 
the cytotoxic response against the DFTD target cells ranged from 20% to greater 
than 50%. Cytotoxicity appeared to plateau at the 25:1 effector to target cell ratio.   
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Figure 5-1. PBMNCs were obtained from five Tasmanian devils. Cytotoxicity was evaluated 
using propidium iodide detection by flow cytometry. (A) In an 18 hour cytotoxicity assay there 
was no evidence for cytotoxicity by non-activated cells. (B) Following stimulation for 48 hours 
with 20 µg/ml concanavalin A there was evidence for dose-dependent cytotoxicity. (Results 
represent mean of duplicate wells)   
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To determine if cytotoxic cells were also present in the spleen and if 24 hour 
stimulation could induce cytotoxicity equivalent to 48 hours, fresh splenocytes and 
PBMNC obtained at necropsy were stimulated with 25 µg/ml of concanavalin A for 
24 and 48 hours. It was also hypothesised that the cytotoxicity was due to activated 
NK cells. Consequently the assay was performed over 4 hours to distinguish from 
cytotoxic T lymphocytes (CTLs), which usually require 18 hours.  
After 24 hours stimulation with concanavalin A, no cytotoxicity was observed with 
either the splenocytes or PBMNC. Instead, the 24 hour stimulated PBMNC effector 
cells appeared to protect the DFTD cells from cell death resulting in an apparent 
inverted cytotoxic dose-curve response. This was not observed with the 24 hour 
stimulated splenocytes which showed no response (Figure 5-2).  
After 48 hours stimulation with concanavalin A both the PBMNC and the splenocytes 
demonstrated dose-dependent cytotoxic responses against DFTD cells. The 
gradients of the dose response curves were similar but the splenocytes had a lower 
level of cytotoxicity. The key findings were that cytotoxic cells are present in the 
spleen, the efficacy was lower than PBMNC and that cytotoxicity was observed at 4 
hours.    
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Figure 5-2. PBMNC and splenocytes were stimulated with 25 µg/ml concanavalin A for 24 or 48 
hours. After treatment the splenocytes and PBMNC were used as effector cells against 
CellTrace Violet labelled C5065 DFTD cells in a 4 hour in vitro cytotoxicity assay. (Results 
represent mean of triplicate wells and error bars SEM)   
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The next section of work addressed four questions aimed at increasing the available 
sources of cytotoxic cells and optimising the activation of these cells into LAK cells. 
Firstly, can lower concentrations of concanavalin A be used to activate LAK cells?  
Secondly, could cytokines alone activate LAK cells? Thirdly, could cryopreserved 
lymphocytes be thawed and activated as LAK cells? Fourthly, could lymph nodes be 
used as an additional source of cytotoxic cells?  
While concanavalin A has a stimulatory role on lymphocytes, too high a 
concentration is cytotoxic and reduces the viability (Leist and Wendel 1996). For this 
reason it may prove advantageous to use a lower concentration of concanavalin A to 
generate LAK cells. Stimulation with 5 µg/ml concanavalin A in RPMI-10 medium for 
72 hours was sufficient to activate Tasmanian devil lymphocytes and resulted in 
dose-dependent cytotoxicity against DFTD cells in an 18 hour in vitro assay (Figure 
5-3 panel A). There was some variability in killing responses between animals with 
the cytotoxicity at the maximum effector to target cell ratio of 100:1 ranging from 40 
to 60%.     
Concanavalin A stimulation of lymphocytes promotes production of cytokines 
including IFN-γ (Miyagi et al 2004, Palacios 1982). To confirm that cytokines would 
activate LAK cells in the absence of concanavalin A, the supernatant from 
Tasmanian devil lymphocytes stimulated with concanavalin A (Con A sup) was 
collected and the concanavalin A inactivated by the addition of mannose. Fresh 
splenocytes obtained during necropsy of a Tasmanian devil were cultured for 48 
hours in RPMI-10 medium supplemented with 10% Con A sup. This resulted in 
activation of cytotoxic cells as evidenced by an 18 hour cytotoxicity assay. The 
cytotoxicity at 100:1 effector to target cell ratio was equivalent to the previously 
observed cytotoxicity for PBMNC stimulated with 5 µg/ml concanavalin A (Figure 5-3 
panels A and B).    
Since access to Tasmanian devils for fresh samples is limited, cryopreservation of 
cytotoxic cells would allow access to more samples including those obtained at 
necropsy. PBMNC and spleens were two sources known to contain lymphocytes that 
could be activated into LAK cells. It was likely that lymph nodes would be an 
additional source available at necropsy. The feasibility of thawing cryopreserved 
PBMNC and lymph node derived lymphocytes and activating them into LAK cells 
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was evaluated. Cells were thawed and cultured for 48 hours in RPMI-10 medium 
supplemented with 10% Con A sup. The freeze thawing process resulted in poor cell 
recovery and therefore the maximum PBMNC effector to target cell ratio was 12:1 
and the maximum lymph node lymphocyte effector to target cell ratio was 50:1 in the 
18 hour cytotoxicity assay. Both cell populations revealed dose-dependent 
cytotoxicity against DFTD target cells (Figure 5-3 panels C and D). The levels of 
cytotoxicity were similar for fresh cell sources (Figure 5-3 panels A and B) and 
thawed cryopreserved cells (Figure 5-3 panels C and D).   
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(C) Frozen PBMNC
      activated with Con A sup
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(D) Frozen lymph node cells
      activated with Con A sup
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Figure 5-3. Effector cells from Tasmanian devils were activated using Con A sup or 
concanavalin A (as described) and then incubated with CellTrace Violet labelled C5065 DFTD 
cells for 18 hours. Cytotoxicity was evaluated using propidium iodide detection by flow 
cytometry. (A) Following stimulation for 72 hours in RPMI-10 media supplemented with 5 µg/ml 
concanavalin A, fresh peripheral blood mononuclear cells (PBMNC) from three Tasmanian 
devils showed evidence for dose-dependent cytotoxicity. (B ) Following stimulation for 48 
hours with 10% Con A sup, fresh splenocytes obtained from a Tasmanian devil and showed 
evidence for dose-dependent cytotoxicity. (C) Cryopreserved PBMNC obtained from a 
Tasmanian devil were thawed, stimulated for 48hours with 10% Con A sup and showed 
evidence for dose-dependent cytotoxicity. (D) Cryopreserved lymph node derived lymphocytes 
obtained from a Tasmanian devil were thawed, stimulated for 48hours with 10% Con A sup and 
showed evidence for dose-dependent cytotoxicity. (Data points represent mean of triplicate 
wells and error bars SEM)  
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5.2.2 Adoptive transfer of LAK cells in vivo trials in NOD/SCID mice 
The previous section demonstrated Tasmanian devil lymphocytes could be activated 
into LAK cells that kill DFTD cells. As a preliminary trial to test if these LAK cells 
could be protective in vivo three NOD/SCID mice were injected with 5 x 105 DFTD 
cells. Two of these mice were co-transplanted with 5 x 106 PBMNC activated with 
Con A sup. After 47 days, when the control mouse developed a tumour that 
approached the maximum permissible size, all the mice were euthanised and 
tumours collected.  The tumours in the LAK cell treated mice were only 3% and 9% 
the size of the control mouse (Figure 5-4). The LAK cells appeared to restrict the 
tumour growth but did not prevent establishment.  
  
 
Figure 5-4. Two NOD/SCID mice (#1 and #2) were co-injected subcutaneously with 5 x 10
5 
DFTD 
cells and 5 x 10
6
 LAK cells from a Tasmanian devil which had been activated with Con A sup. 
A third mouse (Control) was injected with the same quantity of DFTD cells only. At 47 days the 
tumours were then weighed and the mice receiving the LAK cells had tumours which were 3% 
or 9% the size of the control mouse.   
          Control                         Mouse #1                      Mouse #2 
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To improve the efficiency of the adoptive transfer experiments the effector to target 
ratio was increased by reducing the number of DFTD cells to 1x 104 or 2 x 104. This 
was used in preference to increasing the number of effector cells due to the limited 
access to peripheral blood.   
PBMNC from six devils were stimulated with Con A sup for 48 hours and the 
resulting LAK cell populations were co-injected with DFTD cells. Because of the 
variable cell yields the ratio of LAK cell population to DFTD cells ranged from 74:1 to 
490:1. These mice were monitored between 46 to 136 days when they were 
euthanised due to ethical reasons. Increasing the effector to target cell ratio 
prevented DFTD establishment in all seven LAK cell treated mice. However, 
lowering the number of DFTD cells resulted in failure of DFTD establishment in two 
of the four control mice and prolonged the time for tumour development (Table 5-1).    
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Table 5-1. Adoptive transfer into NOD/SCID mice of relatively high Tasmanian devil LAK cell to 
DFTD ratios 
Tasmanian devil 
donor 
Injection 
(number of LAK cells and DFTD cells) 
LAK : DFTD 
cell ratio 
Observation 
Betty  1.7 x10
6 
LAK + 10
4 
DFTD 170:1 
no tumour 
(day 112) 
Grommit 2.4 x10
6
 LAK + 10
4 
DFTD 240:1 
no tumour 
 (day 103) 
Lotti 4.9 x10
6
 LAK + 10
4 
DFTD 490:1 
no tumour  
(day 136) 
Maydin 7.4 x10
5
 LAK + 10
4 
DFTD 74:1 
no tumour  
(day 106) 
Phil 2.2 x10
6
 LAK + 10
4 
DFTD 220:1 
no tumour  
( day 93) 
Elsie 2 x106 LAK + 2 x 104 DFTD 100:1 
no tumour  
(day 46) 
Elsie 2 x106 LAK + 2 x 104 DFTD 100:1 
no tumour  
(day 53) 
Control 10
4 
DFTD cells only  
DFTD tumour 
(day 75) 
Control 10
4 
DFTD cells only  
no tumour  
(day 99) 
Control 2 x 10
4 
DFTD cells only  
DFTD tumour  
(day 53) 
Control 2 x 10
4 
DFTD cells only  
no tumour 
(day 48) 
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Two problems hindering the in vivo LAK cell experiments were the health issues 
associated with the ageing NOD/SCID mice and the failure to reliably establish 
DFTD tumours in the control mice. To overcome this, the number of DFTD cells 
injected was increased to 5 x 104. This would shorten the duration to tumour 
development and consequently the age of the mice. But it also reduced the LAK cell 
to DFTD cell ratio to 20:1.  
PBMNC from a single Tasmanian devil were activated with Con A sup for 48 hours 
and co-injected with DFTD cells into three NOD/SCID mice. Seven control mice 
received DFTD cells only. The mice were monitored for up to 52 days at which time 
all three LAK cell treated mice had developed tumours. At necropsy the control mice 
were examined and five of seven had developed tumours (Table 5-2).  
Increasing the number of injected DFTD cells increased the proportion of control 
mice developing tumours within a reasonable timeframe but the LAK cells failed to 
provide protection (Table 5-2). This may have been the result of using a 20:1 ratio, a 
failure to activate the cells during stimulation with Con A sup, or biological variability 
associated with the Tasmanian devil PBMNC source.  
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Table 5-2. Adoptive transfer into NOD/SCID mice of LAK cells at 20:1 Tasmanian devil LAK cell 
to DFTD cell ratio   
Tasmanian devil 
donor 
Injection 
(number of LAK cells and DFTD cells) 
LAK : DFTD 
cell ratio 
Observation 
Carlotta 10
6
 LAK cells + 5x10
4 
DFTD cells 20:1 
Tumour 
(Day 52) 
Carlotta 10
6
 LAK cells + 5x10
4 
DFTD cells 20:1 
Tumour 
(Day 52) 
Carlotta 10
6
 LAK cells + 5x10
4 
DFTD cells 20:1 
Tumour 
(Day 52) 
Control 5x104 DFTD cells only  
Tumour 
(Day 52) 
Control 5x104 DFTD cells only  
Tumour 
(Day 52) 
Control 5x104 DFTD cells only  
Tumour 
(Day 39) 
Control 5x104 DFTD cells only  
Tumour 
(day 42) 
Control 5x104 DFTD cells only  
Tumour 
(day 46) 
Control 5x104 DFTD cells only  
No tumour 
(Day 52) 
Control 5x104 DFTD cells only  
No tumour 
(Day 52) 
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Since 20:1 LAK cell to DFTD cell ratio did not appear to be protective the ratio was 
increased. PBMNC from four devils were activated with Con A sup for 48 hours and 
co-injected with 5 x 104 DFTD cells at LAK cell to DFTD cell ratios ranging from 50:1 
to 80:1. By day 74 none of the six LAK cell treated mice had established DFTD 
tumours but two of four control mice had developed tumours (Table 5-3). 
 
Table 5-3. Adoptive transfer into NOD/SCID mice of LAK cells at 50:1 to 80:1 Tasmanian devil 
LAK cell to DFTD cell ratios   
Tasmanian devil 
donor 
Injection 
(number of LAK cells and DFTD cells) 
LAK : DFTD 
cell ratio 
Observation 
Bangles 4.1 x 10
6 
LAK cells + 5x10
4 
DFTD cells  80:1 
No tumour  
(Day 68) 
Bangles 4.1 x 10
6 
LAK cells + 5x10
4 
DFTD cells  80:1 
No tumour  
(Day 74) 
Floyd 3.3 x 10
6
 LAK cells + 5x10
4 
DFTD cells 60:1 
No tumour  
(Day 74) 
Cory 3 x 10
6
 LAK cells + 5x10
4 
DFTD cells 60:1 
No tumour  
(Day 74) 
Cory 3 x 10
6
 LAK cells + 5x10
4 
DFTD cells 60:1 
No tumour  
(Day 74) 
Andrea 2.5 x 10
6 
 LAK cells + 5x10
4 
DFTD cells 50:1 
No tumour  
(Day 59) 
Control 5x10
4 
DFTD cells only  
Tumour  
(Day 74) 
Control 5x104 DFTD cells only  
Tumour 
 (Day 74) 
Control 5x104 DFTD cells only  
No tumour  
(Day 74) 
Control 5x104 DFTD cells only  
No tumour 
 (Day 74) 
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As two of the four control mice had developed tumours the next trial used 105 DFTD 
cells and the LAK cells were used at ratios ranging from 7:1 to 22:1. After 45 days 
two of the four LAK cell treated mice had established DFTD tumours compared to 
five of the six control mice. Within the LAK cell treated group of mice there was no 
clear evidence of LAK cell dose-dependent response as 13:1 did not develop a 
tumour but 20:1 did (Table 5-4).  
 
Table 5-4. Adoptive transfer into NOD/SCID mice of LAK cells at 7:1 to 22:1 Tasmanian devil 
LAK cell to DFTD cell ratios  
Tasmanian devil 
donor 
Injection 
(number of LAK cells and DFTD cells) 
LAK : DFTD 
cell ratio 
Observation 
Sedate Ed 2 x 10
6 
LAK cells + 10
5 
DFTD cells 20:1 
Tumour 
(day 45) 
Sedate Ed 7 x 105 LAK cells + 105 DFTD cells 7:1 
Tumour 
(day 45) 
Sedate Ed 2.2 x 106 LAK cells + 105 DFTD cells 22:1 
No tumour 
(day 45) 
Sedate Ed 1.3 x 106 LAK cells + 105 DFTD cells 13:1 
No tumour 
(day 45) 
Control 105 DFTD cells   
Tumour 
(day 45) 
Control 105 DFTD cells   
Tumour 
(day 45) 
Control 105 DFTD cells   
Tumour 
(day 45) 
Control 105 DFTD cells   
Tumour 
(day 45) 
Control 105 DFTD cells   
Tumour 
(day 45) 
Control 105 DFTD cells   
No tumour 
(day 45) 
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Combining all the data from Tables 5-1 to 5-4 into a summary table highlighted the 
need for high LAK cell to DFTD cell ratios to protect mice from tumour development 
as well as the need for sufficient DFTD target cells to establish tumours in control 
mice. Evaluation of the combined LAK cell adoptive transfer trials revealed a 50:1 
LAK cell to DFTD ratio was protective in 13 of 13 mice while a ratio of 20:1 was not 
protective with 5 of 6 mice developing tumours. Lowering the number of DFTD target 
cells appeared to decrease the proportion of control mice which established DFTD 
tumours in a dose-dependent manner (Table 5-5).  
Table 5-5. Summary table of LAK cell adoptive transfer trials  
Summary Table  
LAK cell : DFTD cell  ratio Tumour development 
≥ 50:1 
0 of 13 
mice developed tumours 
≤ 20:1 
5 of 6 
mice developed   tumours 
1 x 10
4
 DFTD cells only controls 
2 of 4 
mice developed tumours 
5 x 10
4
 DFTD cells only controls 
7 of 11 
mice developed tumours 
1 x 10
6 
DFTD cells only controls 
5 of 6 
mice developed tumours 
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5.3 Discussion 
The first chapter revealed that DFTD cells are immunogenic and can be killed by the 
murine immune system. This chapter evaluates ways of stimulating Tasmanian devil 
lymphocytes into cytotoxic cells capable of killing DFTD cells. Adoptive cell transfer 
experiments were then used to evaluate if in vitro activated Tasmanian devil 
lymphocytes could provide adoptive protection in vivo. However, the endangered 
status of the Tasmanian devil limited access for research purposes. As a 
consequence a suitable alternative was required; hence the in vivo work was 
conducted in NOD/SCID mice. As discussed in the second chapter, these mice had 
proven suitable for adoptive transfer using immune cells from BALB/c mice. In this 
chapter adoptive cell transfer from Tasmanian devils into NOD/SCID mice is 
evaluated.  
5.3.1 Overcoming NK resistance of DFTD through LAK cell activation 
Recent research has revealed that DFTD cells downregulate MHC expression 
(Siddle and Kaufman 2013) and thereby avoid immunosurveillance and destruction 
by MHC-restricted lymphocytes. The lack of MHC should make the DFTD cells 
targets for killing by non-MHC restricted lymphocytes such as NK cells (Siddle and 
Kaufman 2013). The development of tumours indicates that NK cells do not kill 
DFTD cells in vivo. It is likely that DFTD tumours are NK-resistant.  
NK-resistant cancers are well documented with human patients. One way to 
overcome NK-resistance in humans involves in vitro activation of the patient’s 
lymphocytes through stimulation with cytokines or mitogens. This activates the cells 
to become lymphokine activated killer (LAK) cells, cytokine induced killer (CIK) cells 
or mitogen activated killer (MAK) cells respectively (Qian et al 2014). These cells 
have the capacity to kill NK resistant tumours in vivo when reintroduced to the 
patient.  
The division into the three categories of LAK, CIK and MAK cells is artificial and not 
without some overlap. The term LAK cells is the original term from the 1980’s used 
to describe lymphocytes activated by cytokines (at that time referred to as 
lymphokines) and cytotoxicity was attributed to NK cells activated by IL-2 (Grimm et 
al 1982, Herberman et al 1987). CIK cells is a term first appearing in the literature in 
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the 1990’s and then recently identified population of cells with both T cell and NK cell 
markers (NKT cells) were attributed as the main cytotoxic cells (Lu and Negrin 
1994). MAK cells refer to lymphocytes activated by mitogens such as concanavalin A 
(Qian et al 2014). MAK cells include NKT cells, NK cells and monocytes activated by 
cytokines produced in response to mitogen stimulation converting them into killer 
cells (Qian et al 2014). Considering that the lymphocytes activated by these three 
methods are usually a mixed population sourced from PBMNC the effector cells 
should not be looked at in isolation but rather in synergy. It is possible to enrich 
specific populations of cells to ascertain the specific role of each. This could mislead 
rather than enlighten since each cell type produces cytokines that either promote or 
inhibit other cell types as a cascade of events. In this thesis the term LAK cell has 
been used to describe the population of Tasmanian devil lymphocytes stimulated 
with cytokines or mitogens. 
When lymphocytes from peripheral blood were cultured with DFTD cells there was 
no evidence for cytotoxicity. As there is evidence for NK cells in peripheral blood 
(Brown et al 2011) the lack of cytotoxicity supports the concept that DFTD cells are 
NK resistant. But when peripheral blood lymphocytes were stimulated with either 
concanavalin A or Con A sup, the activated cells demonstrated a dose-dependent 
cytotoxic response. The significance of this observation is that activated cytotoxic 
cells have the capacity to kill DFTD cells. In chapter three DFTD cells were shown 
not to be resistant to apoptosis. Consequently NK resistance is due to a failure of 
recognition and subsequent activation of cytotoxic cells.  
The stimulation of Tasmanian devil lymphocytes to become LAK cells was tested 
with different incubation times and concanavalin A concentrations. Stimulation with 
concanavalin A for 48 hours consistently induced cytotoxicity and 5 µg/ml was as 
equally effective as 25 µg/ml of concanavalin A. The lower concentration had the 
advantage that it had less toxic effects on lymphocytes. Hence 5 µg/ml was used in 
future experiments.  
Lymphocytes can be directly activated by cytokines (Choi et al 2012, Qian et al 
2014) such as those produced during concanavalin A stimulation. Once the 
cytokines have been produced there is no continuing need for concanavalin A and 
the supernatant from the culture medium (Con A sup) can also promote activation, 
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even with the remaining concanavalin A inactivated (Fidler et al 1976, Palacios 
1982). The addition of supernatant obtained from concanavalin A stimulated 
lymphocytes (Con A sup) at a final concentration of 10% to the culture medium was 
sufficient to activate Tasmanian devil lymphocytes into LAK cells.  
Consequently there were two means of activating Tasmanian devil lymphocytes into 
cytotoxic cells capable of killing DFTD cells. Concanavalin A allowed precise 
conditions to be reproduced whereas different preparations of Con A sup varied 
between batches, most likely due to different levels of the cytokines produced. This 
source of variability added to inter-devil variability in the levels of cytotoxicity with the 
lymphocytes obtained from different Tasmanian devils. Inter-patient and inter-
experimental variability with LAK cells trials have also been reported in human trials 
(Qian et al 2014). 
The ability to activate Tasmanian devil lymphocytes to kill DFTD cells is a significant 
milestone towards development of a treatment or vaccine against DFTD. It reveals 
that DFTD cells can be killed by in vitro activated PBMNC cells. It also highlights that 
effective cytotoxic cells can be extracted from blood. For devils to induce cytotoxicity 
following vaccination it would require cytotoxic cells to be present in secondary 
lymphoid organs such as spleen and lymph nodes. This was investigated with devils 
that had been euthanised for ethical reasons. Following activation, cytotoxicity was 
identified in cells extracted from lymph nodes and the spleen. This important finding 
reveals that Tasmanian devils have a competent immune system that contains cells 
with the capacity to kill DFTD cells in secondary lymphoid organs. 
The failure of their immune recognition (due to MHC downregulation) can be 
overcome by activated lymphocytes in vitro. LAK and MAK cell therapy is when in 
vitro activated lymphocytes are introduced into a patient to target NK resistant 
tumours. This may be a suitable approach to overcome the lack of recognition of 
DFTD cells by Tasmanian devils. To evaluate the efficacy of these approaches a 
reliable supply of lymphocytes was required for experiments. As a consequence, 
evaluation of different lymphocyte sources was undertaken. The level of killing by 
PBMNC was as effective as those obtained from the spleen and lymph nodes. Any 
of these sources would be suitable to perform further cytotoxicity experiments. For 
ethical reasons spleens and lymph nodes could only be obtained at necropsy. 
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Therefore PBMNC are the preferred source for lymphocytes but spleens and lymph 
nodes can be collected opportunistically at necropsy to augment supply.  
A large number of lymphocytes can be obtained at necropsy from the blood, spleen 
and lymph nodes. It is not practical to use all of these cells at time of harvest. A 
possible solution would be cryopreserving cells for later use. It was unknown if 
Tasmanian devil lymphocytes could be cryopreserved, thawed and remain 
functional. As a consequence this was evaluated using lymphocytes sourced from 
blood, spleen and lymph nodes. Tasmanian devil lymphocytes samples were 
cryopreserved, thawed and tested for viability with dye exclusion. Other laboratories 
report between 50 to 70% recovery rate of frozen cells from humans (Jewett et al 
1976, Kleeberger et al 1999) and similar results were obtained with the Tasmanian 
devil lymphocytes. Noteworthy is that platelet contamination negatively impacts 
human lymphocyte cryopreservation (Strong et al 1975) and Tasmanian devil 
lymphocytes have proven difficult to isolate without red blood cell and platelet 
contamination.  
Cryopreservation of Tasmanian devil lymphocytes was possible and would provide a 
readily accessible source for experiments. Cryopreserved samples can be best for 
longitudinal studies (Jewett et al 1976) and frozen human lymphocytes demonstrate 
all the characteristics of fresh cells (Strong et al 1975) and can be preserved for at 
least 12 years (Kleeberger et al 1999). This has facilitated the application of newly 
developed assays to specimens in repositories to measure markers not available at 
the time of collection (Kleeberger et al 1999). Of important significance to the LAK 
and MAK cell therapy with DFTD is the observation that cryopreserved human cells 
have decreased responses to some specific antigens but no significant difference in 
response to concanavalin A (Jewett et al 1976). 
When human samples are cryopreserved there is some shift in the subpopulations 
recovered (Jewett et al 1976, Strong et al 1975). The impact this would have on 
cytotoxic cells in Tasmanian devil lymphocytes was unknown. Consequently, 
functional cytotoxicity assays were used to compare thawed cells and fresh cells for 
their killing of DFTD cells. The observation that following activation thawed 
Tasmanian devil lymphocytes killed DFTD cells equally well as fresh lymphocytes 
reveals the cytotoxic cells and their function were not impacted by cryopreservation. 
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This is therefore a suitable means of ensuring continuous supply of cytotoxic cells for 
experiments.  
Fresh PBMNC is the best source of viable lymphocytes. But access to Tasmanian 
devils is limited and therefore fresh samples are not always available for 
experiments. The ability to cryopreserve Tasmanian devil lymphocytes is significant 
because sample collection is often opportunistic rather than in response to 
researchers’ experimental plans. Cryopreservation allows blood, spleen and lymph 
node derived lymphocytes to be obtained at necropsy which maximises the 
contribution of each Tasmanian devil to the research of DFTD. PBMNC obtained 
during routine veterinary checks can also be cryopreserved to augment supply.  
The necessary reagents to elucidate the cytotoxic cells within the LAK cell population 
are not currently available for Tasmanian devils. Tasmanian devil LAK cell 
cytotoxicity was detected in 4 hour cytotoxicity assays consistent with NK cells being 
the major contributor to the cytotoxicity. But it is almost certainly not just NK cells 
responsible for the events leading to LAK cell killing. Human PBMNC contain 
approximately 15% NK cells and 0.05% NKT cells (Shimizu et al 2006) and the 
synergy of these two cell types is required for LAK killing (Kaneko et al 2000, Miyagi 
et al 2004, Palacios 1982). Despite only a small percentage of the cells being NKT 
cells these cells have a critical role in concanavalin A stimulation. Concanavalin A 
does not directly activate human or mouse NK cells or monocytes but induces IFN-γ 
production by NKT cells which in turn promotes activation of NK cells (Kaneko et al 
2000, Miyagi et al 2004, Palacios 1982). Con A sup also contains macrophage-
activating factor (MAF) and other cytokines that activate macrophages (Fidler et al 
1976).  
It is unknown if Tasmanian devils have NKT cells to undertake this function. What is 
known is that the bandicoot Isoodon macrourus, an Australian marsupial has a 
functioning CD1 gene that would permit lipid antigen presentation to NKT cells if they 
exist in the marsupial (Baker and Miller 2007). The opossum Monodelphis 
domestica, an American marsupial, lacks a functioning CD1 gene and therefore 
cannot present lipid antigens to NKT cells (Baker and Miller 2007). The loss of this 
CD1 gene is believed to have occurred after divergence from Australian marsupials 
(Baker and Miller 2007) making it more likely that the Tasmanian devil has a 
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functioning CD1 gene. The observation that concanavalin A induces cytotoxicity in 
Tasmanian devil lymphocytes is consistent with them have functioning CD1 and NKT 
cells or an alternative pathway to activate NK cells following concanavalin A 
stimulation. This is an important observation as there is a paucity of understanding 
about the Tasmanian devils immune responses and this knowledge contributes to 
the development of a vaccine or treatment for DFTD.  
While LAK cells kill by non-specific activation of NK cells that target NK-resistant 
tumours such as DFTD cells, they also act as a bridge between the innate an 
adaptive immune system. In mice it has been shown that NK-LAK cells express 
IFN-γ which sensitises T cells to IL-2 to promote TH1 cell development and activation 
of macrophages (Geldhof et al 2002). The NK-LAK cells not only kill the NK-resistant 
tumour but also kill M2 macrophages promoting a M1 macrophage response 
(Geldhof et al 2002). The M1 macrophages engage CD8+  T cells generating a CTL 
response against tumours (Geldhof et al 2002). This indicates that LAK cell therapy 
in Tasmanian devils may induce a cascade of immune responses extending beyond 
non-specific targeting of DFTD cells to a specific DFTD response by the adaptive 
immune system.   
In summary, Tasmanian devil lymphocytes can kill DFTD cells in vitro following 
activation by concanavalin A or cytokines. The effector cells can be found in blood, 
spleen or lymph nodes. Both fresh and cryopreserved cells were suitable sources for 
cytotoxic cells.  
5.3.2 Adoptive cell transfer of Tasmanian devil LAK cells 
The in vitro trials showed that activated Tasmanian devil cytotoxic cells could kill 
DFTD cells in vitro but it was unknown if this would translate to in vivo protection. 
The dynamic in vivo environment is different to the plastic substrate environment of 
in vitro cytotoxicity cultures. The in vivo environment provides a complex three-
dimensional structure with supporting cells such as fibroblasts, endothelial cells and 
mesenchymal cells that could support the survival of the DFTD cells against 
cytotoxic LAK cells. The host animal may also provide a source of cytokines, growth 
factors and nutrients not available in the in vitro environment. Tumour cells are 
typically heterogenic and the in vitro cytotoxicity did not reveal 100% killing, 
accordingly some cells survived. It is possible that these surviving cells had the 
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ability to resist LAK killing and in an in vivo setting they would overwhelm the LAK 
cell response and establish a tumour.  
Limited access to Tasmanian devils facilitated the need for an in vivo model to 
evaluate in vivo protection by LAK cells. In the previous chapter NOD/SCID mice 
proved a suitable model to study adoptive cell transfer protection against DFTD. 
Immune cells from immunocompetent BALB/c mice were co-injected with DFTD cells 
into NOD/SCID mice. This not only prevented the establishment of DFTD tumours 
but the transferred murine cells remained functional producing DFTD specific 
antibodies in the new host. The in vivo results complemented the in vitro results and 
revealed information not detectable by in vitro assays alone.  
The protection from adoptive BALB/c cell transfer to NOD/SCID mice required co-
injection of the DFTD cells and the lymphocytes. Protection was less effective if the 
cells were injected into separate subcutaneous sites on the body or at different time 
points. In this chapter, activated Tasmanian devil lymphocytes (LAK cells) were co-
injected with DFTD cells to “devilise” mice. This partial reconstitution of NOD/SCID 
mice with Tasmanian devil lymphocytes facilitated the study of immune responses by 
Tasmanian devil cells in an in vivo setting.  
LAK cell cytotoxicity was evaluated by monitoring tumour growth. LAK cells 
preferentially target their cytotoxicity against tumour cells and are not harmful to 
normal cells in humans (Linn and Hui 2010, Richards 1989) and adoptive transfer of 
Tasmanian devil LAK cells into NOD/SCID mice targeted the DFTD cells and 
showed no adverse response against normal cells as there was no evidence for graft 
versus host disease. Furthermore, even without an appropriate immune system to 
recruit as reinforcement the LAK cells on their own effectively inhibited or prevented 
the establishment of DFTD tumours in the NOD/SCID mice. Most importantly this 
‘devilised mouse model’ provided proof of concept for adoptive cell transfer therapies 
such as LAK cell therapy against DFTD.   
The adoptive transfers were trialled at various ratios of effector (LAK) to target 
(DFTD) cell ratios. It should be noted that the termed effector cell here refers to the 
mixed population of lymphocytes that have been stimulated but not all of these cells 
would be cytotoxic. Ratios of 20:1 or less failed to prevent DFTD tumour 
establishment but did result in smaller tumour growth in the treated mice compared 
 5-24 
 
to the controls. In contrast, ratios of 50:1 or greater prevented DFTD tumour 
establishment in all treated mice. In vitro, 50:1 did not result in 100% cell death but in 
in vivo there were no surviving cells to establish DFTD tumours providing a more 
biologically relevant test for LAK cell activity. This means that for effective treatment 
in Tasmanian devils sufficient number of LAK cells will be required or the protective 
effect of LAK killing will be overwhelmed.    
In human therapies acquiring sufficient number of activated cells to maintain LAK 
killing to achieve full regression has been an obstacle (Cesano et al 1994). This may 
also prove to be the case with Tasmanian devils but since LAK killing is presumed to 
be predominately NK cell mediated establishing a Tasmanian devil NK cell line could 
overcome this obstacle. If a Tasmanian devil NK cell line could be established this 
would supply sufficient cells for in vitro and in vivo trials. This has been the case with 
human trials where NK cell lines have been established and FDA approved (Qian et 
al 2014).  
As previously mentioned concanavalin A will not directly activate NK cells but 
recombinant cytokines could be used as an alternative means of activation for an NK 
cell line. Cultured NK cell lines are effectively allogeneic NK cells that have 
enhanced efficacy in human trials against cancers such as acute myeloid leukaemia 
(AML) (Moretta et al , Murphy and Longo 1997). If DFTD cells upregulate MHC class 
I, which they can do under cytokine stimulation (Siddle et al 2013), then autologous 
LAK cells will see the tumour as self and not target them. On the other hand, 
allogeneic LAK cells would overcome this obstacle and kill the tumours without risk 
of graft-versus-host disease (Moretta et al , Murphy and Longo 1997, Qian et al 
2014). This occurs because the NK cells have KIR receptors that bind to self MHC 
ligands and this acts an inhibitory signal. Allogeneic NK cells often have a KIR 
mismatch with tumour MHC and therefore this leads to greater tumour killing (Miller 
et al 2005).   
The cytotoxic ability of human LAK cells has been clearly demonstrated in vitro 
against tumour cells and in vivo clinical trials (Funk et al 2005, Rosenberg et al 
1985). In this chapter killing of DFTD cells was demonstrated both in vitro and in vivo 
and therefore LAK cell therapy in Tasmanian devils could be possible. While the 
mode of LAK killing is not fully understood, the evidence is consistent with innate 
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immune cells including NK, NKT and macrophages non-specifically targeting 
tumours in a non-MHC restricted manner (Herberman et al 1987, Ishikawa et al 
2012, Miyagi et al 2004). The presence of NK and NKT cells in the Tasmanian devil 
is yet to be confirmed but these results provide evidence of LAK cell functions 
associated with these cell types. 
5.3.3 Conclusions 
The findings in this chapter reveal the Tasmanian devil has a competent immune 
system capable of killing DFTD cells in vivo. This was achieved in all the DFTD 
challenged NOD/SCID mice that received at least a 50:1 LAK cell to DFTD cell ratio. 
The inability to kill DFTD on transmission is either due to a failure to recognise the 
DFTD cells or failure to identify them as non-self. This can be overcome by in vitro 
activation of Tasmanian devil lymphocytes to induce LAK cells which are capable of 
killing DFTD cells both in vitro and in vivo. This killing targeted DFTD cells and 
showed no evidence of harm to normal cells.  
The current study has been in a mouse model which was suitable for studying the 
direct LAK killing of DFTD cells. This model is not suitable to evaluating the 
recruitment of the adaptive immune system. LAK cell therapy has the potential to 
direct the Tasmanian devils resident immune system towards an adaptive DFTD 
specific immune response. This is yet to be shown and will require trials in 
Tasmanian devils which are now justified by the results shown in this chapter.  
LAK cell therapy requires a reliable source of lymphocytes that can be activated. In 
this chapter blood, spleen and lymph nodes have been shown to be suitable 
sources. These cells can be cryopreserved, thawed and the cytotoxic potential is not 
diminished. However, possibly a better source of cells for LAK cell therapy would be 
the establishment of NK cell lines for Tasmanian devils. The cell lines should have 
KIR receptors that are mismatched to the MHC ligands that DFTD cells are capable 
of expressing. This would provide NK cells which would not be inactivated if DFTD 
cells upregulated MHC during treatment. 
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6 Utilisation of the murine model for therapy trials 
6.1 Introduction 
One of the purposes for developing the mouse model to study DFTD was to 
undertake preliminary studies to evaluate treatment options that could be applied to 
the Tasmanian devil. In this chapter four treatments were evaluated for their efficacy 
against DFTD. Two involved the chemotherapeutic drugs afatinib and withaferin A 
that induce apoptosis and promote anti-cancer immunity (Yap et al 2010, Yang et al 
2012). The two other drugs were fucoidan and imiquimod which demonstrate anti-
cancer immunomodulatory activities (Yang et al 2013, Schön et al 2003).  
Afatinib  
The Sanger Research Institute (Elizabeth Murchison, personal communication, 
2012) identified afatinib as a potential treatment for DFTD in an in vitro drug 
sensitivity trial conducted against various cancer cell lines including DFTD cells. 
Afatinib, also known as BIBW2992, is known to decrease proliferation and increase 
apoptosis in some human cancers (Yap et al 2010). They observed decreased 
proliferation of DFTD cells when incubated with afatinib in vitro.  
Afatinib functions as an epidermal growth factor receptor tyrosine kinase inhibitor 
(EGFR-TKI) that irreversibly binds to epidermal growth factor receptor (EGFR) as 
well as human epidermal growth factor receptor 2 (HER2) (Nanjo et al 2013, Yap et 
al 2010). These receptors become activated by EGF-like peptides that act as growth 
factors. To promote tumour growth and survival many cancers upregulate expression 
of both EGFR and EGF-like peptides (Normanno et al 2006). These receptors are 
activated by tyrosine kinase phosphorylation and afatinib prevents phosphorylation.  
First generation drugs, such as erlotinib, gefitinib and lapatinib, had reversible 
binding that did not sustain suppression of phosphorylation while afatinib maintains 
suppression because its covalent bonding to the receptors is irreversible (Yap et al 
2010). EGFR mutations in tumours including T790M point mutations enhanced 
resistance to the first generation drugs but are inhibited by afatinib (Yap et al 2010).  
Withaferin A  
The traditional Indian medicine system, Ayurvedic Medicine, has used the medicinal 
plant Withania somnifera (Indian Winter Cherry) for centuries to treat a variety of 
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ailments. Withaferin A is the bioactive ingredient isolated from this plant that has 
been shown to have immunomodulatory, anti-inflammatory, anti-angiogenic and anti-
tumour properties (Yang et al 2012). The anti-tumour properties of withaferin A can 
inhibit proliferation, induce apoptosis and directly cause necrotic cancer cell death 
while normal cells are unaffected (Grogan et al 2013). Withaferin A preferentially 
targets cancer cells that over-express vimentin resulting in the accumulation of 
vimentin in the perinuclear space (Satelli and Li 2011). It binds to the vimentin, 
degrades it and facilitates increased apoptosis (Patel et al 2013, Satelli and Li 2011).  
DFTD cells are strongly positive for vimentin (Loh et al 2006a) indicating a critical 
role for vimentin in DFTD cells. Vimentin is an intermediate filament protein 
contributing towards structural and functional integrity of quiescent cells. In activated 
cells vimentin promotes adhesion, migration, survival and cell signalling mechanisms 
(Lahat  et al 2010). Over expression of vimentin is generally regarded as supporting 
a poor prognosis for cancers since it is correlated to metastatic disease (Yang et al 
2012).  
Withaferin A selectively targets cancer cells and induces vimentin disassembly 
(Thaiparambil et al 2011, Yang et al 2012). It is effective in the treatment of many 
types of cancer including prostate cancer (Srinivasan et al 2007), breast cancer 
(Stan et al 2008), colon cancer (Koduru et al 2010), cervical cancer (Munagala et al 
2011), glioblastomas (Grogan et al 2013) and head/neck squamous cell cancer 
(Cohen et al 2009). It is a natural product extracted from the plant Withania 
somnifera and is associated with fewer side effects and demonstrates lower toxicity 
than synthetic options (Yang et al 2012). 
Recent pharmacological studies have identified a number of anti-cancer 
mechanisms in addition to targeting vimentin. These include changing the 
architecture of the cytoskeleton, upregulating production of reactive oxygen species 
(ROS) (Grogan et al 2013, Patel et al 2013), inhibiting proteasomal activity and 
contributing towards mitochondrial dysfunction (Yang et al 2012). Gene expression 
analysis following withaferin A treatment showed an upregulation of pro-apoptotic 
Bax and IκB-α proteins and downregulation of a number of cell growth and 
metastasis transducers including c-myc and vimentin (Patel et al 2013, Yang et al 
2012). In human malignant pleural mesothelioma (MPM) cells withaferin A has been 
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shown to induce caspase-3 activation, PARP cleavage and condensed nuclei which 
are characteristics of apoptosis (Yang et al 2012).  
Fucoidan 
Fucoidan is a polysaccharide extracted from seaweed with reported anticancer and 
immunomodulatory activities (Kwak 2014, Yang et al 2013). It is known to target 
numerous receptors and signalling molecules in both tumour cells and immune cells 
(Kwak 2014). Studies have revealed mechanisms of activity that include activation 
and mobilisation of immune cells as well as altering cytokine expression. In this 
chapter fucoidan was evaluated for its potential to alter or enhance immune 
responses against DFTD cells in mice.  
Fucoidan as an immunomodulatory compound is capable of inducing TH1 cytokines 
including IFN-γ, TNF-α and IL-12 while suppressing TH2 cytokines IL-10 and TGF-β 
(Kar et al 2011). Fucoidan treated DCs also direct naïve T cells towards a TH1 
differentiation. In an animal study of Leishmania infection, a blood parasite in 
humans, fucoidan switched the CD4+ T cell TH2 immune response to a TH1 biased 
response resulting in elimination of the parasite (Kar et al 2011). This type of 
TH1:TH2 modulation ratio towards TH1 profiles are required for effective anti-tumour 
responses and hence our interest in fucoidan’s potential role against DFTD.    
Imiquimod 
Imiquimod is a TLR-7 agonist that was being evaluated within our laboratory in 
in vitro studies for its potential to activate innate immune cells. During these trials it 
was observed that in vitro imiquimod treatment stimulated the DFTD cells to 
upregulate MHC class I expression (Patchett 2013). One of the main mechanisms 
exploited by DFTD cells to avoid detection and subsequent destruction on 
transmission is the downregulation of MHC class I molecules (Siddle et al 2013). 
This led to the hypothesis that intratumoural injections of imiquimod could be used to 
upregulate MHC class I in DFTD tumours in vivo. 
In addition to upregulation of MHC class I there are other anti-tumour properties of 
imiquimod that are relevant to induce an immune response against DFTD. 
Imiquimod is an established treatment against cancers including basal cell 
carcinomas (BCCs) (Schön et al 2003). Imiquimod directly induces tumour selective 
apoptosis independent of membrane-bound death receptors (Schön et al 2003). It 
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also promotes cytokine mediated cellular immune responses (Schön et al 2003). Of 
significant relevance to the development of a DFTD vaccine is the ability to use 
imiquimod as an adjuvant in vaccines to promote CD8+ T cell responses (Shackleton 
et al 2004).  
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6.2 Results 
6.2.1 Treatment of DFTD tumours with afatinib  
Afatinib had been shown to kill DFTD cells in an in vitro drug screening trial 
conducted by the Sanger Research Institute (Elizabeth Murchison, personal 
communication, 2012). For this reason it was decided to evaluate the efficacy of 
afatinib on established tumours. Consequently 12 NOD/SCID mice were injected 
with 105 DFTD cells subcutaneously.  
The DFTD cells were given 35 days to form small tumours. This was based on 
results in Chapter four, which determined 1 to 2 mm DFTD tumours would be 
established in most mice that received 105 DFTD cells by this time point. On day 35, 
six mice commenced a series of 21 treatments over 26 days with afatinib (293 
µg/mouse) concealed in peanut butter. This was equivalent to 12.5 mg/kg per dose 
of afatinib, which was the recommendation from the Sanger Research Institute 
(Elizabeth Murchison, personal communication, 2012). The drug was well tolerated 
and apparently palatable in the peanut butter despite being suspended in 10µl 
DMSO per dose. The peanut butter baits were consistently eaten by the mice and 
this monitored by housing the animals individually. Six control mice were not fed 
peanut butter or afatinib. 
Two of the treated mice had to be euthanised for ethical reasons during the trial. This 
was not related to the treatment so they were removed from the results. The last 
treatment was given 60 days after the injection of 105 DFTD cells. The day after the 
final afatinib treatment all mice were sacrificed and tumour mass determined.  
There was significant heterogeneity in tumour size particularly in the control group. 
One of the untreated controls failed to develop a tumour within the 62 days of the 
trial. Three of the six control mice had relatively small tumours ranging from 4 to 9 
mg. Two of the control mice had considerably larger tumours of 55 and 79 mg, which 
caused most of the variation in results. All four afatinib treated mice grew relatively 
small tumours ranging from 4 to 19 mg (Figure 6-1). There was no statistical 
significance between the afatinib treated and untreated groups.  
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Figure 6-1. NOD/SCID mice were injected with 10
5
 C5065 DFTD cells and 35 days later 
commenced 21 daily afatinib treatments (293 µg) over 26 days. The day after completing 
afatinib treatments tumour mass was measured at necropsy. (Horizontal bars represent mean. 
Statistical analysis involved an unpaired two-tailed t-test with 95% CI and revealed there was 
no significant difference between the treated and untreated cohorts)    
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Afatinib treatment of established tumours had not demonstrated any inhibition of 
DFTD growth compared to the controls. This may have been because the effects of 
the afatinib were overwhelmed once the tumour was established. To maximise the 
chance of detecting an in vivo response to afatinib a prophylactic trial was 
undertaken to evaluate if commencing the afatinib prior to DFTD inoculation could 
prevent DFTD establishment.   
Ten NOD/SCID mice were treated with six doses of 293 µg of afatinib concealed in 
peanut butter commencing seven days prior to inoculation with 106 DFTD cells. Ten 
control mice were fed an equivalent amount of peanut butter. The peanut butter and  
baits were consistently eaten by the mice and this monitored by housing the animals 
individually.  For a further 15 days post DFTD inoculation, the treated mice received 
daily doses of 293 µg afatinib and the controls peanut butter alone. Palpation of the 
injection site on the final day of treatment revealed three afatinib treated mice and 
one control mouse showed the first signs of tumour establishment. Periodic 
monitoring for tumours occurred over the next 18 days and the experiment was 
terminated 34 days following inoculation with DFTD cells. At this time all but one 
control mouse had palpable tumours.  
Three of the treated mice and four of the control mice had to be euthanised for 
ethical reasons and their results are not included as they did not complete the full 
course of treatment.  
Necropsy revealed that all treated and untreated mice developed tumours. The 
mean mass of tumours was 50 mg for untreated mice and 53 mg for afatinib treated 
mice. There was significant heterogeneity in tumour mass for both the treated and 
untreated cohorts of mice. The range for untreated mice was 8 to 74 mg and for 
afatinib treated mice 20 to 97 mg. There was no significant reduction in tumour mass 
of afatinib treated mice compared to the control mice (Figure 6-2).  
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Figure 6-2. Mice were treated with daily doses of afatinib (293 µg) for 6 of 7 days prior to 
inoculation with 10
6
 C5065 DFTD. For a further 15 days following DFTD immunisation the 
treated mice received daily doses of afatinib. Tumour mass was measured at necropsy 34 
days after DFTD inoculation. (Horizontal bars represent mean. Statistical analysis involved an 
unpaired two-tailed t-test with 95% CI and revealed there was no significant difference between 
the treated and untreated mice)     
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Despite promising in vitro results for afatinib in the drug screening trial conducted by 
the Sanger Research Institute (Elizabeth Murchison, personal communication, 2012) 
this did not translate into in vivo protection that would prevent the engraftment of 
DFTD in the NOD/SCID mice. A further trial was undertaken to evaluate if the growth 
kinetics were being impacted by afatinib treatment.  
Mice were fed peanut butter for seven days prior to and 21 days after, injection with 
106 DFTD cells. Treated mice received 293 µg of afatinib concealed in the peanut 
butter and the control mice peanut butter alone. Tumour growth was monitored from 
day 22 when three treated mice and one control mouse had tumours that could be 
detected by palpation. There was a high degree of heterogeneity in tumour growth 
that did not correlate to treatment protocol. All afatinib treated mice established 
tumours within 40 days and there was no evidence of tumour growth rate inhibition 
or reduced final tumour volume as a consequence of afatinib treatment (Figure 6-3).  
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Figure 6-3. Growth kinetics for mice fed with 293 µg afatinib 7 days prior and 21 days after 
being subcutaneously injected with 10
6
 C5065 DFTD cells. Treated mice shown in solid blue 
lines and untreated controls shown in dashed red lines. Afatinib did not retard tumour growth 
or prevent establishment of DFTD xenograft.  
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As there was no evidence for anti-DFTD activity an in vitro analysis was performed 
to check that the afatinib had retained its activity. DFTD cells were cultured for 72 
hours and the effect of afatinib on proliferation of DFTD cells was evaluated with an 
MTT assay. Proliferation was inhibited in a dose-dependent response, with 
maximum inhibition at 1 x 10-5  M. These results showed that the afatinib was 
biologically active but that 1 x 10-5 M was required to prevent DFTD proliferation 
(Figure 6-4).   
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Figure 6-4. C5065 DFTD cells were subjected to 72 hours incubation in flat bottom 96 well 
plates with BIBW2992 at various concentrations of afatinib. (Data points represent mean of 
triplicate wells and error bars SEM)  
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6.2.2 Treatment of DFTD tumours with withaferin A  
DFTD tumours have a high expression of vimentin (Loh et al 2006a). The over-
expression of vimentin in cancer promotes faster tumour growth and metastasis. 
Withaferin A has the ability to induce vimentin disassembly (Thaiparambil et al 2011) 
and this might provide a mechanism to target DFTD cells. Consequently, a pilot 
study was undertaken to see if withaferin A treatment merited further investigation.   
Ten NOD/SCID mice were injected with 106 viable DFTD cells. On day 14 half of the 
mice commenced daily withaferin treatments (50 µg/mouse/day as an IP injection) 
five days per week. They received a total of 21 treatments with the last being given 
on day 40. The mice were sacrificed on day 41 and tumour mass determined at 
necropsy.  
Necropsy revealed that all treated and untreated mice developed tumours. The 
mean size of tumours was 33 mg for untreated mice and 64 mg for withaferin treated 
mice. There was significant heterogeneity in tumour size for both the treated and 
untreated cohorts of mice. The range for untreated mice was 4 to 61 mg and for 
withaferin treated mice 14 to 133 mg. There was no significant reduction in tumour 
mass of withaferin treated mice compared to the control mice (Figure 6-5).  
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Figure 6-5. 10 NOD/SCID mice were injected with 10
6
 C5065 DFTD cells. On day 14 five of these 
mice commenced 21 daily IP injections of 50 µg withaferin. The other five remained as 
untreated controls. On day 40 the last injection was given. Tumour mass was measured at 
necropsy 41 days after DFTD inoculation. (Horizontal bars represent mean and SEM. Statistical 
analysis involved a unpaired two-tailed t-test with 95% CI and revealed there was no 
significant difference between the treated and untreated mice)     
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6.2.3 Immunomodulation following fucoidan treatment 
Studies have shown that fucoidans can mobilise and activate immune cells as well 
as alter cytokine expressions (Kwak 2014). In chapter three it was shown that 
C57/BL6 mice generate immune responses against DFTD cells. This chapter 
evaluated if fucoidan can alter or enhance this immune response.  
Five C57BL/6 mice were conditioned with weekly IP injections of 1.25 mg Fucoidan 
(Fucus vesiculosus) for four weeks. The fucoidan was co-injected with 106 viable 
DFTD cells at the 2nd and 4th week. Five C57BL/6 control mice were injected IP with 
DFTD cells but no fucoidan at the 2nd and 4th week. The mice were sacrificed at the 
5th week and spleens harvested for in vitro assays and serum collected for antibody 
analysis.  
During necropsy splenomegaly was visibly obvious in the fucoidan treated mice and 
consequently the spleens were weighed. Figure 6-6 confirmed that IP injection of 
fucoidan significantly increased spleen mass by an average of 77% compared to the 
control mice (P <0.05, Student’s unpaired t-test). This correlated with a significant 
increase in the number of splenocytes recovered from the spleens of the fucoidan 
treated mice compared to the controls (P <0.01, Student’s unpaired t-test) (Figure 
6-6).   
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Figure 6-6. The spleens from fucoidan treated mice and untreated controls were weighed and 
the mean weight for fucoidan treated mice was 138 mg and the controls 78 mg. The 
splenocytes were recovered using histopaque separation. The cell recovery for fucoidan 
treated mice had a mean value of 8.3 x 10
7
 cells per spleen compared to the control
 
mice which 
had a mean value of 3.8 x 10
7
 cells per spleen. Horizontal bars represent mean. (Probability 
calculated by Student’s unpaired t-test * P < 0.05, ** P < 0.01)   
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Splenomegaly induced by fucoidan was due to increased cell number (Figure 6-6). 
To evaluate if the splenomegaly was the result of the expansion or migration of a 
specific population of lymphocytes the splenocytes were immunophenotyped with 
anti-mouse antibodies specific to CD8, CD4, NK cells and the activation marker 
CD69. There was no significant difference between the treated and untreated mice.  
This indicates that fucoidan treatment caused a non-specific increase in the number 
of cells and did not target a specific population. Less than 1% of the splenocytes 
expressed the T cell/NK cell activation marker CD69 and this was not significantly 
increased by fucoidan treatment but the total number of activated cells would have 
been higher in the fucoidan treated mice due to splenomegaly (Figure 6-7).  
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Figure 6-7. Splenocytes from the fucoidan treated mice and the control mice were labelled with 
anti-mouse antibodies specific to CD8, CD4, NK cells and the activation marker CD69. A one 
way ANOVA with Bonferroni’s multiple comparison test was performed revealing no 
significant difference in the population of cells obtained from the spleens of fucoidan treated 
C57/BL6 mice compared to the control C57/BL6 mice. (Horizontal bars represent mean)   
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The most sensitive indicator of immune response against DFTD cells in C57/BL6 
mice has been serum antibody levels. Consequently, DFTD specific antibody levels 
for fucoidan treated mice were evaluated to see if the immune response had been 
altered by fucoidan treatment.  
The fucoidan treated mice demonstrated increased levels of IgG antibody responses 
specific to DFTD cells compared to the control mice. The fucoidan treated mice had 
statistically significant higher levels of IgG1 compared to the untreated controls. 
Three of five fucoidan treated mice had higher levels of IgM than the five controls but 
this was not statistically significant due to the variability in the response. There was 
no significant change to the IgG2a, IgG2b or IgG3 antibody responses (Figure 6-8).   
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Figure 6-8. Serum was collected from the fucoidan treated mice and control mice at necropsy. 
Horizontal bars represents mean of five mice. A one way ANOVA with Bonferroni’s multiple 
comparison test was performed revealing a significant difference (*** P < 0.001) in the 
expression of IgG1 by the fucoidan treated C57/BL6 mice compared to the control C57/BL6 
mice. (Horizontal bars represent mean)   
  
Effect of fucoidan on antibody production 
Antibody isotype 
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Fucoidan treatment had resulted in splenomegaly, enhanced antibody levels and 
elevated cytokine production. It was uncertain if these changes to the immune 
system were pro-tumour or anti-tumour responses. Effective anti-tumour responses 
would promote cell-mediated cytotoxic responses against DFTD cells. For this 
reason, the splenocytes of the fucoidan treated and untreated mice were compared 
for their cytotoxicity against DFTD.  
Rather than observing a cytotoxic response against DFTD cells with the splenocytes 
from the control mice and the fucoidan treated mice revealed less cell death as 
splenocyte ratio increased (Figure 6-9).  
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Figure 6-9. The splenocytes from the five fucoidan treated and the untreated control mice were 
used as effector cells in an 18 hour cytotoxicity assay against CellTrace Violet labelled C5065 
DFTD cells. Propidium iodide was used to determine viability.  
An apparent inverse cytotoxicity-response was observed that was similar for both the 
fucoidan treated and control mice splenocytes. (Data points represent mean of five mice and 
triplicate technical replicates of each. Error bars represent SEM.)  
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The apparent inverse cytotoxicity-response against DFTD cells may have been due 
to the splenocytes inducing proliferation or preventing death of the DFTD cells. To 
evaluate this, the flow cytometry data were analysed as a viability assay to measure 
proliferation. The viable cells were gated and based on fluorescent intensity of 
CellTrace Violet divided cells were identified. These daughter cells were counted as 
a percentage of the viable cells and recorded as proliferation.  
Proliferation of DFTD cells was induced by even low ratios of splenocyte to DFTD 
cells. Proliferation increased in a cell dose-dependent response and was continuing 
to increase at 100:1 splenocyte to DFTD cell ratio. Splenocytes from fucoidan 
treated and untreated control mice produced the same result (Figure 6-10).     
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Figure 6-10. CellTrace Violet fluorescence levels of DFTD cells were used to identify DFTD 
cells which had divided during the 18 hours incubation period of the cytotoxicity assay. These 
daughter cells were counted as a percentage of the viable cells and recorded as proliferation. 
(Data points represent mean of five mice and triplicate technical replicates of each. Error bars 
represent SEM) 
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Fucoidan had increased the number of splenocytes but did not appear to increase 
their cytotoxicity against DFTD cells but did enhance the production of DFTD specific 
antibodies in the serum of treated mice.  Fucoidan treatment may increase the 
sensitivity to non-specific stimuli such as concanavalin A. To investigate this, 
splenocytes from fucoidan treated mice were stimulated with concanavalin A to 
induce LAK cells.    
The LAK cells produced from splenocytes of the control mice induced an apparent 
inverse cytotoxicity-response against DFTD cells consistent with inhibited 
spontaneous death and/or promotion of proliferation. In contrast, the LAK cells from 
the fucoidan treated mice produced an inverse cytotoxicity response until the 3:1 
LAK cell to DFTD cell ratio. This level of inverse cytotoxicity did not continue in a cell 
dose-dependent response and remained relatively stable. There was a highly 
significant difference between the LAK cell killing response of the fucoidan treated 
and the control mouse splenocytes at the highest effector to target cell ratios (Figure 
6-11).    
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Figure 6-11. Splenocytes from fucoidan treated and untreated mice were cultured in RPMI-10 
media supplemented with 5 µg/ml Con A to produce LAK cells. The LAK cells were then used 
as effector cells in an 18 hour cytotoxicity assay against CellTrace Violet labelled C5065 DFTD 
cells. Propidium iodide was used to determine viability.  
An apparent inverse cytotoxicity-response that increased in a cell dose-dependent manner 
was observed for LAK cells from the control mice. In contrast an apparent inverse cytotoxicity 
response that plateaued was observed from the LAK cells from fucoidan treated mice. (Data 
points represent mean of five mice and triplicate technical replicates of each. Error bars 
represent SEM. Two way ANOVA with Bonferroni post-tests were performed ** P < 0.01 and 
*** P < 0.001)  
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The splenocytes from these fucoidan treated and untreated control mice had induced 
proliferation of DFTD cells rather than cytotoxicity (Figure 6-10). The splenocytes 
had been activated into LAK cells and produced an inverse cytotoxic response 
against DFTD cells. The LAK cells from the fucoidan treated mice and the untreated 
controls responded differently. It was unknown if this was due to different abilities to 
induce proliferation in DFTD cells. The flow cytometry data were re-analysed as a 
viability assay to determine the percentage of viable cells that resulted from 
proliferation during the 18 hour incubation period.  
Proliferation of DFTD cells was induced by even low ratios of LAK cells to DFTD 
cells from both the control and fucoidan mice. Proliferation increased in a cell dose-
dependent response for the LAK cells from control mice but remained relatively level 
for the LAK cells from fucoidan treated mice. At 100:1 LAK cell to DFTD cell ratio the 
difference between the proliferation induced by the control mice and the fucoidan 
treated mice was very significant (Figure 6-12).  
Effect of LAK cells on DFTD proliferation
0:
1
3:
1
6:
1
12
:1
25
:1
50
:1
10
0:
1
0
10
20
30 **
Control
Fucoidan
Effector to target cell ratio
P
ro
lif
e
ra
ti
o
n
 (
%
)
 
Figure 6-12. LAK cells were generated from the splenocytes of fucoidan treated and untreated 
mice. The LAK cells were incubated with DFTD cells for 18 hours and DFTD cell proliferation 
was calculated.  
A significantly higher level of proliferation was observed by the LAK cells produced from 
control mice at 100:1 LAK cell to DFTD cell ratio. (Data points represent mean of five mice and 
triplicate technical replicates of each. Error bars represent SEM. Two way ANOVA with 
Bonferroni post-tests were performed ** P < 0.01 and *** P < 0.001)  
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The observation of different responses to DFTD cells by the LAK cells of the 
fucoidan treated mice to the controls indicated functional changes had been induced 
by fucoidan. To investigate this, the flow cytometry data were analysed to determine 
proliferation and cell death.    
When DFTD cells labelled with CellTrace Violet divide the fluorescence is shared 
between the daughter cells and this facilitates evaluation of cell proliferation. Scatter 
plots at 6:1 LAK  to DFTD cell ratio revealed that the DFTD cells which had divided 
were dying. This was similar for DFTD cells cultured with LAK cells from control and 
fucoidan treated mice (Figure 6-13 plots A and C). At 100:1 LAK to DFTD cell ratio 
dividing DFTD cell death occurred in the cultures containing LAK cells from fucoidan 
treated mice (Figure 6-13 plot D). In contrast, the dividing DFTD cells in the cultures 
containing LAK cells from control mice were viable (Figure 6-13 plot B).  
The balance between cytotoxicity and protection of dividing cells shifted towards 
increased cytotoxicity in LAK cells sourced from fucoidan treated mice. In contrast, 
LAK cells sourced from control mice had increasing protective effect that 
overwhelmed any cytotoxic activity as E:T ratios increased (Figure 6-13).  
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Figure 6-13. The scatter plots are representative of the typical responses observed for 
fucoidan treated and untreated mice at 6:1 and 100:1 effector to target (E:T) cell ratios.  There 
are two main intensity levels of CellTrace Violet representing cell division indicated by arrows. 
The fucoidan treated mice LAK cells have killed the dividing DFTD cells while the control mice 
LAK cells have protected the dividing DFTD cells in a E:T cell dose-response.  
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Fucoidan demonstrated an immunomodulatory effect on treated mice. This was 
evident in the splenomegaly (Figure 6-6), enhanced antibody responses (Figure 6-8). 
To further evaluate the immunomodulation effect of fucoidan the splenocytes from 
treated and untreated mice were cultured in vitro with DFTD cells and supernatant 
analysed for cytokine levels after 72 hours.  
There was some variation in the cytokine responses. Splenocyte cultures from the 
fucoidan treated mice showed elevated levels of IL-4, IL-6, IL-10 and TNF-α. There 
was no difference in IFN-γ levels. Splenocyte cultures from four of five control mice 
did not contain detectable IL-10 while one culture had relatively low levels. In 
contrast IL-10 was highly expressed by the splenocytes from the fucoidan treated 
mice.    
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Figure 6-14. Splenocytes from fucoidan treated C57/BL6 mice and control mice were incubated 
at 100:1 ratio with C5065 DFTD cells for 72 hours. A CBA TH1/ TH2/TH17 microbead cytokine kit 
was used to evaluate the cytokine levels in the culture supernatant. (Horizontal bars represent 
the mean of five mice. Statistical analysis involved a Student’s unpaired two-tailed t-test with 
95% CI. ** P < 0.01 and * P < 0.05)  
Effect of fucoidan on cytokines produced by splenocytes 
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Splenocytes from fucoidan treated mice and control mice stimulated with 
concanavalin A produced LAK cells that had significantly different activity against 
DFTD cell survival (Figure 6-12). To further evaluate the DFTD specific activity of 
these LAK cells they were cultured in vitro for 72 hours with DFTD cells and the 
supernatant was analysed for cytokine production.  
Supernatants from concanavalin A stimulated splenocytes (LAK cells) from the 
fucoidan treated mice contained significantly lower levels of IL-2, IL-4 TNF-α and 
IFN-γ than the supernatants from concanavalin A stimulated splenocytes (LAK cells) 
from the untreated mice. The other tested cytokines IL-6, IL-17a and IL-10 appeared 
to be lower but this was not statistically significant (Figure 6-15).   
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Cytokines produced following in vitro concanavalin A stimulation  
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Figure 6-15. Splenocytes from fucoidan treated C57/BL6 mice and control mice were incubated 
for 48 hours in RPMI-10 medium supplemented with 5 µg/ml Con A. These splenocytes were 
then incubated at 100:1 ratio with C5065 DFTD cells for 72 hours. A CBA TH1/ TH2/TH17 
microbead cytokine kit was used to evaluate the cytokine levels in the culture supernatant. 
(Horizontal bars represent mean of five mice. Statistical analysis involved a Student’s unpaired 
two-tailed t-test with 95% CI. ** P < 0.01 and * P < 0.05)  
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6.2.4 Intratumoural injections of imiquimod 
Imiquimod had been shown to induce upregulation of MHC class I expression of 
DFTD cells when added to the culture medium (Patchett 2013). The ability to 
upregulate MHC class I expression in vivo would be an important step towards 
inducing immune responses by Tasmanian devils against DFTD cells. To test if 
direct intratumoural injections of imiquimod could upregulate MHC class I expression 
of DFTD tumour cells in situ, six NOD/SCID mice were engrafted with DFTD 
tumours. When the tumours had grown to a size that was clearly visible, five of the 
mice received 100 µg of imiquimod in 100 µl daily intratumoural injections for three 
days. One mouse was the untreated control. One day after the third imiquimod 
injection the tumours were harvested and disassociated into single cell suspension. 
The cells were then labelled with serum collected from a Tasmanian devil (Missy 
serum # 11-4-12) which reacts against IFN-γ treated cultured DFTD cells but not un-
treated cultured cells. It has been presumed that the serum binds to MHC class I but 
this is not verified. There was no monoclonal antibody for surface MHC class I on 
Tasmanian devil cells at this point of time so the serum from Missy was the best 
available indicator of upregulation of MHC class I.  
As shown in Figure 6-16 nearly 100% of the cells obtained from the tumours treated 
with imiquimod labelled positive with Missy serum. In comparison the untreated 
tumour had bi-modal labelling with Missy serum and approximately 50% of the cells 
obtained from the untreated tumour labelled positive.  
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Figure 6-16. DFTD tumour cells were labelled with serum from a Tasmanian devil that 
contained antibodies specific for IFN-γ treated DFTD cells. DFTD xenograft cells obtained from 
the untreated mouse (shown in blue) demonstrated bi-modal labelling with Missy serum # 11-
4-12. DFTD xenograft cells obtained from the five imiquimod treated mice (shown in red) had 
nearly 100% of the cells label positive.   
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When an antibody specific for Tasmanian devil β2-microglobulin became available, 
four NOD/SCID mice were engrafted with DFTD tumours. When the tumours had 
grown to a size that was clearly visible, two of the mice received 100 µg of imiquimod 
in 100 µl daily intratumoural injections for three days. The other two mice remained 
untreated. The day after the third imiquimod injection the tumours were harvested 
and disassociated into single cell suspension.  
Tumours that were treated with imiquimod had an increased expression of β2-
microglobulin compared to the untreated tumours. This is consistent with the results 
of the previous paragraph using devil serum which reacts against IFN-γ treated 
DFTD cells. These results provide evidence that imiquimod upregulates MHC 
because β2-microglobulin is transported to the surface of cells as part of the MHC 
molecule (Figure 6-17 panel A). Missy’s serum 11-4-12 differentiated between the 
imiquimod treated and untreated tumours which is consistent with the premise that 
MHC+ DFTD are targeted by this serum (Figure 6-17 panel B).  
 
   
 
Figure 6-17. Murine DFTD tumour cells were labelled with Missy’s serum or anti-β2-
microglobulin. Cells obtained from the untreated mice (shown in black or grey) had low 
fluorescence intensity. Cells obtained from the two imiquimod treated mice (shown in blue or 
red) showed a positive shift in fluorescence levels for both Missy’s serum and anti-β2-
microglobulin.  
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6.3 Discussion 
A major impediment to developing an effective vaccine or immunotherapy against 
DFTD is the lack of access to Tasmanian devils for clinical trials. Any 
immunotherapy trial should be conducted in the host species but since this is not 
always possible we developed an informative mouse model. This will allow us to 
undertake preliminary studies to evaluate treatment options that could be applied to 
the Tasmanian devil. 
In this chapter, four treatments were evaluated for their efficacy against DFTD. Two 
of these were chemotherapy drugs that targeted specific pathways within the DFTD 
cells. The other two were compounds that modulated the immune response of the 
host. One of these, imiquimod, also had a direct effect on the DFTD cells.  
6.3.1 Afatinib  
It was unknown if the anti-DFTD activity of afatinib observed in vitro by the Sanger 
Research Institute (Elizabeth Murchison, personal communication, 2012) would 
translate to protection against DFTD in vivo. To evaluate the efficacy of afatinib in 
vivo, NOD/SCID mice were fed daily with afatinib concealed in peanut butter. This 
was to represent the use of meat baits that was envisioned for Tasmanian devils in 
the wild if afatinib was effective. This was an efficient drug delivery method for the 
mice as they preferentially consumed the peanut butter over their normal diet.  
In the first afatinib trial, DFTD cells were given sufficient time to establish as small 
tumours before afatinib treatment commenced. This represented the effect of afatinib 
consumed by diseased Tasmanian devils in the wild. The day after the last dose the 
treated and untreated mice were sacrificed and tumour growth determined at 
necropsy. There was no evidence of any inhibition of DFTD growth in vivo as a result 
of afatinib treatment.  
In the second afatinib trial, prophylactic therapy was assessed that represented what 
would occur in the wild if a healthy Tasmanian devil consumed afatinib baits prior to 
disease exposure. Afatinib treatment was commenced 7 days prior to DFTD 
inoculation and continued for a further 15 days afterwards. When the mice were 
examined at necropsy there was no evidence of any protection against DFTD 
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engraftment or inhibition of DFTD growth as a result of afatinib prophylactic 
treatment.  
The third afatinib trial evaluated if the growth kinetics of DFTD were altered by 
afatinib treatment. Mice were fed afatinib 7 days prior to and 21 days after, injection 
with DFTD cells. Afatinib treatment had no effect on DFTD establishment or rate of 
growth.  
A fourth afatinib experiment was undertaken in vitro. This confirmed the afatinib used 
in our in vivo trials had a comparable level of biological activity as that used by the 
Sanger Research Institute. To determine the concentration of afatinib required to 
completely prevent DFTD proliferation our in vitro experiment extended the upper 
range of afatinib concentration beyond that tested by the Sanger Institute (Elizabeth 
Murchison, personal communication, 2012). It required fiftyfold increase in afatinib 
compared to the highest levels tested at the Sanger Research Institute to stop 
proliferation.   
The promising in vitro results did not translate in vivo. Both as a prophylactic 
treatment and as a treatment against established DFTD tumours afatinib did not 
protect the NOD/SCID mice or cause regression of the tumours. Possible 
explanations could be the mode of drug delivery, dosage, or the in vivo environment 
itself. 
If Afatinib proved to be protective against DFTD the intention was to lace baits of 
meat with the drug for distribution in the wild since the drug can be taken orally. This 
approach has a long history of being used successfully to deliver vaccines, drugs 
and poisons to free roaming wild populations of carnivores (Knobel 2001, Linhart et 
al 1993). In Australia, aerial distribution of strychnine baits were used in the 1940’S 
to control predators of livestock (Linhart et al 1993). Currently 1080 predator-baiting 
is practised in Australia to protect native fauna from introduced species such as the 
red fox (Vulpes vulpes) (Kinnear et al 2010).  
Placing afatinib concealed in food is not recommended by the manufacturer who 
advises a fasting period of 3 hours before and one hour after taking afatinib 
(Boehringer Ingelheim International 2014). In human trials the consumption of 
afatinib with high fat food decreases exposure to the drug between 39 and 50% 
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(Boehringer Ingelheim International 2014). Since food baits would be the only 
practical option for Tasmanian devils the use of food baits for the mouse trial was 
valid despite reducing efficiency of drug delivery.  
Even if 50% of the drug was unavailable because of the high fat content, the dose 
given to the mice based on the animal’s weight was 10 to 20 times the dose 
recommended by the manufacturer for human trials. (Boehringer Ingelheim 
International 2014, Yap et al 2010). The dose of 12.5 mg/kg per day of afatinib was 
recommended by the Sanger Research Institute (Elizabeth Murchison, personal 
communication, 2012). 
The lack of in vivo response to afatinib may be due to the in vivo environment itself. 
Responders to afatinib in human trials tend to relapse after developing resistance 
(Nanjo et al 2013). This resistance can be due to tumour heterogeneity or 
hepatocyte growth factor (HGF) (Nanjo et al 2013). HGF can be over expressed by 
tumours as an autocrine resistance mechanism (Nanjo et al 2013). Another 
significant source of HGF can be the stromal fibroblasts that change the tumour 
microenvironment in a paracrine fashion (Nanjo et al 2013). If DFTD cells were the 
source of HGF then resistance to afatinib in the in vitro setting would have been 
observed. The observation of afatinib activity against DFTD cells in vitro but not in 
vivo could be explained by HGF. Resistance to HGF can be overcome by combining 
afatinib treatment with 10 mg/kg crizotinib. This is a toxic therapy that causes severe 
intestinal mucosal damage and can be lethal if the dosage is not carefully monitored 
(Nanjo et al 2013). Although combined afatinib and crizotinib therapy may prove 
effective against DFTD, it could be too toxic to distribute by baits in the wild.  
Afatinib is not a treatment that warrants further in vivo trials. Monotherapy with 
afatinib has shown minimal benefits in human clinical trials with severe adverse 
effects (Nanjo et al 2013). There may be value in studying the effects of afatinib on 
DFTD cells in vitro to further our knowledge about the functional pathways and 
mechanisms in DFTD cells.   
  
 6-32 
 
6.3.2 Withaferin A 
Withaferin A is associated with fewer side effects and lower toxicity compared to 
afatinib (Yang et al 2012). Of the many anti-cancer mechanisms of withaferin A, the 
one pertinent to this work was the ability of withaferin A to disassemble vimentin 
(Thaiparambil et al 2011, Yang et al 2012). DFTD cells express high levels of 
vimentin (Loh et al 2006a, Tovar 2012). Many studies have revealed regulatory 
functions of vimentin in cancers that promote cell migration, enhanced invasive 
capacity and stimulate proliferation (Satelli and Li 2011). Therefore, over-expression 
of vimentin indicates an aggressive cancer associated with metastatic disease and 
poor prognosis (Yang et al 2012). As well, secreted vimentin can protect tumours by 
neutralising NK cell activity through blocking the NKp46 receptors (Satelli and Li 
2011). 
Despite DFTD cells expressing vimentin and the promising human trials, withaferin A 
did not appear to have any effect on DFTD cells in NOD/SCID mice. All mice 
developed tumours, growth rates were the same and there was no reduction in the 
size of established tumours. There are several possibilities for this result. It may be 
due to the dose and number of fractions of withaferin A. The withaferin A dose in this 
study approached the maximum tolerated dose but was divided into 21 fractions.  
Excessive levels of withaferin A can be toxic and the toxic effect of withaferin A is 
cumulative while the tumour killing effect is not (Kamath et al 1999, Sharada et al 
1996).Tumour cells may be able to tolerate, or recover from, low levels of withaferin 
A whereas high acute levels of withaferin A may be required for anti-tumour activity 
(Kamath et al 1999, Sharada et al 1996). Investigations by other researchers have 
revealed that three daily doses of 30 mg/kg or two daily doses of 40 mg/kg is the 
maximum tolerated dose of withaferin A. This may be more effective than a similar 
dose divided in more fractions (Kamath et al 1999, Sharada et al 1996).  
This pilot study was conducted in NOD/SCID mice with the aim of determining if 
withaferin A had anti-DFTD activity in vivo. In vitro studies could guide the choice of 
concentration but the dose rates in vivo can only be determined in vivo. Due to the 
long-term nature of this study, time did not permit further in vivo studies. Such 
studies would have included two or three intraperitoneal injections with higher doses. 
Established tumours could be directly injected with withaferin A to determine if 
intratumoural injections target DFTD cells more efficiently than systemic treatment.   
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6.3.3 Fucoidan 
Fucoidan treatment resulted in splenomegaly due to an overall increase in cell 
numbers. Analysis of the T cell/NK cell activation marker CD69 did not provide any 
evidence for an increase in the activation of these cells. As it is unlikely that 
proliferation caused the splenomegaly, mobilisation of cells to the spleen may have 
occurred. The significant increase in DFTD-specific IgG1 antibody in the serum of 
fucoidan treated mice implicates B cell activation with CD4 helper T cell mediated 
isotype switching.  
Fucoidan has been shown to be an immunomodulatory compound that modulates 
the ratio of TH1:TH2 immune responses towards TH1 profiles (Kar et al 2011). 
However, in this study fucoidan polarised the immune response against DFTD cells 
towards a TH2 response. This was evident in the significantly high level of IgG1 in 
the serum of fucoidan treated mice that were challenged with DFTD cells compared 
to mice challenged with DFTD cells only. Splenocytes from the fucoidan treated mice 
produced very high levels of IL-10 (TH2 cytokine) and elevated levels of IL-6 when 
cultured with DFTD cells in vitro. This is explains the IgG1expression observed in the 
mice since IL-6 and IL-10 promote the switch to the IgG1 isotype by B cells. Such 
TH2 responses are very effective against bacterial infections but less so against 
cancers which are better targeted by TH1 responses. 
Fucoidan treatment of mice did not increase cytotoxic activity by their splenocytes 
against DFTD cells. What was observed was an apparent inverse cytotoxicity-
response curve by both the treated and untreated mouse splenocytes. This indicated 
that the splenocytes, rather than being cytotoxic, were protecting DFTD cells from 
spontaneous cell death or promoting proliferation of DFTD cells. This function was 
not altered by fucoidan treatment. 
However, fucoidan treatment did alter function of splenocytes stimulated by 
concanavalin A into LAK cells. Concanavalin A stimulation of splenocytes from 
fucoidan treated mice resulted in different effects on DFTD cell survival in vitro and 
different cytokine production when cultured with DFTD cells. LAK cells from the 
fucoidan treated mice killed dividing cells preventing proliferation. The LAK cells from 
the control mice did not kill dividing cells promoting proliferation.   
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Further evidence that fucoidan treatment transformed the potential of splenocytes to 
react to concanavalin A stimulation was evident in the cytokines detected in 
supernatant when these LAK cells where cultured in vitro with DFTD cells. The 
supernatants from control mice sourced LAK cells had significantly higher levels of 
IFN-γ, IL-2 and TNF-α compared to the supernatants from LAK cells sourced from 
fucoidan treated mice. Supernatants from fucoidan treated mice had barely 
detectable levels of IFN-γ and significantly lower levels of IL-2 and TNF-α. This 
suggests that the cytokines were either being produced at lower levels or were being 
consumed at higher levels.  
These cytokine results are perplexing because they appear to contradict the 
increased cytotoxicity of dividing DFTD cells by LAK cells sourced from fucoidan 
treated mice. LAK cells secrete IFN-γ and TNF-α when stimulated with tumour cells 
(Naganuma et al 1996) yet the fucoidan LAK cells did not appear to produce IFN-γ 
and had lower levels of TNF compared to the LAK cells from the control mice. One 
possible explanation could be that the fucoidan LAK cells promoted expression of 
suppressive cytokines such as TGF-β which inhibits secretion of IFN-γ and TNF-α. 
This TGF-β could be produced by the LAK cells themselves as a negative feedback 
mechanism or certain tumours are known to express TGF-β to promote survival 
(Naganuma et al 1996). TGF-β was not included in the cytokine profile in this pilot 
study but should be included in any further studies. The cytokines could also have 
been consumed within the culture and may reflect greater activation. 
The conclusions that can be drawn from these experiments are that fucoidan is a 
potent immunomodulating agent. However there was no evidence that it promoted 
anti-DFTD responses that were worth further investigation. Fucoidan has been 
described as an immunomodulatory compound that induces TH1 cytokines including 
IFN-γ while suppressing TH2 cytokines like IL-10 (Kar et al 2011). In these 
experiments fucoidan had no influence on IFN-γ levels and in stark contrast to the 
observation by Kar et al. (2011) it induced IL-10 production to very significant levels. 
Fucoidan treatment of DFTD inoculated mice resulted in a TH2 polarisation of 
immune response to DFTD cells. This was evident in the induction of TH2 cytokines 
such as IL-10 and IL-6 and the isotype switching to the TH2 antibody IgG1. This 
switching of immune response by fucoidan towards a TH2 response appears to be 
DFTD specific but it is a compound worthy of further study by immunologists.   
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6.3.1 Imiquimod 
One of the main mechanisms exploited by DFTD cells to avoid detection and 
subsequent destruction following transmission is the absence of MHC class I 
molecules on the surface of the cells (Siddle et al 2013). This is due to 
downregulation of genes responsible for the antigen processing pathway. These 
include β2-microglobulin, TAP1, TAP2, CIITA, DMB as well as Class II B and A 
(Siddle et al 2013). 
Importantly this downregulation is not due to structural mutations but rather to 
epigenetic mechanisms that can be reversed. These genes can be turned back on 
by stimulating DFTD cells in vitro with IFN-γ (Siddle et al 2013). Stimulation with 
imiquimod also induces the upregulation of surface MHC class I in vitro (Patchett 
2013). This led to the hypothesis that intratumoural injections of imiquimod could be 
used to upregulate surface MHC class I within established DFTD tumours in vivo. If 
this hypothesis proved true then it was envisioned that successful immunotherapy 
could be developed based on intratumoural injections of imiquimod to make the 
DFTD tumour visible to the host’s immune system.  
To test this hypothesis, DFTD tumours in NOD/SCID mice were treated with 
imiquimod.  This resulted in the upregulation of MHC on the cell surface indicated by 
the detection of β2-microglobulin. Imiquimod has the capacity to upregulate the 
genes required for DFTD cells to express MHC. The NOD/SCID mouse model 
provided the proof of concept that this could be achieved in vivo through 
intratumoural injections.  
Canine Transmissible Venereal Tumor is the only other known naturally occurring 
infectious cancer and provides the exemplar for the importance of MHC in tumour 
regression.  Transmission between dogs is facilitated by downregulation of MHC and 
disease resolution occurs following naturally occurring upregulation of MHC 
expression in the new host leading to lifelong immunity (Das and Das 2000, Hsiao et 
al 2008).  
By expressing MHC the DFTD cells should be killed by the immune system 
preventing development of DFTD tumours and curing established disease. This 
would contribute towards development of a vaccine to protect healthy Tasmanian 
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devils. It is also the most promising option to date to treat DFTD in diseased devils. 
However, the NOD/SCID mice lack the appropriate immune system components to 
determine if this immunotherapy would ultimately achieve tumour regression and 
lifelong immunity. This work needs to progress to Tasmanian devils and the mouse 
model will provide the opportunity to optimise the treatment protocol before this 
occurs.  
In addition to upregulation of MHC class I there are other anti-tumour properties of 
imiquimod that are relevant to induce an immune response against DFTD. 
Imiquimod directly induces tumour selective apoptosis independent of membrane-
bound death receptors (Schön et al 2003). This should result in enhanced 
presentation to the immune system of DFTD antigens via phagocytes. It also 
promotes production of cytokines through agonistic stimulation of TLR7 in immune 
cells that mediate cellular immune responses (Broomfield et al 2009, Schön et al 
2003).  
The results of this chapter also provided evidence that the antibodies produced by a 
Tasmanian devil following immunisation with IFN-γ treated DFTD cells targeted MHC 
molecules or other surface antigens associated with the upregulation of MHC by 
IFN-γ. This is important knowledge for the team working on a vaccine against DFTD. 
It reveals that upregulation of MHC makes the cells immunogenic. The Tasmanian 
devils immune system can target the DFTD cells and may become educated to 
tumour associated antigens that are unique or overexpressed on naturally occurring 
DFTD cells.   
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7 Final discussion 
The Tasmanian devil is being driven to extinction by Devil Facial Tumour Disease. 
DFTD is a malignant tumour cell line transmitted as an allograft through social 
interaction, especially biting, when devils squabble over food, sex and territory 
(Obendorf and McGlashan 2008). The most devastating aspects of the disease are 
that it has proven 100% fatal, is readily transmitted between Tasmanian devils and 
there is no evidence of immune or resistant Tasmanian devils in the wild (Belov 
2012, McCallum and Jones 2006). To overcome the difficulty of working with an 
endangered species, this project developed an informative mouse model to study 
DFTD.  
At the commencement of this thesis in 2010 it was assumed that MHC was 
expressed by DFTD cells and therefore how DFTD was transmissible was a matter 
of conjecture (Siddle et al 2007). Two possibilities were that the DFTD cells had 
unique features which prevented them from being immunogenic or that, as a 
consequence of substantial chromosome alterations (Pearse and Swift 2006), the 
cells could not be killed because the apoptotic pathway had been disrupted. The 
mouse model and associated work from this thesis discounted both of these 
possibilities. Firstly, apoptosis of DFTD cells was detected in vitro following exposure 
to camptothecin or UV radiation revealing the cells had competent apoptotic 
pathways. Secondly, the work in chapters three and four revealed that DFTD cells 
induce an immune response. Initially this was demonstrated through mice rejecting 
the DFTD cells through xenogeneic mechanisms. Immune competent mice produced 
DFTD specific antibodies and rejected tumours while immunocompromised mice did 
not. Protection could be transferred from immune competent BALB/c mice to 
immunocompromised NOD/SCID mice by adoptive transfer of splenocytes.  
The demonstration that DFTD cells were immunogenic in mice did not explain why 
the cells were not targeted by the Tasmanian devil’s immune system. The thrust of 
the research at this point of time into DFTD was testing the widely accepted 
hypothesis that transmission was facilitated by limited MHC diversity within the 
Tasmanian devil population causing DFTD cells to be perceived as self (Siddle et al 
2007). This hypothesis was based on the fact that MHC was expressed at the mRNA 
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level (Belov 2012, Siddle et al 2007).  In 2012 this was still cited by experts in the 
field of DFTD (Belov 2012). By late 2012, newly developed antibodies revealed that 
MHC and β2-microglobulin were not present on the DFTD cell surface and this 
hypothesis lost credibility (Siddle et al 2013). Genes essential to the antigen-
processing pathway, including β2-microglobulin and TAP genes associated with 
antigen presentation were shown to be epigenetically downregulated resulting in the 
failure of functional MHC class I molecules being transported to the cell surface 
(Siddle et al 2013).  
The lack of MHC expression on the cell surface provides the best explanation to date 
for how DFTD cells avoid allogeneic recognition. This mechanism is also exploited 
by the other naturally occurring transmissible tumour, CTVT (Chiang et al 2013).The 
lack of MHC class I makes the cells invisible to the new host’s immune system and 
prevents them being targeted by CD8+ T cells (Das and Das 2000, Siddle et al 
2013). The absence of MHC class I should make the cells targets for NK cells. CTVT 
cells maintain very low levels of MHC expression to resist NK cell killing (Das and 
Das 2000). It is possible that DFTD cells also express low levels of MHC but the lack 
of suitable antibodies against surface epitopes for MHC hinders investigations of this 
question.  
The work in chapter five provided evidence that DFTD cells are NK cell resistant as 
there was no spontaneous killing of DFTD cells by Tasmanian devil lymphocytes, 
despite evidence of functional NK cells (Brown et al 2011). Further evidence of NK 
resistance comes from studies of xenograft rejection in chapter four. Splenocytes 
from DFTD immunised BALB/c mice but not splenocytes from naïve mice always 
protected NOD/SCID mice from DFTD tumour cells. This provided evidence for a 
primed adaptive immune response. Furthermore, the use of genetically modified 
mice including athymic CBA/nu mice, which have functional NK cells, indicated that 
NK cells alone did not protect against DFTD cells. Even though priming is necessary 
it could be possible that activated NK cells kill or antibodies generated by primed B 
cells facilitate ADCC killing by NK cells but spontaneous NK killing is not occurring.  
NK-resistance in human cancers can be overcome by harvesting a patient’s 
lymphocytes and activating them in vitro to generate lymphokine activated killer 
(LAK) cells. These LAK cells are then reintroduced into the patient and have the 
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capacity to kill NK-resistant tumour cells while leaving healthy cells unharmed (Linn 
and Hui 2010, Richards 1989). The mitogen concanavalin A or the supernatant from 
concanavalin A stimulated lymphocytes (Con A sup) activated Tasmanian devil 
lymphocytes into LAK cells capable of killing DFTD cells in vitro (Brown 2013). 
Before proceeding to trials on Tasmanian devils it was necessary to demonstrate in 
vivo efficacy in mice to collect more information about the dynamics of LAK killing.   
This model was established in chapter five when it was initially shown that 
NOD/SCID mice can accept Tasmanian devil lymphocytes without graft versus host 
or host versus graft rejection. LAK cells were generated in vitro using concanavalin A 
or Con A sup stimulation. When they were co-injected with DFTD cells it provided an 
in vivo setting to study tumour rejection. Depending on the ratio of LAK cells to DFTD 
cells, protection for the NOD/SCID mice ranged from reduced tumour formation to 
complete protection. Notably this demonstrated allograft killing by Tasmanian devil 
lymphocytes in vivo without risking DFTD infection of healthy Tasmanian devils. 
The key findings from these experiments provided further support that the 
Tasmanian devil has a competent immune system capable of killing DFTD cells. This 
presumably required tolerance to DFTD being surmounted. LAK cells overcome this 
tolerance and target DFTD cells in vitro and in vivo. This would be achieved because 
LAK cells are activated NK cells with increased expression of receptors to promote 
cytotoxicity including TRAIL, NKG2D and the natural cytotoxicity receptors NKp30, 
NKp44 and NKp46 (Childs and Berg 2013). Normal cells are not targeted by LAK 
cells because they express MHC that inhibits NK activity (Linn and Hui 2010, 
Richards 1989). This work provides evidence that the immune system of Tasmanian 
devils can eliminate DFTD and that a vaccine or immunotherapy against DFTD in 
Tasmanian devils is achievable.   
The ability to generate LAK cells from Tasmanian devil lymphocytes provides insight 
into the composition of their immune system. Lack of appropriate antibodies hinders 
investigations into the Tasmanian devil’s immune system and functional analysis is 
often used to envisage what is occurring in their immune system. Recent evidence 
has indicated Tasmanian devils have cells that function like NK cells (Brown 2013, 
Brown et al 2011) but a lack of appropriate antibodies has prevented their isolation. 
NK cells on their own are not activated by concanavalin A  and stimulation of LAK 
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cells in humans requires concanavalin A binding to NKT cells which then express 
IFN-γ leading to activation of NK cells (Kaneko et al 2000, Miyagi et al 2004, 
Palacios 1982). The observation that concanavalin A stimulates Tasmanian devil 
lymphocytes into LAK cells indicates that Tasmanian devils not only have NK cells 
but also NKT cells. Consequently, this work provides supporting evidence for NK 
cells in Tasmanian devils. The presence of functional NKT cells is also suggested, 
but requires confirmation. This contributes to an expansion of our knowledge of the 
Tasmanian devil immune system.  
The existence of NKT cells in the Tasmanian devil increases potential 
immunotherapy approaches to trial against DFTD. NKT cells make potent targets for 
immunotherapy because they have a significant role in promoting anti-tumour 
responses (Bassiri et al 2014). The NKT cells directly kill some tumours but they also 
have an indirect effect by producing IFN-α, IL-4, IL-13, IL-17, TNF-α and GM-CSF 
which in turn activates DCs, NK cells, CD8+ T cells and induces enhanced Ig 
production by B cells (Bassiri et al 2014, O’Konek et al 2012). 
A thorough investigation of Tasmanian devil LAK cell activity at this point in time is 
not possible due to lack of suitable antibodies. However, knowledge from mouse and 
human studies suggest a conserved mode of function in LAK cell activity between 
species (Rosenberg et al 1986). This knowledge provides insight into how LAK cell 
therapy could be beneficial to developing immunotherapy against DFTD. The 
possible chain of events for LAK cells activation and function follows. The LAK cells 
that are generated by the NKT cells directly kill NK-resistant tumours while 
generating IFN-γ in the tumour microenvironment (Diefenbach et al 2000). The IFN-γ 
then upregulates β2-microglobulin and MHC class I in tumours with downregulated 
MHC (De Fries and Golub 1988, Siddle et al 2013). The newly expressed MHC then 
makes the tumours vulnerable to direct CTL killing (De Fries and Golub 1988). The 
LAK cells amplify the CTL response by lysing M2 macrophages that promote 
tolerance and activate M1 macrophages which present tumour antigens to CD8+ T 
cells to generate CTLs (Geldhof et al 2002). These functions have been observed in 
mice and humans and if they also were to occur in Tasmanian devils these may 
provide lifelong immunity.  
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The limitation of the NOD/SCID mouse for LAK cell trials is restricted to evaluation of 
direct LAK cell killing activity. The generation of CTLs and editing of macrophages 
cannot be evaluated in NOD/SCID mice because they lack an immune system to 
work in synergy with the LAK cells. However, the mouse model has been invaluable 
in providing the first evidence of in vivo activity of Tasmanian devil LAK cells.  
The mouse model provides the intermediate step between identifying agents in vitro 
and testing them with the Tasmanian devil. Studies in vitro can be used to screen a 
range of agents that have the potential to target DFTD. But to obtain more complete 
understanding studies need to be undertaken in vivo. The in vitro cultures test the 
therapeutic agent on DFTD cells in isolation. This is not the same as the in vivo 
tumour microenvironment which provides a complex multi-cellular niche, ongoing 
nutrients and the production of cytokines and growth factors which influence tumour 
survival. In this thesis the mouse model was used to test afatinib, withaferin A, 
fucoidan and imiquimod.  
Afatinib promotes apoptosis and inhibits proliferation in some cancers (Yap et al 
2010) and when tested in vitro against DFTD cells was shown to inhibit proliferation. 
Because afatinib directly targets tumour cells and does not require involvement of an 
immune system, NOD/SCID mice engrafted with DFTD tumours provided a suitable 
in vivo setting to further evaluate the function of afatinib against DFTD cells. Despite 
anti-DFTD activity by afatinib in vitro this did not translate in vivo. At the dose used 
there was no evidence of prophylactic protection, regression of established DFTD 
tumours or altered DFTD growth kinetics. Possible explanations for the lack of 
protection include mode of delivery, dosage, bioavailability or the in vivo environment 
itself. The mouse model could be used further to determine dosage, alternative 
administration route or combined therapies to provide effective afatinib based 
treatment. The lack of protection in the mouse model and the foreseeable difficulties 
of treating a wild population with such an agent meant there was no immediate 
justification to proceed to trials on Tasmanian devils. The mouse model provided the 
preliminary data prior to any potential trial with Tasmanian devils and thus avoided 
using Tasmanian devils prior to determining efficacy in vivo.  
Withaferin A is another therapeutic agent that was evaluated using the NOD/SCID 
mouse model to provide preliminary data to inform potential treatment of Tasmanian 
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devils. Withaferin A is a plant extract known to target cancer cells over-expressing 
vimentin (Thaiparambil et al 2011). DFTD cells over-express vimentin which 
promotes aggressive tumour growth and metastatic disease. A pilot study did not 
provide evidence for prophylactic protection or inhibition of DFTD by withaferin A at 
the given dose. The mouse model will be used to determine effective dose and dose 
fractions before any treatment proceeds to Tasmanian devils. If efficacy is not 
demonstrated in mice then Tasmanian devils will be spared unnecessary trials.  
Immunocompetent C57/BL6 mice were used to evaluate the immunomodulating 
activity of fucoidan, a seaweed extract, on mice injected with DFTD cells. Fucoidan 
was shown to be a potent immunomodulating agent that altered both cytokine and 
antibody production. Fucoidan polarised the murine response to a TH2 response 
against DFTD and did not enhance cytotoxicity. While showing no particular promise 
against DFTD these results add to the evidence that fucoidan alters the immune 
system and may be beneficial in other disease states.  
DFTD tumour cells avoid immune recognition because they do not express MHC. 
Consequently upregulation of MHC should overcome this failure of recognition as 
demonstrated with CTVT. When CTVT cells are transplanted in the experimental 
setting, within weeks CTVT progresses to a stage that triggers epigenetic 
upregulation of MHC on the surface of the cells (Das and Das 2000, Hsiao et al 
2008). This makes the cells visible to the host’s immune system resulting in tumour 
regression and lifelong immunity (Belov 2012). Consequently, the new knowledge 
that DFTD transmission and avoidance of immunosurveillance is facilitated by 
epigenetic downregulation of MHC directed researchers attention towards exploring 
means of inducing MHC expression in DFTD cells (Siddle et al 2013).  
Research focused on the idea of upregulating MHC in DFTD cells in vitro. This was 
achieved through stimulation with recombinant devil IFN-γ (Siddle et al 2013). The 
expectation of researchers included that DFTD cells expressing MHC may provide 
the starting point for an effective vaccine against DFTD (Siddle et al 2013). As well, 
DFTD cells expressing MHC may provide a means of immunotherapy. This could be 
achieved by injecting existing tumours with MHC+ DFTD cells that would attract 
immune cells to the tumour site and induce the production of IFN-γ. This IFN-γ would 
stimulate wild-type DFTD cells to express MHC molecules (Siddle et al 2013) and in 
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turn this could lead to a cascade of responses that would educate the immune 
system to DFTD specific antigens and promote regression and lifelong immunity.  
As a safeguard these MHC+ cells would require inactivation before use as a vaccine 
for Tasmanian devils or immunotherapy for diseased Tasmanian devils. The mouse 
model provided insight into the best means of inactivating DFTD cells without 
reducing their immunogenicity. As shown in chapter three, irradiation of DFTD cells 
was preferable to freeze-thawing or sonicating DFTD cells. Irradiation maintained the 
integrity of the cells and the surface antigens while preventing their proliferation.   
The mouse studies in chapter three revealed a primary intraperitoneal immunisation 
with a second intraperitoneal immunisation two weeks later produced the highest 
antibody responses. The subcutaneous route is favoured in Tasmanian devils to 
mimic infection route but this may not induce the most beneficial immune response 
and may not be appropriate for the development of a vaccine. The prime-boost 
intraperitoneal immunisation protocol could boost antibody responses in Tasmanian 
devils enhancing the efficacy of the treatment.   
An alternative means to induce upregulation of MHC class I on DFTD cells could 
involve intratumoural injections of a therapeutic agent. One such agent, imiquimod, 
when tested in vitro against DFTD cells appeared to alter gene expression of DFTD 
cells resulting in upregulation of β2-microglobulin and MHC class I (Patchett 2013). 
The NOD/SCID and athymic nude mouse models were used in chapter six to test the 
ability of imiquimod in vivo to upregulate β2-microglobulin and MHC. Imiquimod 
injected directly into established DFTD tumours in mice upregulated expression of 
MHC and β2-microglobulin. It is reasonable to assume that the same outcome would 
occur if the protocol was repeated in diseased Tasmanian devils. Considering the 
role of MHC in CTVT this would make DFTD cells visible to the Tasmanian devil’s 
immune system (Belov 2012). Furthermore, if DFTD followed the same path as 
CTVT (Murchison 2008) then lifelong immunity would be predicted.  
Potentially there are many more anti-tumour activities of imiquimod that would be 
relevant to DFTD. Imiquimod is a synthetic imidazoquinoline that targets TLR7 and 
induces innate and adaptive immunity, selectively induces apoptosis in tumour cells 
and  counteracts immunosuppression in the tumour microenvironment by inducing 
pro-inflammatory cytokines such as IFN-γ,TNF-α, IL-12 and macrophage 
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inflammatory protein (MIP)-1 (Clark et al 2008, Gorden et al 2005, Schön et al 2003, 
Wolf et al 2007). Evaluation of imiquimod’s immunomodulatory functions will require 
trials in Tasmanian devils since the NOD/SCID and athymic nude mice lack 
appropriate immune system capabilities.  
Imiquimod is a drug already approved and widely used for topical application against 
various human skin cancers (Adams 2009). Oral administration to provide systemic 
treatment has proven ineffective in human trials (Witt et al 1993) and there is a 
paucity of published accounts where imiquimod was administered via intratumoural 
injections. This thesis extended the use of imiquimod to a novel veterinary 
application and administration by intratumoural injection. The use of intratumoural 
injections against DFTD would be of great interest to the treatment of many human 
and veterinary cancers if it is shown to be effective.  
There are other potential applications for imiquimod that could be evaluated using 
immunocompetent mice. Imiquimod also has potential to be used as an adjuvant in 
vaccines to promote CD8+ T cell responses (Shackleton et al 2004). This could 
initially be evaluated by immunising immunocompetent mice with DFTD cells and 
seeing if the inclusion of imiquimod enhances the immune responses. Particular 
attention should also be given to dendritic cell responses since imiquimod is also 
known to activate DCs in vivo through the TLR7 (Shackleton et al 2004). This may 
provide a means of generating dendritic cell based immunotherapy avoiding the in 
vitro activation step.  
Conclusions  
Much of the early knowledge of DFTD resulted from establishment of DFTD cell lines 
(Pearse and Swift 2006). These established cell lines continue to provide the 
foundations for research into DFTD ranging from genetic analyses, testing 
therapeutic agents and vaccine development. Mouse models provide a bridge 
between in vitro cell cultures and in vivo work in Tasmanian devils. Mouse models 
should be viewed as animal cultures that overcome some of the limitations of cell 
culture and assume advantages of the in vivo environment (Frese and Tuveson 
2007). The mouse model allows the study of DFTD establishment and growth in a 
three dimensional substrate of stromal cells that provide nutrients, angiogenesis and 
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paracrine growth factors that are absent in a two-dimensional colony of cells 
adhering to a plastic substrate. 
 Mice represent an invaluable resource to evaluate treatment options for DFTD by 
providing a substitute to Tasmanian devils. Specific treatments identified in vitro can 
be tested in vivo before proceeding to trials in Tasmanian devils. The advantages 
include easier ethics approval, lower husbandry costs, no need to maintain animals 
after experiments have concluded and veterinary assistance is not required for 
treatments.   
In this thesis the first mouse models were based on xenograft rejection mechanisms. 
This provided valuable evidence that DFTD cells were immunogenic and could be 
eliminated by immune system responses in vivo. The use of immunocompromised 
mice allowed the implantation of xenografts to study the establishment and growth of 
DFTD cells in a permissive in vivo environment. A significant advance in the mouse 
model was when adoptive transfer of Tasmanian devil lymphocytes and DFTD cells 
to NOD/SCID mice provided protection against development of DFTD tumours. This 
facilitated the study of allograft responses against the implanted xenograft DFTD 
tumours.       
In this thesis a number of treatments were tested in various strains of mice. Some 
promising treatments such as afatinib, withaferin A, LAK cells and imiquimod were 
discovered in the in vitro setting of cell cultures. These therapies were then 
evaluated in vivo with the mouse model. In the cases of afatinib and withaferin A the 
in vivo studies did not provide supporting evidence to proceed to trials in the 
Tasmanian devil. In contrast, the in vivo studies provided compelling evidence to 
prioritise further development of both LAK cells and imiquimod treatments towards 
trials in Tasmanian devils.   
Through DFTD, nature has provided an ideal model to study cancer, vaccine 
development, immunotherapy and chemotherapy in a naturally occurring cancer in 
an animal with a competent immune system. The clonal nature of the disease allows 
replicate trials in multiple animals and multiple generations.  
DFTD is not just a Tasmanian problem but a global opportunity and by producing an 
immunological solution for DFTD we will extend our knowledge and treatment 
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options for many human cancers. The costs associated with immunotherapy trials 
would be substantial. But put in the global context, millions of dollars are spent 
developing animal models to study cancer in an artificial setting. DFTD provides an 
excellent opportunity to study cancer in a natural setting if sufficient funding is 
available.  
Future directions  
This thesis provided an informative mouse model to undertake preliminary studies to 
evaluate treatment options against DFTD. Two promising treatments that were 
identified in the mouse model were LAK cells and imiquimod therapy.  
LAK cell studies could be extended by evaluating the cascade of immune events 
associated with LAK cell killing of DFTD cells. This may require imaging studies to 
identify and describe the cell phenotypes that engage and kill the DFTD cells in vitro. 
Reconstitution of mice with adoptive transfer of Tasmanian devil lymphocytes may 
facilitate evaluating if direct LAK cell killing is augmented by engagement of the 
adaptive immune system especially CTLs. Identifying different means of activating 
LAK cells and establishing allogeneic Tasmanian devil NK cell lines would also 
advance the LAK cell studies. These could all be tested in the mouse model before 
proceeding to Tasmanian devil trials.  
This thesis provided the first evidence that we have identified a means of modifying 
DFTD tumours in vivo to express MHC. This was achieved by intratumoural injection 
of imiquimod. The potent anti-DFTD effects of imiquimod justify further evaluation of 
how best to utilise TLR agonists in the treatment of Tasmanian devils and if this 
should be as a monotherapy or a combined therapy. The mouse model provides the 
opportunity to study TLR agonists in vivo.  
Future studies with withaferin A should be undertaken in the athymic nude or Rag/2 
mice because they have functional NK cells. Withaferin A causes vimentin 
disassembly. Over expression of vimentin by cancer cells blocks NK receptors 
preventing them from targeting malignant cells. It is possible that withaferin A will 
remove this protection from DFTD cells allowing them to become targets for NK 
cells. This can only be assessed in vivo with competent NK cells.   
It is important that this work is translated to Tasmanian devils. Diseased Tasmanian 
devils could be treated with autologous and allogeneic LAK cells and tumour 
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biopsies could be examined by IHC for infiltrating cytotoxic cells. The use of 
allogeneic LAK cells as a vaccine adjuvant to enhance protection should also be 
trialled in Tasmanian devils. Establishment of an allogeneic NK cell line would 
support these trials.  
Imiquimod is the most promising option to date to treat DFTD in diseased devils. The 
mouse model provides the means of optimising the treatment protocol before 
proceeding to trials on Tasmanian devils. However, it is necessary to confirm that 
up-regulation of MHC makes the DFTD cells targets for cytotoxic Tasmanian devil 
lymphocytes. This would involve in vitro assays to detect proliferation of cytotoxic T 
cells when cultured with MHC+ DFTD cells. This would provide the rationale for 
proceeding to trials in Tasmanian devils.  
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